Oligosaccharide Compounds and Complexes

Cationic and ionizable oligosaccharide conjugates address the challenges of nucleic acid delivery by enhancing stability and membrane penetration, resulting in improved efficacy and safety for targeted agent delivery.

JP2024543247APending Publication Date: 2024-11-20BIONTECH SE +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024524377
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-29
Filing Date
2022-10-21
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Existing nucleic acid delivery systems face challenges due to instability, poor membrane penetration, manufacturing difficulties, and insufficient safety and efficacy, particularly in lipid- or polymer-based compositions.

Method used

Development of cationic and/or ionizable oligosaccharide conjugates for targeted delivery of biological agents, including small molecules and nucleic acids, with specific structural formulations to enhance stability and efficacy.

Benefits of technology

The oligosaccharide conjugates provide improved stability and membrane penetration, leading to enhanced delivery and expression of therapeutic agents, offering safer and more effective targeted delivery solutions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543247000001_ABST
    Figure 2024543247000001_ABST
Patent Text Reader

Abstract

The present disclosure provides compounds of formula I, as well as complexes and compositions comprising compounds of formula I, which are useful, for example, for the delivery of certain pharmaceutical agents, including nucleic acids.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Targeted delivery and expression of therapeutic and / or prophylactic agents such as nucleic acids present certain challenges due to the instability of nucleic acids and their inability to penetrate cell membranes.Some approaches, including the use of lipid or polymer-based systems, are promising, but suffer from drawbacks related to manufacturing difficulties, poor structural definition, and high polydispersity.In addition, many of these compositions lack sufficient safety and efficacy for use in the delivery of therapeutic agents. Summary of the Invention

[0002] The present disclosure provides, inter alia, cationic and / or ionizable oligosaccharide conjugates that overcome certain deficiencies associated with previous compositions and are useful for targeted delivery of biological agents, including small molecules and nucleic acids.

[0003] In some embodiments, the present disclosure provides a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S;a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S- and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5; However, A is A 1 If (i) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N+ (H) It will never become 3, (ii) Each R 1 and R 2 is -(CH2)5-CH3, or -(CH2) 13 -CH3, not X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iii) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both of them cannot be -(CH2)2-NH-C(S)-NH-(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iv) Provided is an oligosaccharide in which Cy is a compound, or a pharmaceutically acceptable salt thereof, that is not triazolyl.

[0004] In some embodiments, the present disclosure provides a complex comprising an oligosaccharide described herein and a nucleic acid.

[0005] In some embodiments, the present disclosure provides a method of increasing or causing an increase in expression of RNA in a target in a subject, comprising administering to the subject a complex described herein.

[0006] In some embodiments, the present disclosure provides methods of treating and / or preventing a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate described herein.

[0007] In some embodiments, the present disclosure provides a method for preparing an oligosaccharide of formula II, comprising: [ka] In the presence of an acid, a compound of formula III [ka] with a compound of formula IV, [ka] During the ceremony, Each R a is optionally substituted -C1-C 20 is aliphatic, Z 1 is an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's zcan be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Z a -PG 1 But Z 1 and one R z But, PG 1 is substituted with a group, PG 1 is a suitable nitrogen protecting group. [Brief explanation of the drawings]

[0008] [Figure 1A] 1 is a plot showing the hydrodynamic diameter of exemplary compositions containing modRNA formulated with certain oligosaccharides at different N / P ratios. [Figure 1B] 1 is a plot showing the zeta potential of exemplary oligosaccharides at different N / P ratios. [Figure 1C] 1 is a bar graph showing quantified ex vivo luminescence 6 hours after injection of an exemplary composition comprising modRNA in different organs and at different N / P ratios. [Figure 1D] 1 is a bar graph showing the hydrodynamic diameter of exemplary compositions comprising modRNA. [Figure 1E] 1 is a bar graph showing the zeta potential of exemplary compositions. [Figure 1F] 1 is a bar graph showing quantified ex vivo luminescence in different organs 6 hours after injection of an exemplary composition comprising modRNA. [Figure 1G] 1 is a bar graph showing the hydrodynamic diameter of exemplary compositions comprising modRNA. [Figure 1H] 1 is a bar graph showing the zeta potential of exemplary oligosaccharide compositions. [Figure 1I] 1 is a bar graph showing quantified ex vivo luminescence in the spleen 6 hours after injection of a composition comprising modRNA. [Figure 2A]1 is a bar graph showing the hydrodynamic diameter of exemplary compositions comprising modRNA formulated at different N / P ratios. [Figure 2B] 1 is a bar graph showing the zeta potential of exemplary compositions at different N / P ratios. [Figure 2C] 1 is a bar graph showing quantified ex vivo luminescence 6 hours after injection of an exemplary composition comprising modRNA in different organs and at different N / P ratios. [Figure 2D] 1 is a bar graph showing the hydrodynamic diameter of exemplary compositions comprising modRNA. [Figure 2E] 1 is a bar graph showing the zeta potential of exemplary compositions. [Figure 2F] 1 is a bar graph showing quantified ex vivo luminescence in the spleen 6 hours after injection of a composition comprising modRNA. [Figure 2G] 1 is a bar graph showing quantified ex vivo luminescence in different organs 6 hours after injection of a composition comprising modRNA. [Figure 3A] 1 is a bar graph showing the percentage of free RNA quantified by gel electrophoresis of exemplary compositions comprising modRNA at different N / P ratios from 0 to 3 for either JRL13 or JRL45. [Figure 3B] 1 is a plot showing the zeta potential after formulating an exemplary composition comprising modRNA at different N / P ratios with either JRL13 or JRL45. [Figure 3C] 1 is a plot showing the hydrodynamic diameter of exemplary compositions comprising modRNA at different N / P ratios using either JRL13 or JRL45. [Figure 3D] 1 is a bar graph showing expression of luciferase-encoding modRNA following transfection of C2C12 cells, with exemplary compositions prepared at N / P6 and containing modRNA comprising either JRL13 or JRL45 at 25 ng of RNA / well. [Figure 3E]1 is a bar graph showing quantified ex vivo luminescence in different organs 6 hours after injection of 10 μg of an exemplary composition comprising modRNA formulated in N / P3 using either JRL13 or JRL45. [Figure 3F] FIG. 1 is a bar graph showing the quantified ex vivo luminescence in different organs 6 hours post-injection and assessing the total flux [p / s] ratio from the JRL13 to JRL45 groups. [Figure 3G] 1 is a bar graph showing quantified ex vivo luminescence in different organs following injection of a composition comprising pDNA complexed with either JRL13 (compound 8) or JRL45 (compound 10). [Figure 4A] 1 is a plot showing the hydrodynamic diameter of exemplary complexes containing RNA formulated at different N / P ratios. [Figure 4B] 1 is a bar graph showing the zeta potential of exemplary compositions, including RNA, at different N / P ratios. [Figure 4C] 1 is a bar graph showing quantified bioluminescence over the experimental period of exemplary compositions with indicated N / P ratios, including modRNA and JRL13. [Figure 4D] 1 is a bar graph showing quantified bioluminescence over the experimental period of exemplary compositions with the indicated N / P ratios, including saRNA and JRL13. [Figure 5A] 1 is a bar graph showing the hydrodynamic diameter of complexes containing saRNA and different oligosaccharides formulated in N / P6. [Figure 5B] Bar graph showing bioluminescence quantified over the experimental period and normalized to the JRL13-saRNA group. [Figure 5C] 1 is a graph showing quantified bioluminescence at each measurement time point for an exemplary composition. [Figure 6A] 1 is a bar graph showing the hydrodynamic diameter of exemplary complexes formulated with modRNA and different oligosaccharides at different N / P ratios. [Figure 6B] 1 is a bar graph showing quantified bioluminescence over the duration of the experiment. [Figure 7A] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated with modRNA and different oligosaccharides in N / P6. [Figure 7B] 1 is a bar graph showing bioluminescence quantified over the experimental period and normalized to the JLF41-modRNA group. [Figure 8A] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated at different N / P ratios. [Figure 8B] 1 is a bar graph showing the zeta potential of compositions containing modRNA at different N / P ratios. [Figure 8C] 1 is a bar graph showing quantified bioluminescence over the experimental period for various exemplary compositions. [Figure 9A] 1 is a bar graph showing the hydrodynamic diameter of exemplary compositions. [Figure 9B] 1 is a bar graph showing quantified bioluminescence over the experimental period for exemplary oligosaccharide formulations. [Figure 10A] 1 is a bar graph showing the hydrodynamic diameter of certain complexes. [Figure 10B] 1 is a bar graph showing quantified bioluminescence over the experimental period for exemplary oligosaccharide formulations. [Figure 10C] 1 is a bar graph showing the quantified responses of CD8 positive T cells from spleen samples of treated mice 20 days after sc administration. [Figure 11A] 1 is a bar graph showing the hydrodynamic diameter of complexes containing RNA formulated at different N / P ratios. [Figure 11B] 1 is a bar graph showing the zeta potential of RNA at different N / P ratios. [Figure 11C] 1 is a bar graph showing quantified bioluminescence over the experimental period for modRNA groups. [Figure 11D] 1 is a bar graph showing quantified bioluminescence over the experimental period for the saRNA groups. [Figure 12A] 1 is a bar graph showing the hydrodynamic diameter of complexes containing RNA formulated at different N / P ratios. [Figure 12B] 1 is a plot showing serological levels of specific IgG to HA during the course of the experiment at a serum dilution of 1:300. [Figure 12C] 1 is a plot showing the endpoint titration of serological levels of specific IgG to HA. [Figure 12D] 1 is a bar graph showing CD8 / CD4 responses to HA peptide pools. [Figure 13A] Plot showing hydrodynamic diameters of complexes formulated in N / P6 but using different surfactants, with surfactant to JLF99 ratios between 0:1 and 0.5:1 (C14-pMeOx45 is C14 alkyl-poly(2-methyl-2-oxazoline)45, C14pSar23 is C14 alkyl-poly(sarcosine)23, and Tween20 is polysorbate 20). [Figure 13B] FIG. 10 is a plot showing the hydrodynamic diameter of complexes formulated at N / P6 with either Tween 20 or Tween 40 and surfactant to JLF99 ratios between 0 and 1.5. [Figure 13C] 1 is a plot showing expression of luciferase-encoding modRNA 24 hours after transfection of C2C12 cells. An exemplary composition has N / P6, where modRNA and either Tween 20 or Tween 40 at different detergent and JLF99 ratios were formulated at 100 ng RNA / well. This example represents three independent experiments (n=3) that were technically repeated three times. [Figure 13D] 1 is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of HepG2 cells, with an exemplary composition having N / P6, modRNA, and either Tween 20 or Tween 40 at different detergent and JLF99 ratios formulated at 100 ng RNA / well. This example represents three independent experiments (n=3) that were technically repeated three times. [Figure 13E] 1 is a bar graph showing the hydrodynamic diameter of complexes formulated in N / P6 with different oligosaccharide to surfactant ratios (T20 refers to Tween 20). [Figure 13F] 1 is a bar graph showing quantified bioluminescence over the experimental period, expressed as the area under the curve (T20 refers to Tween 20). [Figure 13G] 1 is a plot showing quantified bioluminescence over the duration of the experiment (T20 refers to Tween 20). [Figure 13H] The images show bioluminescence in the ventral axis 6 hours after injection of each group with a composition containing modRNA (T20 refers to Tween 20). [Figure 14A] 1 is a graph showing the hydrodynamic diameter of compositions comprising saRNA complexed with different oligosaccharides. [Figure 14B] 1 is a plot showing serological levels of specific IgG over time in the indicated formulations. [Figure 14C] 1 is a plot showing the endpoint titration of serological levels of specific IgG to HA for provided formulations. [Figure 14D] 1 is a bar graph showing CD8 / CD4 responses to HA peptide pools of the provided formulations. [Figure 15A] 1 is a bar graph showing the hydrodynamic diameter of compositions containing modRNA formulated with JLF99 and different polysorbates in N / P6. [Figure 15B] Quantified bioluminescence at the injection site at different time points over the course of the experiment is shown. [Figure 15C] Quantitative bioluminescence in the liver 6 hours and 24 hours after injection of modRNA is shown. [Figure 16A] 1 is a plot showing the serological levels of specific IgG to HA of the provided formulations over the indicated time periods (days 0, 14, 28, and 49). [Figure 16B] 1 is a plot showing the specific neutralization titers over the course of a given formulation over the indicated time period. [Figure 16C] 1 is a plot showing the endpoint titration of serological levels of specific IgG to HA for provided formulations. [Figure 16D]1 is a plot showing the CD8 / CD4 response to HA peptide pools of the provided formulations. [Figure 17A] 1 is a plot showing the serological levels of specific IgG to HA using different RNA complexes formulated with JLF99 at different time points over the course of the experiment. [Figure 17B] 1 is a plot showing the endpoint titration of serological levels of specific IgG to HA using different RNA platforms formulated in JLF99. [Figure 17C] 1 is a plot showing CD8 / CD4 responses to HA peptide pools from different RNA platforms formulated with JLF99. [Figure 18A] 1 is a plot showing average liver radiance with exemplary compositions including JFL99 or JLF218. [Figure 18B] 10A-10C are images showing bioluminescence in the ventral axis 6 hours after injection of exemplary formulations in each group. [Figure 19A] 1 is a plot showing IL-6 secretion by hPBMCs upon exposure to different doses of test formulations. [Figure 19B] 1 is a plot showing TNF-α secretion by hPBMCs upon exposure to different doses of test formulations. [Figure 19C] 1 is a plot showing IL-1β secretion by hPBMCs upon exposure to different doses of test formulations. [Figure 19D] 1 is a plot showing IFN-γ secretion by hPBMCs upon exposure to different doses of test formulations. [Figure 19E] 1 is a plot showing serological levels of specific IgG to HA in test formulations. [Figure 19F] 1 is a plot showing the endpoint titration of serological levels of specific IgG to HA. [Figure 19G] 1 is a bar graph showing CD8 / CD4 responses to HA peptide pools. [Figure 19H] 1 is a bar graph showing the hydrodynamic diameter of different test formulations. [Figure 20A] Serological levels of specific IgG to HA over the course of the example are shown. [Figure 20B] End-point titration of serological levels of specific IgG against HA is shown. [Figure 20C] CD8 / CD4 responses to HA peptide pools are shown. [Figure 21A] Serological levels of specific IgG to HA over the course of the example are shown. [Figure 21B] End-point titration of serological levels of specific IgG against HA is shown. [Figure 21C] CD8 / CD4 responses to HA peptide pools are shown. [Figure 22A] Serological levels of specific IgG to HA over the course of the example are shown. [Figure 22B] End-point titration of serological levels of specific IgG against HA is shown. [Figure 22C] CD8 / CD4 responses to HA peptide pools are shown. [Figure 23A] Serological levels of specific IgG to Gc over the course of the example are shown. [Figure 23B] End-point titration of serological levels of specific IgG against Gc is shown. [Figure 23C] 1 shows T cell responses to Gc peptides. DETAILED DESCRIPTION OF THE INVENTION

[0009] definition The compounds of the present disclosure generally include those described above and are further exemplified by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise specified. For the purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition. Furthermore, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Edition: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.

[0010] Unless otherwise indicated, structures depicted herein are intended to include all stereoisomeric (e.g., enantiomeric or diastereomeric) forms of the structure, as well as all geometric or conformational isomeric forms of the structure. For example, both the R and S configurations of each stereocenter are contemplated as part of this disclosure. Thus, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the provided compounds are within the scope of this disclosure. For example, in some cases, Table 1 depicts one or more stereoisomers of a compound, and unless otherwise specified, each stereoisomer is represented alone and / or as a mixture. Unless otherwise specified, all tautomeric forms of the provided compounds are within the scope of this disclosure.

[0011] Unless otherwise stated, structures depicted herein are meant to include compounds that differ only in the presence of one or more isotopically enriched atoms, for example, the replacement of a hydrogen by deuterium or tritium, or 13 C or 14 Compounds having this structure including the replacement of a carbon with a C-rich carbon are within the scope of this disclosure.

[0012] About or Approximately: As used herein, the term "about" or "approximately," when applied to one or more values ​​of interest, refers to a value similar to a stated reference value. Generally, a person skilled in the art familiar with the context will fully understand the relevant degree of difference encompassed by "about" or "approximately" in that context. For example, in some embodiments, the term "about" or "approximately" can encompass a range of values ​​within (i.e., ±) 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the reference value.

[0013] Administration: As used herein, the term "administering" or "administration" typically refers to administration of a composition to a subject to achieve delivery of the composition or agent contained therein to a target site or site to be treated. Those of skill in the art will recognize various routes available for administration to a subject, e.g., a human, under appropriate circumstances. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some specific embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, transdermal (e.g., may be or include one or more of topical cutaneous, intradermal, interdermal, transdermal, etc.), enteral, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, intraorgan (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, intravitreal, etc. In some embodiments, administration may be parenteral. In some embodiments, administration may be oral. In some specific embodiments, administration may be intravenous. In some specific embodiments, administration may be subcutaneous. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve the application of a set number of doses. In some embodiments, administration may involve administration that is intermittent (e.g., multiple doses separated in time) and / or periodic (e.g., individual doses separated by a common period of time) administration. In some embodiments, administration may involve continuous administration (e.g., perfusion) for at least a selected period of time. In some embodiments, administration may involve a prime-and-boost protocol. A prime-and-boost protocol may involve administration of a first dose of a pharmaceutical composition (e.g., an immunogenic composition, e.g., a vaccine), followed, after a set interval of time, by administration of a second or subsequent dose of a pharmaceutical composition (e.g., an immunogenic composition, e.g., a vaccine). In the case of an immunogenic composition, a prime-and-boost protocol may result in an increased immune response in a patient.

[0014] Aliphatic: The term "aliphatic" refers to a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturated units, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic (also referred to herein as "cycloaliphatic"), and has a single or multiple points of attachment to the remainder of the molecule. Unless otherwise specified, an aliphatic group contains 1 to 12 aliphatic carbon atoms. As used herein, it is understood that aliphatic groups can also be divalent (e.g., encompassing divalent hydrocarbon chains that are saturated or contain one or more unsaturated units, e.g., -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, etc.). In some embodiments, an aliphatic group contains 1 to 6 aliphatic carbon atoms (e.g., C 1-6 In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms (e.g., C 1-5 In some embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms (e.g., C 1-4 In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms (e.g., C 1-3 ), and in still other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms (e.g., C 1-2 In some embodiments, "cycloaliphatic" refers to a monocyclic C group that is fully saturated or contains one or more units of unsaturation, but is not aromatic and has a single or multiple points of attachment to the rest of the molecule. 3-8 Hydrocarbon or bicyclic C 7-10 "Aliphatic groups" refers to hydrocarbons. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups, and hybrids thereof. Preferred aliphatic groups are C 1-6 It is alkyl.

[0015] Alkyl: The term “alkyl” used alone or as part of a larger moiety refers to an alkyl group having 1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 1 to 3, or 1 to 2 carbon atoms (unless otherwise specified) (e.g., C1-12 , C 1-10 , C 1-8 , C 1-6 , C 1-4 , C 1-3 , or C 1-2 ), means a saturated, optionally substituted, straight or branched chain hydrocarbon group. Exemplary alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, and heptyl.

[0016] Alkenyl: The term “alkenyl,” used alone or as part of a larger moiety, refers to an alkyl group having at least one double bond and having 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, or 2 to 3 carbon atoms (unless otherwise specified) (e.g., C 2-12 , C 2-10 , C 2-8 , C 2-6、 C 2-4 , or C 2-3 ), an optionally substituted straight-chain, branched-chain, or cyclic hydrocarbon group. Exemplary alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, and heptenyl. The term "cycloalkenyl" refers to an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having from about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl, and cycloheptenyl.

[0017] Alkynyl: The term “alkynyl,” used alone or as part of a larger moiety, refers to an alkyl group having at least one triple bond and having 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, or 2 to 3 carbon atoms (unless otherwise specified) (e.g., C 2-12 , C 2-10 , C 2-8 , C 2-6 , C 2-4 , or C 2-3), an optionally substituted straight or branched chain hydrocarbon group. Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and heptynyl.

[0018] Analog: As used herein, the term "analog" refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an "analog" exhibits significant structural similarity to the reference substance, e.g., sharing a core or consensus structure, but also differs in certain distinct ways. In some embodiments, an analog is a substance that can be produced from a reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be produced through the implementation of a synthetic process that is substantially similar (e.g., shares multiple steps) with the synthetic process that produces the reference substance. In some embodiments, an analog is produced, or can be produced, by the implementation of a synthetic process that is different from the synthetic process used to produce the reference substance.

[0019] Aryl: The term "aryl" refers to an alkyl group having a total of 5 to 14 ring members (e.g., C5-C 14 ) refers to monocyclic and bicyclic ring systems in which at least one ring in the system is aromatic and each ring in the system contains 3 to 7 ring members. In some embodiments, an "aryl" group refers to a ring system containing 6 to 12 total ring members (e.g., C6-C 12 ). The term "aryl" may be used interchangeably with the term "aryl ring." In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, including phenyl, biphenyl, naphthyl, anthracyl, and the like, which may bear one or more substituents. Unless otherwise specified, an "aryl" group is a hydrocarbon. In some embodiments, an "aryl" ring system is an aromatic ring (e.g., phenyl) fused to a non-aromatic ring (e.g., cycloalkyl). Examples of fused aryl rings include: [ka] Examples include:

[0020] Associated: As used herein, two events or entities are "associated" with one another when the presence, level, and / or form of one correlates with that of the other. For example, a particular entity (e.g., a polypeptide, gene signature, metabolite, microorganism, etc.) is considered associated with a particular disease, disorder, or condition if its presence, level, and / or state correlates with the occurrence and / or susceptibility of the disease, disorder, or condition (e.g., across a relevant population). In some embodiments, two or more entities are physically "associated" with one another when they interact directly or indirectly to be in physical proximity and / or remain in close proximity to one another. In some embodiments, two or more entities that are physically associated with one another are covalently linked to one another. In some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another, but are non-covalently associated, for example, by hydrogen bonding, van der Waals interactions, hydrophobic interactions, magnetism, and combinations thereof.

[0021] Biological sample: As used herein, the term "biological sample" typically refers to a sample obtained or derived from a biological source of interest (e.g., a tissue or organism or cell culture) as described herein. In some embodiments, the source of interest comprises an organism such as an animal or a human. In some embodiments, the biological sample is or comprises a biological tissue or fluid. In some embodiments, a biological sample can be or include bone marrow, blood, blood cells, ascites, tissue or fine needle biopsy samples, cell-containing bodily fluids, suspended nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural effusion, feces, lymph, gynecological fluids, skin swabs, vaginal swabs, oral swabs, nasal swabs, washings or lavage fluids such as ductal lavage or bronchoalveolar lavage, aspirates, scrapings, bone marrow specimens, tissue biopsy specimens, surgical specimens, feces, other bodily fluids (e.g., sperm, sweat, tears), secretions, and / or excretions, and / or cells therefrom, etc. In some embodiments, a biological sample is or includes cells obtained from an individual. In some embodiments, the obtained cells are or include cells from the individual from whom the sample is obtained. In some embodiments, a sample is a "primary sample" obtained directly from a source of interest by any suitable means. For example, in some embodiments, the primary biological sample is obtained by a method selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of bodily fluids (e.g., blood, lymph, stool, etc.), etc. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing the primary sample (e.g., by removing one or more components and / or adding one or more agents), e.g., filtration using a semi-permeable membrane. Such a "processed sample" can include, for example, nucleic acids or proteins extracted from the sample or obtained by subjecting the primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and / or purification of certain components, etc.

[0022] Carrier: As used herein, the term "carrier" refers to a diluent, adjuvant, excipient, or vehicle used in administering a composition. In some exemplary embodiments, a carrier can comprise sterile liquids such as, for example, water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc. In some embodiments, a carrier is or comprises one or more solid ingredients.

[0023] Combination therapy: As used herein, the term "combination therapy" refers to a situation in which a subject is exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents or modalities) simultaneously. In some embodiments, the two or more regimens may be administered simultaneously. In some embodiments, the regimens may be administered sequentially (e.g., all "doses" of a first regimen are administered before any dose of a second regimen). In some embodiments, the agents are administered in overlapping dosing regimens. In some embodiments, "administration" of a combination therapy may include administering one or more agent(s) or modality(s) in combination to a subject receiving other agent(s) or modality(s). For clarity, combination therapy does not require that the individual agents be administered together in a single composition (or even necessarily simultaneously), although in some embodiments, two or more agents or their active portions may be administered together in a combined composition or even a combined compound (e.g., as part of a single chemical complex or covalent conjugate).

[0024] Comparable: As used herein, the term "comparable" refers to two or more agents, substances, circumstances, sets of conditions, etc. that may not be identical to one another, but that are sufficiently similar to permit a comparison between them, where one of skill in the art would understand that conclusions can be reasonably drawn based on the observed differences or similarities. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by multiple substantially identical characteristics and one or a few different characteristics. One of skill in the art will understand what level of identity is required for two or more such agents, substances, circumstances, sets of conditions, etc. to be considered comparable in any given situation in context. For example, one of skill in the art will understand that sets of circumstances, individuals, or populations are comparable to one another if they are characterized by a sufficient number and type of substantially identical characteristics to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are attributable to or indicative of differences in those different characteristics.

[0025] Composition: Those skilled in the art will understand that the term "composition" can be used to refer to a separate physical entity that includes one or more defined components. Generally, unless otherwise specified, a composition can be in any form, e.g., gas, gel, liquid, solid, etc.

[0026] Cycloaliphatic: As used herein, "cycloaliphatic" refers to a monocyclic C ring that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has single or multiple points of attachment to the rest of the molecule. 3-8 Hydrocarbon or bicyclic C 7-10 Refers to hydrocarbons.

[0027] Cycloalkyl: As used herein, the term "cycloalkyl" refers to an optionally substituted saturated monocyclic or multicyclic ring system of about 3 to about 10 ring carbon atoms. Exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0028] Dosage form or unit dosage form: Those of skill in the art will understand that the term "dosage form" can be used to refer to a physically discrete unit of an active agent (e.g., a therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined amount of the active agent. In some embodiments, such amount is a unit dosage (or all of it) appropriate for administration according to a dosing regimen (i.e., a therapeutic dosing regimen) that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population. Those of skill in the art will understand that the total amount of a therapeutic composition or agent to be administered to a particular subject is determined by one or more attending physicians and may involve the administration of multiple dosage forms.

[0029] Dosing regimen or treatment regimen: Those skilled in the art will understand that the terms "dosing regimen" and "treatment regimen" can be used to refer to a set of unit doses (typically more than one) typically administered to a subject separately over time periods. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which can include one or more doses. In some embodiments, a dosing regimen includes multiple doses, each spaced in time from the other doses. In some embodiments, the individual doses are separated from each other by equidistant periods. In some embodiments, a dosing regimen includes multiple doses, and the individual doses are separated by two different periods. In some embodiments, all doses within a dosing regimen are of the same unit dose. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen includes a first dosing at a first dosage amount, followed by one or more additional doses at a second dosage amount that is different from the first dosage amount. In some embodiments, the dosing regimen comprises a first dosing at a first dosage amount, followed by one or more additional dosings at a second dosage amount that is the same as the first dosage amount. In some embodiments, the dosing regimen correlates with a desired or beneficial outcome when administered within a relevant population (i.e., is a therapeutic dosing regimen).

[0030] Excipient: As used herein, the term "excipient" refers to a non-therapeutic agent that may be included in a pharmaceutical composition, for example, to provide or contribute to a desired consistency or stabilizing effect. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.

[0031] Heteroaliphatic: As used herein, the term "heteroaliphatic" or "heteroaliphatic group" refers to an optionally substituted hydrocarbon moiety having, in addition to carbon atoms, 1 to 5 heteroatoms, which may be straight-chained (i.e., unbranched), branched, or cyclic ("heterocyclic"), fully saturated, or may contain one or more units of unsaturation, but is not aromatic. The term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of basic nitrogen. The term "nitrogen" also includes substituted nitrogen. Unless otherwise specified, heteroaliphatic groups contain 1 to 10 carbon atoms, in which 1 to 3 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen, and sulfur. In some embodiments, heteroaliphatic groups contain 1 to 4 carbon atoms, in which 1 to 2 carbon atoms are optionally and independently replaced with heteroatoms selected from oxygen, nitrogen, and sulfur. In yet other embodiments, heteroaliphatic groups contain 1 to 3 carbon atoms, with one carbon atom optionally and independently replaced with a heteroatom selected from oxygen, nitrogen, and sulfur. Suitable heteroaliphatic groups include, but are not limited to, linear or branched heteroalkyl, heteroalkenyl, and heteroalkynyl groups. For example, heteroaliphatic groups of 1 to 10 atoms include exemplary groups such as -O-CH, -CH-O-CH, and -O-CH-CH-O-CH-CH-O-CH.

[0032] Heteroaryl: The terms "heteroaryl" and "heteroar-" are used alone or as part of a larger moiety, e.g., "heteroaralkyl" or "heteroaralkoxy" refer to a monocyclic or bicyclic ring group (e.g., a 5- or 6-membered monocyclic heteroaryl or a 9- or 12-membered bicyclic heteroaryl) having 5 to 12 ring atoms, 6, 10, or 14 pi electrons shared in the cyclic arrangement, and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of a basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyridyl, imidazo[4,5-b]pyridyl, imidazo[4,5-c]pyridyl, pyrrolopyridyl, pyrrolopyrazinyl, thienopyrimidinyl, triazolopyridyl, and benzisoxazolyl. As used herein, the terms "heteroaryl" and "heteroara-" also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, and the radical or point of attachment is on the heteroaromatic ring (i.e., a bicyclic heteroaryl ring having 1 to 3 heteroatoms). Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzothiadiazolyl, benzoxazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyrido[2,3-b]-1,4-oxazin-3(4H)-one, 4H-thieno[3,2-b]pyrrole, and benzisoxazolyl.Heteroaryl groups can be monocyclic or bicyclic. The term "heteroaryl" can be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," all of which include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions independently are optionally substituted.

[0033] Heteroatom: As used herein, the term "heteroatom" means nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.

[0034] Heterocycle: As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and refer to a stable 3- to 8-membered monocyclic, 7- to 12-membered bicyclic, or 10- to 16-membered polycyclic heterocyclic moiety that is either saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four, heteroatoms as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR +(such as N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiamorpholinyl. A heterocyclyl group can be monocyclic, bicyclic, tricyclic, or polycyclic, preferably monocyclic, bicyclic, or tricyclic, more preferably monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions are independently optionally substituted. Bicyclic heterocyclic rings also include groups in which a heterocyclic ring is fused to one or more aryl rings. Exemplary bicyclic heterocyclic groups include indolinyl, isoindolinyl, benzodioxolyl, 1,3-dihydroisobenzofuranyl, 2,3-dihydrobenzofuranyl, tetrahydroquinolinyl, [ka] The bicyclic heterocyclic ring may be a spirocyclic ring system (e.g., a 7- to 11-membered spirocyclic fused heterocyclic ring having, in addition to carbon atoms, one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) as defined above). The bicyclic heterocyclic ring may also be a bridged ring system (e.g., a 7- to 11-membered bridged heterocyclic ring having 1, 2, or 3 bridging atoms).

[0035] Nucleic Acid / Polynucleotide: As used herein, the term "nucleic acid" refers to a polymer of at least 10 or more nucleotides. In some embodiments, a nucleic acid is or comprises DNA. In some embodiments, a nucleic acid is or comprises RNA. In some embodiments, a nucleic acid is or comprises peptide nucleic acid (PNA). In some embodiments, a nucleic acid is or comprises single-stranded nucleic acid. In some embodiments, a nucleic acid is or comprises double-stranded nucleic acid. In some embodiments, a nucleic acid comprises both single-stranded and double-stranded portions. In some embodiments, a nucleic acid comprises a backbone comprising one or more phosphodiester bonds. In some embodiments, a nucleic acid comprises a backbone comprising both phosphodiester and non-phosphodiester bonds. For example, in some embodiments, a nucleic acid can comprise a backbone comprising one or more phosphorothioate or 5'-N-phosphoramidite bonds and / or one or more peptide bonds, e.g., "peptide nucleic acids." In some embodiments, a nucleic acid comprises one or more, or all, naturally occurring residues (e.g., adenine, cytosine, deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, guanine, thymine, uracil). In some embodiments, a nucleic acid comprises one or more, or all, non-naturally occurring residues. In some embodiments, the non-natural residue comprises a nucleoside analog (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 6-O-methylguanine, 2-thiocytidine, methylated bases, intercalating bases, and combinations thereof).In some embodiments, the non-natural residue comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to that of the natural residue. In some embodiments, the nucleic acid has a nucleotide sequence that encodes a functional gene product, such as an RNA or a polypeptide. In some embodiments, the nucleic acid has a nucleotide sequence that includes one or more introns. In some embodiments, nucleic acids can be prepared by isolation from natural sources, enzymatic synthesis (e.g., polymerization based on a complementary template in vivo or in vitro, replication in a recombinant cell or system, or chemical synthesis. In some embodiments, nucleic acids are at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12 1,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, or 20,000 or more residues or nucleotides in length.

[0036] Nucleic acid particles: "Nucleic acid particles" can be used to deliver nucleic acids to a desired target site (e.g., a cell, tissue, organ, etc.). Nucleic acid particles can be formed from at least one cationic lipid or cationically ionizable lipid or lipid-like material, at least one cationic polymer such as protamine, or a mixture thereof, and nucleic acid. Nucleic acid particles include lipid nanoparticle (LNP)-based and lipoplex (LPX)-based formulations.

[0037] Nucleotide: As used herein, the term "nucleotide" refers to its art-recognized meaning. When a number of nucleotides is used, for example, as an indicator of the size of a polynucleotide, a certain number of nucleotides refers to the number of nucleotides on a single strand, for example, a polynucleotide.

[0038] Oral: As used herein, the phrases "oral administration" and "orally administered" have their art-understood meanings, meaning administration of a compound or composition by mouth.

[0039] Parenteral: As used herein, the terms "parenteral administration" and "parenterally administered" have their art-understood meanings and refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.

[0040] Partially unsaturated: As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond between ring atoms. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aromatic (e.g., aryl or heteroaryl) moieties as defined herein.

[0041] Patient or Subject: As used herein, the term "patient" or "subject" refers to any organism to which a provided composition is or can be administered, for example, experimental, diagnostic, prophylactic, cosmetic, and / or therapeutic purposes. Typical patients or subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is human. In some embodiments, the patient or subject suffers from or is prone to one or more disorders or conditions. In some embodiments, the patient or subject exhibits one or more symptoms of a disorder or condition. In some embodiments, the patient or subject has been diagnosed with one or more disorders or conditions. In some embodiments, the patient or subject is undergoing or has undergone a particular therapy to diagnose and / or treat a disease, disorder, or condition.

[0042] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to an active agent formulated with one or more pharmaceutically acceptable carriers. In some embodiments, the active agent is present in a unit dose suitable for administration in a treatment or dosing regimen that exhibits a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition may be specially formulated for administration in solid or liquid form, including oral administration, e.g., drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., buccal, sublingual, and those targeted for systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, e.g., by subcutaneous, intramuscular, intravenous, or epidural injection, e.g., as a sterile solution or suspension, or sustained-release formulation; topical application, e.g., as a cream, ointment, or controlled-release patch or spray applied to the skin, lungs, or oral cavity; vaginal or rectal administration, e.g., as a pessary, cream, or foam; sublingual; ophthalmic; transdermal; or compatible with the nose, lungs, and other mucosal surfaces.

[0043] Pharmaceutically acceptable: As used herein, the phrase "pharmaceutically acceptable" means compounds, materials, compositions, and / or dosage forms that are, within the scope of good medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0044] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or organ filler, diluent, excipient, or solvent encapsulating material, that is involved in carrying or transporting a compound of interest from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, for example, sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffer solutions; polyesters, polycarbonates, and / or polyanhydrides; and other non-toxic, compatible substances used in pharmaceutical formulations.

[0045] Pharmaceutically acceptable salt: As used herein, the term "pharmaceutically acceptable salt" means a salt of a compound that is suitable for use in a pharmaceutical context, i.e., a salt that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, within the scope of good medical judgment, commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19 (1977). In some embodiments, pharmaceutically acceptable salts include, but are not limited to, non-toxic acid addition salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or formed by using other methods used in the art, such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxybenzoate, benzoic acid, benzoates ... Examples of suitable salts include dimethylsulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc.In some embodiments, pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed, where appropriate, using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates, and arylsulfonates.

[0046] Polycyclic: As used herein, the term "polycyclic" refers to a saturated or unsaturated ring system having two or more rings (e.g., heterocyclyl, heteroaryl, cycloalkyl, or aryl rings) with 7 to 20 atoms, in which one or more carbon atoms are common to two adjacent rings. For example, in some embodiments, a polycyclic ring system refers to a saturated or unsaturated ring system having three or more rings (e.g., heterocyclyl, heteroaryl, cycloalkyl, or aryl rings) with 14 to 20 atoms, in which one or more carbon atoms are common to two adjacent rings. The rings in a polycyclic ring system may be fused (i.e., bicyclic or tricyclic), spirocyclic, or a combination thereof. Exemplary polycyclic rings are steroids.

[0047] Polypeptide: As used herein, the term "polypeptide" typically has its art-recognized meaning of a polymer of at least three or more amino acids. Those of skill in the art will understand that the term "polypeptide" is intended to be sufficiently general to encompass not only polypeptides having the complete sequences described herein, but also polypeptides that represent functional, biologically active, or characteristic fragments, portions, or domains of such complete polypeptides (e.g., fragments, portions, or domains that retain at least one activity). In some embodiments, polypeptides may contain L-amino acids, D-amino acids, or both, and / or may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, for example, terminal acetylation, amidation, methylation, and the like. In some embodiments, polypeptides may contain (e.g., be or include) natural amino acids, unnatural amino acids, synthetic amino acids, and combinations thereof (e.g., may be peptidomimetics).

[0048] Prevention or prophylaxis: As used herein, the terms "prevention" or "prophylaxis," when used in connection with the occurrence of a disease, disorder, and / or condition, means reducing the risk of the disease, disorder, and / or condition occurring and / or delaying the onset of one or more characteristics or symptoms of the disease, disorder, or condition. Prevention may be considered complete when the onset of the disease, disorder, or condition has been delayed for a predetermined period of time.

[0049] Reference: As used herein, describes a standard or control against which a comparison is made. For example, in some embodiments, an agent, animal, individual, population, sample, sequence, or value of interest is compared to a reference or control agent, animal, individual, population, sample, sequence, or value. In some embodiments, the reference or control is tested and / or determined substantially contemporaneously with the test or determination of interest. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as will be understood by one of skill in the art, a reference or control is determined or analyzed under conditions or circumstances comparable to those being evaluated. One of skill in the art will understand when there is sufficient similarity to justify reliance on and / or comparison to a particular reference or control considered.

[0050] Ribonucleotide: As used herein, the term "ribonucleotide" encompasses unmodified ribonucleotides and modified ribonucleotides. For example, unmodified ribonucleotides include the purine bases adenine (A) and guanine (G) and the pyrimidine bases cytosine (C) and uracil (U). Modified ribonucleotides can include one or more modifications, including, but not limited to, (a) terminal modifications, such as 5'-terminal modifications (e.g., phosphorylation, dephosphorylation, conjugation, inverted linkages, etc.), 3'-terminal modifications (e.g., conjugation, inverted linkages, etc.), (b) base modifications, such as substitution with a modified base, a stabilized base, a destabilized base, or a base that base pairs with an expanded repertoire of partners, or a conjugated base, (c) sugar modifications (e.g., at the 2' or 4' position) or sugar substitutions, and (d) internucleoside linkage modifications, including modifications or substitutions of phosphodiester bonds. The term "ribonucleotide" also encompasses ribonucleotide triphosphates, including modified and unmodified ribonucleotide triphosphates.

[0051] Ribonucleic acid (RNA): As used herein, the term "RNA" refers to a polymer of ribonucleotides. In some embodiments, the RNA is single-stranded. In some embodiments, the RNA is double-stranded. In some embodiments, the RNA includes both single-stranded and double-stranded portions. In some embodiments, the RNA can include a backbone structure as described in the definition of "nucleic acid / polynucleotide" above. The RNA can be a regulatory RNA (e.g., siRNA, microRNA, etc.) or a messenger RNA (mRNA). In some embodiments, the RNA is an mRNA. In some embodiments, the RNA is an mRNA, and the RNA typically includes a poly(A) region at its 3' end. In some embodiments, the RNA is an mRNA, and the RNA typically includes an art-recognized cap structure at its 5' end, for example, for recognition and binding of the mRNA to a ribosome to initiate translation. In some embodiments, the RNA is synthetic RNA. Synthetic RNA includes RNA synthesized in vitro (e.g., by enzymatic and / or chemical synthesis).

[0052] Sample: As used herein, the term "sample" typically refers to an aliquot of material obtained from or derived from a source of interest. In some embodiments, the source of interest is a biological or environmental source. In some embodiments, the source of interest can be or include a cell, tissue, or organism, such as a microorganism, a plant, or an animal (e.g., a human). In some embodiments, the source of interest is or includes a biological tissue or fluid. In some embodiments, the source of interest can be or include a preparation generated in a production process. In some embodiments, a sample is a "primary sample" obtained directly from the source of interest by any suitable means. In some embodiments, as will be clear from the context, the term "sample" refers to a preparation obtained by processing a primary sample (e.g., by removing one or more components and / or adding one or more agents).

[0053] Substituted or optionally substituted: As described herein, compounds of the invention can contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally," means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. "Substituted" applies to one or more hydrogens that are either explicit or implicit from the structure (e.g., [ka] At least [ka] refers to, [ka] At least [ka] (refers to "optionally substituted"). Unless otherwise specified, an "optionally substituted" group can have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituents can be the same or different at all positions. Combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. As used herein, the term "stable" refers to a compound that remains substantially unchanged when subjected to conditions that permit the compound's production, detection, and, in certain embodiments, its recovery, purification, and use for one or more of the purposes provided herein. Groups described as "substituted" preferably have 1 to 4 substituents, more preferably 1 or 2 substituents. Groups described as "optionally substituted" can be unsubstituted or "substituted" as described above.

[0054] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen, -(CH) 0-4 R, -(CH2) 0-4 OR, -O(CH2) 0-4 R o , -O-(CH2) 0-4 C(O)OR°, -(CH2) 0-4 CH(OR)2, -(CH2) 0-4 -(CH2) which may be substituted with SR, R° 0-4 Ph, R° may be substituted -(CH2) 0-4 O(CH2) 0-1 Ph, may be substituted with R° -CH=CHPh, may be substituted with R° -(CH 0-4 O(CH2) 0-1 -Pyridyl, -NO2, -CN, -N3, (CH2) 0-4 N(R)2, -(CH2) 0-4 N(R)C(O)R, -N(R)C(S)R, -(CH2) 0-4 N(R)C(O)NR2, N(R)C(S)NR2, -(CH2) 0-4 N(R)C(O)OR, -N(R)N(R)C(O)R, N(R)N(R)C(O)NR2, N(R)N(R)C(O)OR, -(CH2) 0-4 C(O)R, C(S)R, -(CH2) 0-4 C(O)OR, -(CH2) 0-4 C(O)SR, (CH2) 0-4 C(O)OSiR3, -(CH2) 0-4 OC(O)R, -OC(O)(CH2) 0-4 SR°, -(CH2) 0-4 SC(O)R, -(CH2) 0-4 C(O)NR2, -C(S)NR2, -C(S)SR°, -SC(S)SR°, (CH2) 0-4 OC(O)NR2, C(O)N(OR)R, -C(O)C(O)R, -C(O)CH2C(O)R, -C(NOR)R, (CH2) 0-4 SSR, -(CH2) 0-4 S(O)R, -(CH) 0-4 S(O)2OR, -(CH2) 0-4 OS(O)2R, -S(O)2NR2, (CH2) 0-4S(O)R, N(R)S(O)2NR2, -N(R)S(O)2R, -N(OR)R, -C(NH)NR2, -P(O)2R, P(O)R2, OP(O)R2, -OP(O)(OR)2, SiR3, -(C 1-4 linear or branched alkylene)ON(R)2, or -(C 1-4 linear or branched alkylene)C(O)ON(R)2, where each R may be substituted as defined below and is independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2- (a 5- to 6-membered heteroaryl ring), or a 3- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definitions, two independent occurrences of R taken together with their intervening atom(s) form a 3- to 12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0055] Suitable monovalent substituents on R (or the ring formed by two independent occurrences of R and their intervening atoms) are independently halogen, —(CH) 0-2 R ● ,-(Halo R ● ), -(CH2) 0-2 OH, -(CH2) 0-2 OR ● , -(CH2) 0-2 CH(OR ● )2, O(Halo R ● ), -CN, -N3, -(CH2) 0-2 C(O)R ● , -(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR ● , -(CH2) 0-2 SR ● , -(CH2) 0-2 SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR ● , -(CH2)0-2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3. C(O)SR ● , -(C 1-4 Linear or branched alkylene)C(O)OR ● , or -SSR ● and each R ● is unsubstituted or, if preceded by "halo", substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R include =0 and =S.

[0056] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include ═O ("oxo"), ═S, ═NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2-3 O-, or -S(C(R * 2)) 2-3 S- is mentioned, R * Each independent occurrence of may be substituted as defined below with hydrogen, C 1-6 aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents attached to adjacent substitutable carbons of an "optionally substituted" group include -O(CR * 2) 2-3 O- and R * Each independent occurrence of may be substituted as defined below with hydrogen, C 1-6Selected from aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0057] R * Suitable substituents on the aliphatic group include halogen, -R ● , (Halo R ● ), OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, and each R ● is unsubstituted or, if preceded by "halo", substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0058] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CHC(O)R † , S(O)2R † , S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † are listed, and each R † are independently hydrogen, C which may be substituted as defined below 1-6 an aliphatic, unsubstituted -OPh, or unsubstituted 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, regardless of the above definitions, R †two independent occurrences of together with their intervening atom(s) form an unsubstituted 3-12 membered saturated, partially unsaturated, or mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0059] R † Suitable substituents on the aliphatic group are independently halogen, —R ● , (Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or NO2, and each R ● is unsubstituted or, if preceded by "halo", substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 3-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0060] Small molecule: As used herein, the term "small molecule" refers to a low molecular weight organic and / or inorganic compound. Generally, a "small molecule" is a molecule that is less than about 5 kilodaltons (kD) in size. In some embodiments, a small molecule is less than about 4 kD, 3 kD, 2 kD, or 1 kD. In some embodiments, a small molecule is less than about 800 daltons (D), 600 D, 500 D, 400 D, 300 D, 200 D, or 100 D. In some embodiments, a small molecule is less than about 2000 g / mol, less than about 1500 g / mol, less than about 1000 g / mol, less than about 800 g / mol, or less than about 500 g / mol. In some embodiments, a small molecule is not a polymer.

[0061] Those skilled in the art will understand, upon reading this disclosure, that certain small molecule compounds described herein, including, for example, the oligosaccharide compounds described herein, may be provided and / or utilized in any of a variety of forms, such as, for example, crystalline forms (e.g., polymorphs, solvates, etc.), salt forms, protected forms, prodrug forms, ester forms, isomeric forms (e.g., optical and / or structural isomers), isotopic forms, etc.

[0062] Those skilled in the art will appreciate that certain small molecule compounds (e.g., the oligosaccharide compounds described herein) have structures that can exist in one or more stereoisomeric forms. In some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of an individual enantiomer, diastereomer, or geometric isomer, or in the form of a mixture of stereoisomers; in some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of a racemic mixture.

[0063] Those skilled in the art will appreciate that certain small molecule compounds (e.g., the oligosaccharide compounds described herein) have structures that can exist in one or more tautomeric forms. In some embodiments, such small molecules may be utilized in accordance with the present disclosure in the form of individual tautomers or in forms that interconvert between tautomers.

[0064] Those skilled in the art will recognize that a particular small molecule compound (e.g., an oligosaccharide compound described herein) may have a structure that allows for isotopic substitution (e.g., in the case of H, 2 H or 3 H, 12 In the case of C 11 C. 13 C, or 14 C. 14 In the case of N 13 N or 15 N, 16 In the case of O 17 O or 18 O. 35 Cl or 37 In the case of Cl 36 Cl, 19 In the case of F 18F, 127 In the case of I 131 It will be understood that such small molecules have one or more isotopically modified forms, or mixtures thereof, in accordance with the present disclosure.

[0065] In some embodiments, a reference to a particular small molecule compound (e.g., an oligosaccharide compound described herein) may refer to a particular form of that compound. In some embodiments, a particular small molecule compound may be provided and / or utilized in the form of a salt (e.g., an acid addition or base addition salt, depending on the compound), and in some such embodiments, the salt form may be a pharmaceutically acceptable salt form.

[0066] In some embodiments, if a small molecule compound is a naturally occurring or naturally found compound, the compound may be provided and / or utilized in accordance with the present disclosure in a form that differs from that in which it naturally occurs or is found in nature. One skilled in the art will understand that in some embodiments, the absolute or relative amount of a compound, or a preparation of a particular small molecule compound (e.g., an oligosaccharide compound described herein) containing a particular form thereof, will differ from the compound present in a reference preparation or source (e.g., a primary sample from a source of interest, such as a biological or environmental source) in terms of the absolute or relative amount of the compound or form present (e.g., with respect to other components of the preparation that contain other forms of the compound). Thus, in some embodiments, for example, a preparation of a single stereoisomer of a small molecule compound may be considered to be a distinct form from a racemic mixture of the compound, a particular salt of a small molecule compound may be considered to be a distinct form from another salt form of the compound, a preparation that includes only forms of the compound that contain one stereoisomer of the double bond ((Z) or (E)) may be considered to be a distinct form from forms of the compound that contain the other stereoisomer of the double bond (E) or (Z), and a preparation in which one or more atoms are isotopes different from those present in a reference preparation may be considered to be a distinct form.

[0067] Those skilled in the art will recognize that in small molecule structures, the symbols [ka] It will be further understood that the term "atom" refers to the point of attachment between two atoms.

[0068] Therapeutic Agent: As used herein, the term "therapeutic agent" generally refers to any agent that induces a desired pharmacological effect when administered to an organism. In some embodiments, an agent is considered to be a therapeutic agent if it shows a statistically significant effect across an appropriate population. In some embodiments, the appropriate population may be a population of model organisms. In some embodiments, the appropriate population may be defined by various criteria, such as a particular age group, sex, genetic background, pre-existing clinical condition, etc. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay the onset, reduce the severity, and / or reduce the incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. In some embodiments, a "therapeutic agent" is a drug that has been, or needs to be, approved by a government agency before it can be commercially available for administration to humans. In some embodiments, a "therapeutic agent" is a drug that requires a medical prescription for administration to humans.

[0069] Treat: As used herein, the terms "treat," "treatment," or "treating" refer to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. Treatment may be administered to subjects who do not exhibit signs of the disease, disorder, and / or condition. In some embodiments, treatment may be administered to subjects who exhibit only early signs of the disease, disorder, and / or condition, for example, to reduce the risk of developing conditions associated with the disease, disorder, and / or condition.

[0070] Polycationic Oligosaccharide Compounds The present disclosure relates, inter alia, to compounds which are oligosaccharides of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S- and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R zare independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5; However, A is A 1 If (i) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (ii) Each R 1 and R 2 is -(CH2)5-CH3, or -(CH2) 13 -CH3, not X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iii) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both of them cannot be -(CH2)2-NH-C(S)-NH-(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iv) A composition comprising a compound, or a pharmaceutically acceptable salt thereof, wherein Cy is not triazolyl.

[0071] As described herein, A is A 1 , A 2 , or A 3 is. [ka]

[0072] In some embodiments, A is A 1 or A 2 In some embodiments, A is A 1 In some embodiments, A is A 2 In some embodiments, A is A 3 In some embodiments, A is A 1 and the oligosaccharide is a compound of formula Ia, [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0073] In some embodiments, the compound is an oligosaccharide of formula Ia: [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S- and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's zcan be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; however, (i) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (ii) Each R 1 and R 2 is -(CH2)5-CH3, or -(CH2) 13 -CH3, not X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iii) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both of them cannot be -(CH2)2-NH-C(S)-NH-(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iv) Cy is a non-triazolyl oligosaccharide, or a pharmaceutically acceptable salt thereof.

[0074] In some embodiments, A is A 2 and the oligosaccharide is a compound of formula Ib, [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0075] In some embodiments, the compound is an oligosaccharide of formula Ib: [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c, and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S- and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S, or a pharmaceutically acceptable salt thereof.

[0076] In some embodiments, A is A 3 and the oligosaccharide is a compound of formula Ic, [ka] or a pharmaceutically acceptable salt thereof, wherein p, R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination. In some embodiments, the oligosaccharide is a compound of formula Ic: [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 and R2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S- and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's zcan be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is 1, 2, 3, 4, or 5, or a pharmaceutically acceptable salt thereof.

[0077] In some embodiments, p is 1 and the oligosaccharide is a compound of formula Ic-i: [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0078] In some embodiments, p is 2 and the oligosaccharide is a compound of formula Ic-ii: [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0079] In some embodiments, p is 3 and the oligosaccharide is a compound of formula Ic-iii: [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0080] In some embodiments, p is 4 and the oligosaccharide is a compound of formula Ic-iv: [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0081] In some embodiments, p is 5 and the oligosaccharide is a compound of formula Ic-v: [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0082] Generally, as described herein, R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R1 or R 2 At least one instance of is not H. In some embodiments, R 1 and R 2 each independently, in each instance, R a , and -C(O)-R a In some embodiments, R 1 and R 2 Each of R a In some embodiments, R 1 and R 2 Each of R a and each R a are independently C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a is one or more R b is optionally replaced by

[0083] In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C1-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C1-C optionally substituted with 14 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C1-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and R a may independently be one or more Rb C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of R a and each R a independently, C5-C 10 In some embodiments, R 1 and R 2 Each of R a and each R a are independently methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and n-nonyl. 1 and R 2 Each of R a and each R a is, independently, [ka] is selected from.

[0084] In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b C3-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of R a and each R ais independently selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0085] In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of R a and each R a is phenyl.

[0086] In some embodiments, R 1 and R 2 Each of R a and each R a may independently be one or more R b In some embodiments, R is a 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1 and R 2 Each of R a and each R a may independently be one or more R b and optionally substituted with 3 to 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S.

[0087] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a are independently C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a is one or more R b is optionally replaced by

[0088] In some embodiments, R 1and R 2 Each of the groups is -C(O)-R a In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b C1-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b C1-C optionally substituted with 14 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b C1-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b C5-C optionally substituted with 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a independently, C5-C 10 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R ais independently selected from methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, or n-nonyl. 1 and R 2 Each of the groups is -C(O)-R a and each R a is, independently, [ka] is selected from.

[0089] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b C3-C optionally substituted with 20 In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b Polycyclic C optionally substituted with 10 -C 20 In some embodiments, R 1 or R 2 One or more of the [ka] is.

[0090] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a is independently phenyl.

[0091] In some embodiments, R 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b In some embodiments, R is a 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, optionally substituted with 1 and R 2 Each of the groups is -C(O)-R a and each R a may independently be one or more R b and optionally substituted with 3 to 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S.

[0092] In some embodiments, R 1 and R 2 each of which independently [ka] is selected from.

[0093] As described herein, each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)Rc , -C(O)NHR c , and -NHC(O)NHR c In some embodiments, R b is halogen. In some embodiments, R b is -N3. In some embodiments, R b is R c In some embodiments, R b -OR c In some embodiments, R b -SR c In some embodiments, R b -NHR c In some embodiments, R b is -C(O)-R c In some embodiments, R b is -OC(O)R c In some embodiments, R b is -NHC(O)R c In some embodiments, R b is -C(O)NHR c In some embodiments, R b is -NHC(O)NHR c is.

[0094] As described herein, each R c are independently optionally substituted C-C 20 Aliphatic, C3-C 20 In some embodiments, R is selected from cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S. c is an optionally substituted C1-C 20 In some embodiments, R c is an optionally substituted C3-C 20 In some embodiments, R cis an optionally substituted C5-C6 aryl. In some embodiments, R c is an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, R c is an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0095] As described herein, X 1 and X 2 are each independently selected from -S- and -NH-. 1 is -S-. In some embodiments, X 1 is —NH—. In some embodiments, X 2 is -S-. In some embodiments, X 2 is -NH-. In some embodiments, X 1 and X 2 are each -S-. In some embodiments, X 1 and X 2 are each —NH—. In some embodiments, X 1 is -S- and X 2 is —NH—. In some embodiments, X 1 is -NH- and X 2 is -S-.

[0096] As described herein, Y 1 and Y 2 each independently represents an optionally substituted C 1-30 is an aliphatic group, and Y 1 and / or Y 2One or more carbons of the group are optionally and independently substituted with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO-. As described herein, Y 1 and Y 2 is a divalent moiety with one end X 1 or X 2 The other end is bonded to the Z group. 1 or Z 2 It is understood that the bond is to a group.

[0097] In some embodiments, Y 1 and Y 2 are each independently C1-C 10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic-C( S) selected from NH-C0-C4 aliphatic, C0-C4-aliphatic-NHC(O)-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4 aliphatic.

[0098] In some embodiments, Y 1 and Y 2 are C1-C 10 In some embodiments, Y is aliphatic. 1 and Y 2 are each methylene, ethylene, propylene, or butylene. 1 and Y 2 are each -CH2-CH2-.

[0099] In some embodiments, Y 1 and Y 2 are, respectively, C0-C4-aliphatic-NHC(O)NH-C0-C4 aliphatic.

[0100] In some embodiments, Y 1 and Y 2 are C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic, respectively.

[0101] In some embodiments, Y 1 and Y 2 are each —CH—CH—NHC(O)NH—CH—CH—

[0102] In some embodiments, Y 1 and Y 2 are C0-C4-aliphatic-NHC(S)NH-C0-C4 aliphatic, respectively.

[0103] In some embodiments, Y 1 and Y 2 are C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic, respectively.

[0104] In some embodiments, Y 1 and Y 2 are each —CH—CH—NHC(S)NH—CH—CH—

[0105] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 1 and Y 2 are each C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are each —CH—CH—C(O)NH—CH—CH—

[0106] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 1 and Y 2are each C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are each —CH—CH—NHC(O)—CH—CH—.

[0107] In some embodiments, Y 1 and Y 2 are each C-C-aliphatic-NHSO-C-C-aliphatic. 1 and Y 2 are each C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 1 and Y 2 are each -CH2-CH2-NHSO2-CH2-CH2-.

[0108] In some embodiments, Y 1 is C1-C 10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic- selected from C(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4.

[0109] In some embodiments, Y 1 is C1-C 10 In some embodiments, Y is aliphatic. 1 is methylene, ethylene, propylene, or butylene. In some embodiments, Y 1 is -CH2-CH2-.

[0110] In some embodiments, Y 1 is C-C-aliphatic-NHC(O)NH-C-C-aliphatic. In some embodiments, Y 1is C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(O)NH-CH2-CH2-.

[0111] In some embodiments, Y 1 is C-C-aliphatic-NHC(S)NH-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(S)NH-CH2-CH2-.

[0112] In some embodiments, Y 1 is C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-C(O)NH-CH2-CH2-.

[0113] In some embodiments, Y 1 is C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHC(O)-CH2-CH2-.

[0114] In some embodiments, Y 1 is C-C-aliphatic-NHSO-C-C-aliphatic. In some embodiments, Y 1 is C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 1 is -CH2-CH2-NHSO2-CH2-CH2-.

[0115] In some embodiments, Y 2 is C1-C10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4aliphatic, C0-C4-aliphatic- selected from C(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4.

[0116] In some embodiments, Y 2 is C1-C 10 In some embodiments, Y is aliphatic. 2 is methylene, ethylene, propylene, or butylene. In some embodiments, Y 2 is -CH2-CH2-.

[0117] In some embodiments, Y 2 is C-C-aliphatic-NHC(O)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(O)NH-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(O)NH-CH2-CH2-.

[0118] In some embodiments, Y 2 is C-C-aliphatic-NHC(S)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(S)NH-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(S)NH-CH2-CH2-.

[0119] In some embodiments, Y 2 is C-C-aliphatic-C(O)NH-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-C(O)NH-C1-C4 aliphatic. In some embodiments, Y 2is -CH2-CH2-C(O)NH-CH2-CH2-.

[0120] In some embodiments, Y 2 is C-C-aliphatic-NHC(O)-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHC(O)-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHC(O)-CH2-CH2-.

[0121] In some embodiments, Y 2 is C-C-aliphatic-NHSO-C-C-aliphatic. In some embodiments, Y 2 is C1-C4-aliphatic-NHSO2-C1-C4 aliphatic. In some embodiments, Y 2 is -CH2-CH2-NHSO2-CH2-CH2-.

[0122] Generally, as described herein, each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and a 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S.

[0123] In some embodiments, the moiety X 1 -Y 1 -Z 1 teeth, [ka] is.

[0124] In some embodiments, the moiety X 2 -Y 2 -Z 2 teeth, [ka] is.

[0125] Generally, as described herein, Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from:

[0126] In some embodiments, Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is selected from.

[0127] In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2 are each an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 and Z 2are each selected from optionally substituted piperdinyl, piperazinyl, and morpholinyl. 1 and Z 2 are each an optionally substituted 5-14 membered heteroaryl ring having 1-3 heteroatoms selected from N, O, and S.

[0128] In some embodiments, Z 1 and Z 2 are respectively -N + (M)3. In some embodiments, Z 1 and Z 2 are respectively -N + (C0-C6 aliphatic-R z )3. In some embodiments, Z 1 and Z 2 are respectively -N + (R z )3. In some embodiments, Z 1 and Z 2 are respectively -N + H3. In some embodiments, Z 1 and Z 2 are respectively -N + H(R z )2. In some embodiments, Z 1 and Z 2 are respectively -N + H(C1-C6 aliphatic)2. In some embodiments, Z 1 and Z 2 are respectively -N + (H)2CH3. In some embodiments, Z 1 and Z 2 are respectively -N + H(CH3)2. In some embodiments, Z 1 and Z 2 are respectively -N + (CH3)3.

[0129] In some embodiments, Z 1 and Z 2 are respectively -N + (R z)2-C1-C6 aliphatic-N + (R z )3. In some embodiments, Z 1 and Z 2 are respectively -N + (R z )(C1-C6 aliphatic-N + (R z ) 3) 2. In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.

[0130] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.

[0131] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.

[0132] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.

[0133] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is.

[0134] In some embodiments, Z 1 and Z2 are, respectively, [ka] is.

[0135] In some embodiments, Z 1 is an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 are each an optionally substituted 5-6 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 is an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 1 is selected from optionally substituted piperdinyl, piperazinyl, and morpholinyl.

[0136] In some embodiments, Z 1 -N + (M)3. In some embodiments, Z 1 -N + (C0-C6 aliphatic-R z )3. In some embodiments, Z 1 -N + (R z )3. In some embodiments, Z 1 -N + H3. In some embodiments, Z 1 -N + H(R z )2. In some embodiments, Z 1 -N + H(C1-C6 aliphatic)2. In some embodiments, Z 1 -N + (H)2CH3. In some embodiments, Z 1 -N + H(CH3)2. In some embodiments, Z 1 -N + (CH3)3.

[0137] In some embodiments, Z 1 -N + (R z )2-C1-C6 aliphatic-N + (R z )3. In some embodiments, Z 1 -N + (R z )(C1-C6 aliphatic-N + (R z )3)2.

[0138] In some embodiments, Z 1 teeth, [ka] is.

[0139] In some embodiments, Z 1 teeth, [ka] is.

[0140] In some embodiments, Z 1 teeth, [ka] is.

[0141] In some embodiments, Z 1 teeth, [ka] is.

[0142] In some embodiments, Z 1 teeth, [ka] is.

[0143] In some embodiments, Z1 teeth, [ka] is.

[0144] In some embodiments, Z 2 is an optionally substituted 5-14 membered heterocyclyl ring having 1-3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 are optionally substituted 5- to 6-membered heterocyclyl rings each having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 is an optionally substituted 6-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S. In some embodiments, Z 2 is selected from optionally substituted piperdinyl, piperazinyl, and morpholinyl.

[0145] In some embodiments, Z 2 -N + (M)3. In some embodiments, Z 2 -N + (C0-C6 aliphatic-R z )3. In some embodiments, Z 2 -N + (R z )3. In some embodiments, Z 2 -N + H3. In some embodiments, Z 2 -N + H(R z )2. In some embodiments, Z 2 -N + H(C1-C6 aliphatic)2. In some embodiments, Z 2 -N + (H)2CH3. In some embodiments, Z 2 -N + H(CH3)2. In some embodiments, Z 2 -N+ (CH3)3.

[0146] In some embodiments, Z 2 -N + (R z )2-C1-C6 aliphatic-N + (R z )3.

[0147] In some embodiments, Z 2 -N + (R z )(C1-C6 aliphatic-N + (R z )3)2.

[0148] In some embodiments, Z 2 teeth, [ka] is.

[0149] In some embodiments, Z 2 teeth, [ka] is.

[0150] In some embodiments, Z 2 teeth, [ka] is.

[0151] In some embodiments, Z 2 teeth, [ka] is.

[0152] In some embodiments, Z 2 teeth, [ka] is.

[0153] In some embodiments, Z 2 teeth, [ka] is.

[0154] Generally, as described herein, each M is independently —C-C aliphatic —R z , or -C0-C6 aliphatic -N + (R z In some embodiments, each M is a C-C aliphatic -R z In some embodiments, each M is -C0-C6 aliphatic-N + (R z )3. In some embodiments, each M is N + (R z In some embodiments, each M is -C1-C6 aliphatic-N + (R z In some embodiments, each M is N + (R z )3, and each R z is H, or C1-C6 aliphatic. In some embodiments, each M is N + (R z )3 and two or more R z together with the atoms to which they are attached form an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S.

[0155] Generally, as described herein, each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20or two or more R selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S; z can be taken together with the atoms to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0156] In some embodiments, each R z is H. In some embodiments, each R z is an optionally substituted C-C aliphatic. In some embodiments, each R z is an optionally substituted C3-C 20 In some embodiments, each R z is an optionally substituted C-C aryl. In some embodiments, each R z is an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S.

[0157] In some embodiments, each R z is an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S. In some embodiments, two or more R z can be taken together with the atom to which they are attached to form an optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S.

[0158] In some embodiments, two or more R z can be taken together with the atom to which they are attached to form an optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S.

[0159] In some embodiments, Z 1 R on the part z and Z 2 R on the part z can be taken together to form a 4- to 6-membered heterocycle having 1 to 3 heteroatoms selected from N, O, and S.

[0160] As used herein, a "cationic" moiety is a group that has a net positive charge. As used herein, an "ionizable" moiety is a group that may have a neutral charge at a certain pH, but may become charged (e.g., cationic) at a different pH. For example, in some embodiments, the ionizable moiety becomes cationic (i.e., positively charged) at physiological pH (e.g., a pH of about 7.4). Furthermore, in some embodiments, a cationic or ionizable moiety, Z, as described herein, 1 and Z 2 The moiety further comprises one or more suitable counterions (e.g., anions for each cationic or ionizable moiety). For example, in some embodiments, Z 1 and Z 2 The moieties include counterions that are halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates, and arylsulfonates.

[0161] In some embodiments, Z 1 and Z 2 The moieties include a counterion that is acetate (CH3COO-), chloride (Cl-), iodide (I-), bromide (Br-), or fluoride (F-). Reference to a particular counterion, such as those shown in Table 1, is intended to encompass a single charged moiety as well as all chemically feasible counterions.

[0162] In some embodiments, Z 1 and Z 2 are each independently [ka] [ka] is selected from.

[0163] In some embodiments, Z 1 and Z 2 are, respectively, [ka] is. As described herein, with respect to Formula I, A is A 1 If (i) each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both are -S-, not Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) 3 is not possible, and (ii) each R 1 and R 2、 is -(CH2)5-CH3, or -(CH2) 13 -CH3, not X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never be 3, and (iii) each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both of them cannot be -(CH2)2-NH-C(S)-NH-(CH2)2-, and Z 1 and Z 2 Both are -N+ (H) It is not 3, and (iv) Cy is not triazolyl.

[0164] In some embodiments, the compound of formula I is a compound of formula Id: [ka] or a pharmaceutically acceptable salt thereof, wherein n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6; a , Y 1 , Y 2 , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0165] In some embodiments, the oligosaccharide is a compound of formula Id: [ka] or a pharmaceutically acceptable salt thereof, wherein: Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each R c are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6; however, (i) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (ii) Each R 1 and R 2 is -(CH2)5-CH3, or -(CH2) 13 -CH3, not X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iii) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y2 Both of them cannot be -(CH2)2-NH-C(S)-NH-(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iv) Cy is a compound that is not triazolyl, or a pharmaceutically acceptable salt thereof.

[0166] In some embodiments, the compound of formula Id is a compound of formula Id-i: [ka] or a pharmaceutically acceptable salt thereof, wherein R a , Z 1 , and Z 2 are as described in classes and subclasses herein, both alone and in combination.

[0167] In some embodiments, the disclosure provides a compound in Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] Table 1-10 Table 1-11 Table 1-12 Table 1-13 Table 1-14 Table 1-15 Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-41

[0168] In some embodiments, provided compounds are provided and / or utilized in the form of a salt (e.g., a pharmaceutically acceptable salt). Reference to a compound provided herein is understood to include a reference to the salt, unless otherwise indicated. Furthermore, reference to a particular salt herein, e.g., in Table 1, is intended to include a reference to the free base form of the compound, so long as such compound is chemically feasible.

[0169] The exemplary compounds in Table 1 may contain a counterion (e.g., Cl - , I -Although the present invention is presented as specific salts (e.g., chloride salts, iodide salts, etc.) including cationic nitrogen groups (e.g., chloride salts, iodide salts, etc.), one of skill in the art will understand that any suitable counterion can be used in combination with the cationic nitrogen groups of Table 1. Thus, Table 1 is intended to encompass any positively charged nitrogen group associated with any chemically feasible counterion. Thus, the specific counterions provided above are provided by way of example and are not intended to be limiting.

[0170] In some embodiments, the present disclosure provides a composition comprising a compound selected from the following: [Table 2]

[0171] In some embodiments, the compositions described herein do not include JRL13 or JRL45.

[0172] Complexes and Compositions The compounds described herein, when incorporated into complexes with RNA, exhibit unexpectedly improved properties, particularly compared to previously described complexes. Furthermore, the present disclosure encompasses the insight that cationic and / or ionizable oligosaccharides are surprisingly useful for the delivery and targeted expression of certain therapeutic agents, e.g., nucleic acids, RNA.

[0173] Previous research on cationic oligosaccharides has focused on their use with DNA. Specifically, Carbajo-Gordillo et al. reported the use of certain oligosaccharides for DNA nanocomplexation and delivery. See Carbajo-Gordillo et al., Chem. Comm., 55:8227-8230 (2019). However, the oligosaccharide-DNA complexes reported by Carbajo-Gordillo et al., specifically when complexed with RNA, exhibit surprisingly different properties than those reported in the present application. For example, the compositions reported herein, in some embodiments, exhibit different in vivo behavior, such as targeting different systems in the body (i.e., causing increased expression of RNA relative to other parts of the body), and can be prepared with significantly reduced oligosaccharide to nucleic acid ratios. For at least these reasons, the complexes reported herein exhibit unexpected advantages over previously reported complexes.

[0174] For example, merely for comparison, as detailed in Example 2, pDNA complexed with JRL13 provides a complex that targets primarily to the liver (see Figure 3G). In contrast, complexing JRL13 with mRNA provides a complex that targets primarily to the lung (see Figure 3E). Similarly, complexing pDNA with JRL45 provides a complex that is expressed primarily in the lung (see Figure 3G). Instead, complexing JRL45 with mRNA targets the spleen, with only a small amount of the complex being expressed in the lung (see Figure 3E). These results are surprising. Previous studies have not suggested that complexing a particular oligosaccharide with DNA provides a composition for targeting one system, while complexing the same oligosaccharide with RNA provides a complex that targets a different system.

[0175] Furthermore, the compositions reported herein exhibit an improved ratio of cationic moieties, or ionizable cationic groups (on the oligosaccharide) to anionic moieties (on the nucleic acid). For example, as described herein, the complexes comprise a molar ratio of cationic groups to anionic groups, referred to as the "N / P ratio." As described herein, the N / P ratio refers to the molar ratio of cationic groups (or ionizable groups that can become cationic, referred to as the "N" in N / P) in a composition comprising a cationic oligosaccharide compound to anionic groups in a composition comprising mRNA (referred to as the "P" in N / P). The compositions reported herein exhibit a favorable ratio compared to previously reported complexes with DNA, thereby providing concentrated complexes for RNA delivery. For example, the Carbajo-Gordillo complex requires an N / P ratio of approximately 20:1 for effective targeting and delivery of pDNA. In contrast, the complexes of the present invention comprise an N / P ratio of less than 20:1. It is understood that the N / P ratio may also be expressed as a single digit, e.g., 5, and the numerical value set forth herein is referred to as a ratio of X:1. For example, an N / P of 5 is intended to refer to an N / P of 5:1. Similarly, an N / P of 10 is intended to refer to an N / P of 10:1, etc.

[0176] For example, in some embodiments, the N / P ratios of the complexes reported herein are less than 20:1. In some embodiments, the N / P ratios of the complexes reported herein are 15:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 12:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 10:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 5:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 2:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are 1:1 or less. In some embodiments, the N / P ratios of the complexes reported herein are from about 1:1 to about 15:1. In some embodiments, the N / P ratios of the complexes reported herein are from about 1:1 to about 12:1. In some embodiments, the N / P ratios of the complexes reported herein are from about 1:1 to about 10:1. In some embodiments, the N / P ratio of the complexes reported herein is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, or about 19:1.

[0177] In some embodiments, the complexes described herein have a diameter of about 30 nm to about 300 nm. In some embodiments, the complexes described herein have a diameter of about 50 nm to about 200 nm. In some embodiments, the complexes described herein have a diameter of about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 nm. In some embodiments, the complexes described herein have a diameter of about 30 nm to about 150 nm. In some embodiments, the complexes described herein have a diameter of about 30 nm to about 100 nm. In some embodiments, the complexes described herein have a diameter of less than 100 nm. In some embodiments, the complexes described herein have a diameter of about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nm.

[0178] In some embodiments, the compositions or conjugates described herein further comprise a pharmaceutically acceptable surfactant. In some embodiments, the pharmaceutically acceptable surfactant is selected from polysorbates (e.g., polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), polysorbate 60 (Tween 60), and polysorbate 80 (Tween 80)), poloxamers, and amphiphilic groups comprising a moiety selected from polyalkylene glycols (e.g., polyethylene glycol), poly(2-oxazoline), poly(2-methyl-2-oxazoline), polysarcosine, polyvinylpyrrolidone, and poly[N-(2-hydroxypropyl)methacrylamide], wherein the moiety comprises one or more C 12 -C 20 It is bonded to an aliphatic group.

[0179] In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075 to about 1:3. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075 to about 1:1.5. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:1. In some embodiments, the molar ratio of oligosaccharide to surfactant is about 1:0.0075, about 1:0.01, about 1:0.1, about 1:0.5, about 1:1, about 1:1.5, about 1:2, about 1:2.5, or about 1:3.

[0180] In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:3. In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:1.5. In some embodiments, the surfactant is a polysorbate. In some embodiments, the molar ratio of oligosaccharide to polysorbate is 1:0.0075 to 1:1. In some embodiments, the molar ratio of oligosaccharide to polysorbate is about 1:0.0075, about 1:0.01, about 1:0.1, about 1:0.5, about 1:1, about 1:1.5, about 1:2, about 1:2.5, or about 1:3.

[0181] In some embodiments, a complex comprising an oligosaccharide and a pharmaceutically acceptable surfactant has a diameter of about 30 nm to about 150 nm. In some embodiments, a complex described herein has a diameter of about 30 nm to about 100 nm. In some embodiments, a complex comprising an oligosaccharide and a pharmaceutically acceptable surfactant has a diameter of less than 100 nm. In some embodiments, a complex comprising an oligosaccharide and a pharmaceutically acceptable surfactant has a diameter of about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nm.

[0182] RNA In some embodiments, the complexes described herein comprise one or more oligosaccharide compositions and a nucleic acid. In some embodiments, the nucleic acid is RNA.

[0183] In some embodiments, the RNA applicable to the techniques described herein is single-stranded RNA. In some embodiments, the RNA disclosed herein is linear RNA. In some embodiments, the single-stranded RNA is non-coding RNA in that its nucleotide sequence does not contain an open reading frame (or its complementary strand). In some embodiments, the single-stranded RNA has a nucleotide sequence that encodes (or is the complementary strand of) a polypeptide or multiple polypeptides (e.g., epitopes) of the present disclosure.

[0184] In some embodiments, the RNA is or comprises siRNA, miRNA, or other non-coding RNA.

[0185] In many embodiments, the related RNAs comprise at least one open reading frame (ORF) (e.g., are mRNAs), in some embodiments, the related RNAs comprise a single ORF, and in some embodiments, the related RNAs comprise more than one ORF.

[0186] In some embodiments, the RNA comprises, for example, an ORF encoding a polypeptide of interest, or encoding multiple polypeptides of interest. In some embodiments, the RNA produced in accordance with the techniques provided herein comprises multiple ORFs (e.g., encoding multiple polypeptides). In some embodiments, the RNA produced in accordance with the techniques provided herein comprises a single ORF encoding multiple polypeptides. In some such embodiments, the polypeptide is or comprises an antigen or epitope (e.g., an associated antigen) thereof.

[0187] In some embodiments, an ORF for use in accordance with the present disclosure encodes a polypeptide that includes a signal sequence that is functional in mammalian cells, e.g., an endogenous signal sequence or a heterologous signal sequence. In some embodiments, the signal sequence directs secretion of the encoded polypeptide, and in some embodiments, the signal sequence directs transport of the encoded polypeptide to a defined cellular compartment, preferably the cell surface, the endoplasmic reticulum (ER), or an endosomal-lysosomal compartment.

[0188] In some embodiments, the ORF encodes a polypeptide that includes a multimerization element (e.g., a native or heterologous multimerization element). In some embodiments, an ORF that encodes a surface polypeptide (e.g., includes a signal sequence that directs surface localization) includes a multimerization element.

[0189] In some embodiments, the ORF encodes a polypeptide that includes a transmembrane element or domain.

[0190] In some embodiments, the ORF is codon-optimized for expression in a particular host, eg, a mammalian host, eg, a human cell.

[0191] In some embodiments, the RNA comprises unmodified uridine residues, and RNA comprising only unmodified uridine residues may be referred to as "uRNA." In some embodiments, the RNA comprises one or more modified uridine residues, and in some embodiments, such RNA (e.g., RNA comprising fully modified uridine residues) is referred to as "modRNA." In some embodiments, the RNA may be a self-amplifying RNA (saRNA). In some embodiments, the RNA may be a trans-amplifying RNA (taRNA) (see, e.g., WO2017 / 162461).

[0192] In some embodiments, the relevant RNA comprises a portion encoding a polypeptide or a portion encoding multiple polypeptides. In certain embodiments, such a portion or portions may encode a polypeptide or polypeptides that is or includes a biologically active polypeptide or portion thereof (e.g., an enzyme or cytokine, or a therapeutic protein such as a replacement protein or antibody or portion thereof). In certain embodiments, such a portion or portions may encode a polypeptide or polypeptides that is or includes an antigen (or epitope thereof), cytokine, enzyme, etc. In some embodiments, the encoded polypeptide or polypeptides may be or include one or more neoantigens or neoepitopes associated with a tumor. In some embodiments, the encoded polypeptide or polypeptides may be or include one or more antigens (or epitopes thereof) of an infectious agent (e.g., a bacterium, fungus, virus, etc.). In certain embodiments, the encoded polypeptide may be a variant of a wild-type polypeptide.

[0193] In some embodiments, the single-stranded RNA (e.g., mRNA) may include a region encoding a secretion signal (e.g., a region encoding a secretion signal that enables the encoded target entity or entities to be secreted upon translation by the cell). In some embodiments, such a region encoding a secretion signal may be or include a non-human secretion signal. In some embodiments, such a region encoding a secretion signal may be or include a human secretion signal.

[0194] In some embodiments, a single-stranded RNA (e.g., an mRNA) can include at least one non-coding element (e.g., to improve RNA stability and / or translation efficiency). Examples of non-coding elements include, but are not limited to, a 3' untranslated region (UTR), a 5' UTR, a cap structure (e.g., in some embodiments, an enzymatically added cap; in some embodiments, a co-transcriptional cap), a polyadenine (polyA) tail (e.g., in some embodiments, can be or include 100 or more A residues, and / or in some embodiments can include one or more "interrupt" [i.e., non-A] sequence elements), and any combination thereof. Exemplary embodiments of such non-coding elements can be found, for example, in WO2011015347, WO2017053297, US10519189, US10494399, WO2007024708, WO2007036366, WO2017060314, WO2016005324, WO2005038030, WO2017036889, WO2017162266, and WO2017162461, each of which is incorporated herein by reference in its entirety.

[0195] form At least four forms of unmodified uridine containing RNA useful in pharmaceutical compositions (e.g., immunogenic compositions or vaccines) have been developed: mRNA (uRNA), nucleoside-depleted mRNA (modRNA), self-amplifying mRNA (saRNA), and trans-amplifying RNA.

[0196] Characteristics of the unmodified uridine platform may include, for example, one or more of inherent adjuvant effect, good tolerability and safety, and potent antibody and T cell responses.

[0197] The characteristics of the modified uridine (e.g., pseudouridine) platform may include reduced adjuvant effect, blunted immune sensor activation capacity, and thus increased antigen expression, good tolerability and safety, and strong antibody and CD4+ T cell responses. As described herein, the present disclosure provides insight that such strong antibody and CD4+ T cell responses may be particularly useful for vaccination.

[0198] Characteristics of a self-amplifying platform may include, for example, long-term polypeptide (eg, protein) expression, good tolerability and safety, and high potential for efficacy at very low vaccine doses.

[0199] In some embodiments, a self-amplifying platform (e.g., RNA) comprises two nucleic acid molecules, one nucleic acid molecule encoding a replicase (e.g., a viral replicase) and another nucleic acid molecule capable of being replicated by the replicase in trans (a trans-replication system) (e.g., a repcon). In some embodiments, a self-amplifying platform (e.g., RNA) comprises multiple nucleic acid molecules, the nucleic acids encoding multiple replicases and / or replicas.

[0200] In some embodiments, the trans-replication system comprises the presence of both nucleic acid molecules within a single host cell.

[0201] In some such embodiments, the nucleic acid encoding the replicase (e.g., a viral replicase) is unable to autonomously replicate in a target cell and / or target organism, hi some such embodiments, the nucleic acid encoding the replicase (e.g., a viral replicase) lacks at least one conserved sequence element important for (+)-strand template-based (-)-strand synthesis and / or (+)-strand template-based (-)-strand synthesis.

[0202] In some embodiments, the self-amplifying RNA comprises a 5'-cap, and in some trans-replication systems, at least the RNA encoding the replicase is capped. Without wishing to be bound by any one theory, it has been found that the 5'-cap can be important for high-level expression of the gene of interest in trans.

[0203] In some embodiments, the self-amplifying platform does not require viral particle propagation (e.g., is not associated with undesired viral particle formation). In some embodiments, the self-amplifying platform is incapable of forming viral particles.

[0204] In some embodiments, the RNA may contain an internal ribosome entry site (IRES) element. In some embodiments, the RNA does not contain an IRES site, specifically, in some embodiments, the saRNA does not contain an IRES site. In some such embodiments, translation of the gene of interest and / or replicase is not driven by an IRES element. In some such embodiments, the IRES element is replaced with a 5'-cap. In some such embodiments, the replacement with a 5'-cap does not affect the sequence of the polypeptide encoded by the RNA.

[0205] In some embodiments, the complexes described herein comprise a modRNA, a saRNA, a taRNA, or a uRNA. In some embodiments, the complexes comprise a modRNA. In some embodiments, the complexes comprise a saRNA. In some embodiments, the complexes comprise a taRNA. In some embodiments, the complexes comprise a uRNA.

[0206] How to use The conjugates described herein are useful for the treatment and prevention of the diseases, disorders, and conditions described herein in subjects. In some embodiments, the disclosure provides a method of treating a disease, disorder, or condition comprising administering to a patient a conjugate described herein. In some embodiments, the disclosure provides a use of a conjugate described herein for the treatment of a disease, disorder, or condition. In some embodiments, the disease, disorder, or condition is an infectious disease, cancer, an autoimmune disease, or a rare disease.

[0207] In some embodiments, the infectious disease is caused by or associated with a viral pathogen. In some embodiments, the viral pathogen is from a family selected from the families Poxviridae, Rhabdoviridae, Filoviridae, Paramyxoviridae, Hepadnaviridae, Coronaviridae, Caliciviridae, Picornaviridae, Reoviridae, Retroviridae, and Orthomyxoviridae. In some embodiments, the infectious disease is caused by or associated with a virus selected from SARS-CoV-2, influenza, Crimean-Congo hemorrhagic fever (CCHF), Ebola virus, Lassa virus, Marburg virus, HIV, Nipah virus, and MERS-CoV.

[0208] In some embodiments, the infectious disease is caused by or associated with a bacterial pathogen. In some embodiments, the bacterial pathogen is Actinomyces israelii, bacillus antracis, Bacteroides fragilis, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campolobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium idphteriae, Ehrlichia canis, Ehrlichia chaffeensis, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Pseudomonas aeruginosa, Nocardia asteroids, Rickettsia ricektssii, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Shigelladysenteriae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Treponema pallidum, Vibrio cholerae, and Yersinia pestis.

[0209] In some embodiments, the infectious disease is caused by or associated with a parasite, hi some embodiments, the parasite is of a family selected from Plasmodium, Leishmania, Cryptosporidium, Entamoeba, Trypanosomas, Schistosomes, Ascaris, Echinococcus, and Taeniidae.

[0210] In some embodiments, the disease, disorder, or condition is cancer, hi some embodiments, the cancer is selected from bladder cancer, breast cancer, colorectal cancer, renal cancer, lung cancer, lymphoma, melanoma, oral / oropharyngeal cancer, pancreatic cancer, prostate cancer, thyroid cancer, and uterine cancer.

[0211] In some embodiments, the disease, disorder, or condition is a genetic disorder. In some embodiments, the genetic disorder is associated with a gain-of-function or loss-of-function mutation.

[0212] In some embodiments, the disease, disorder, or condition is an autoimmune disease, hi some embodiments, the autoimmune disease is selected from Addison's disease, celiac disease, rheumatoid arthritis, lupus, inflammatory bowel disease, dermatomyositis, multiple sclerosis, diabetes, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis, pernicious anemia, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, and Sjogren's syndrome vasculitis.

[0213] In some embodiments, the disease, disorder, or condition is a rare disease. As described herein, a rare disease refers to a life-threatening or chronically debilitating disease that has a very low incidence rate (e.g., less than 1 / 2000 people) and requires a special combination of efforts to address it.

[0214] In some embodiments, the present disclosure provides conjugates that can selectively target specific systems in the body. As used herein, reference to "targeting" a specific system refers to causing increased expression of RNA derived from the cargo in the conjugate in the desired system. For example, in some embodiments, the conjugates described herein can selectively target the lung, liver, spleen, heart, brain, lymph nodes, bladder, kidney, and pancreas. As described herein, a conjugate "selectively targets" an organ if a single target expresses mRNA at 65% or more of the amount expressed in other organs after administration (e.g., 65% or more of the mRNA in the entire body is expressed from a single organ, with the remaining 35% distributed among one or more different organs). In some embodiments, the conjugates described herein selectively target the lung. In some embodiments, the conjugates described herein selectively target the liver. In some embodiments, the conjugates described herein selectively target the spleen. In some embodiments, the conjugates described herein selectively target the heart.

[0215] Method of delivery The present disclosure provides, inter alia, a conjugate (e.g., a pharmaceutical composition or pharmaceutical formulation referred to herein) administered to a subject. For example, in some embodiments, the conjugate is administered as monotherapy. In some embodiments, the conjugate is administered as part of a combination therapy. In some embodiments, the concentration of total RNA (e.g., the total concentration of all of the one or more RNA molecules) in the pharmaceutical compositions described herein is from about 0.01 mg / mL to about 0.5 mg / mL, or from about 0.05 mg / mL to about 0.1 mg / mL.

[0216] Pharmaceutical compositions, as used herein, may further comprise pharmaceutically acceptable excipients, including any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersing or suspending aids, surface active agents, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, etc., suitable for the particular dosage form desired. Remington's The Science and Practice of Pharmacy, 21st Edition, A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety) discloses various excipients used in formulating pharmaceutical compositions and known techniques for their preparation. Except insofar as any conventional excipient vehicle is incompatible with the substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated within the scope of the present disclosure.

[0217] In some embodiments, the excipients are approved for human and veterinary use. In some embodiments, the excipients are approved by the U.S. Food and Drug Administration. In some embodiments, the excipients are pharmaceutical grade. In some embodiments, the excipients meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.

[0218] Pharmaceutically acceptable excipients used in the preparation of pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and / or granulating agents, surface active agents and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants, and / or oils. Such excipients may optionally be included in the pharmaceutical preparation. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweeteners, flavoring agents, and / or perfumes may be present in the composition, according to the discretion of the formulator.

[0219] General considerations in the formulation and / or manufacture of pharmaceutical products can be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).

[0220] In some embodiments, the pharmaceutical compositions provided herein may be formulated using one or more pharmaceutically acceptable carriers or diluents, as well as any other known adjuvants and excipients, according to conventional techniques, e.g., as disclosed in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005, which is incorporated herein by reference in its entirety.

[0221] The pharmaceutical conjugates and compositions described herein can be administered by any suitable method known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration may depend on several factors, including, but not limited to, the stability and / or pharmacokinetics and / or pharmacodynamics of the pharmaceutical compositions described herein.

[0222] In some embodiments, the pharmaceutical compositions described herein are formulated for parenteral administration, which typically includes modes of administration other than enteral and topical administration by injection, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0223] In some embodiments, the pharmaceutical compositions described herein are formulated for intravenous administration. In some embodiments, pharmaceutically acceptable carriers that may be useful for intravenous administration include sterile aqueous solutions or dispersions and sterile powders for preparing sterile injectable solutions or dispersions.

[0224] In certain embodiments, the pharmaceutical compositions described herein are formulated for subcutaneous (sc) administration. In certain embodiments, the pharmaceutical compositions described herein are formulated for intramuscular (im) administration.

[0225] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, dispersions, powders (e.g., lyophilized powders), microemulsions, lipid nanoparticles, or other ordered structures suitable to high drug concentrations. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In many cases, it is preferable to include an isotonic agent, for example, a polyalcohol such as sugar, mannitol, sorbitol, or sodium chloride, in the composition. In some embodiments, prolonged absorption of injectable compositions can be achieved by including an agent that delays absorption, for example, monostearate salts and gelatin.

[0226] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by microfiltration sterilization.

[0227] In some embodiments, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0228] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions described herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0229] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the presence of microorganisms can be ensured both by sterilization procedures and by the inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents such as sugars and sodium chloride in the pharmaceutical compositions described herein. In addition, prolonged absorption of injectable pharmaceutical forms can be achieved by including agents that delay absorption, such as aluminum monostearate and gelatin.

[0230] Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing into association the active ingredient(s) with a diluent or other excipient and / or one or more other accessory ingredients, and then, if necessary and / or desired, shaping and / or packaging the product into a desired single- or multi-dosage unit.

[0231] Pharmaceutical compositions according to the present disclosure may be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition comprising a predetermined amount of at least one RNA product produced using the systems and / or methods described herein.

[0232] In some embodiments, the active agent that can be included in the pharmaceutical compositions described herein is or includes a therapeutic agent administered in a combination therapy described herein. The pharmaceutical compositions described herein can be administered in combination therapy, i.e., in conjunction with other agents. In some embodiments, such a therapeutic agent can include an agent that depletes or functionally inactivates regulatory T cells. For example, in some embodiments, the combination therapy can include a provided pharmaceutical composition and at least one immune checkpoint inhibitor.

[0233] In some embodiments, the pharmaceutical compositions described herein may be administered in conjunction with radiation therapy and / or autologous peripheral stem cell or bone marrow transplantation.

[0234] In some embodiments, the pharmaceutical compositions described herein can be frozen to allow for long-term storage.

[0235] Although the description of pharmaceutical compositions provided herein is directed primarily to pharmaceutical compositions suitable for administration to humans, it will be understood by those skilled in the art that such compositions are generally suitable for administration to animals of all kinds. Modifications of pharmaceutical compositions suitable for administration to humans to make them suitable for administration to a variety of animals are well understood, and an ordinarily skilled veterinary pharmacologist can design and / or implement such modifications with no more than routine experimentation, if any.

[0236] Methods of preparing the compositions described herein As described herein, the present disclosure provides, inter alia, a method for preparing an oligosaccharide of formula II, comprising: [ka] In the presence of an acid, a compound of formula III [ka] with a compound of formula IV, [ka] During the ceremony, Each R a is optionally substituted -C1-C 20 is aliphatic, Z 1 is an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Z a -PG 1 But Z 1 and one R z But, PG 1 is substituted with a group, PG 1 is a suitable nitrogen protecting group.

[0237] In some embodiments, the method of preparing a compound of Formula III comprises contacting a compound of Formula V with an acid; [ka] and then contacting the resulting product with CSCl2 to obtain a compound of formula III, wherein PG 2 is a suitable acid-sensitive nitrogen protecting group.

[0238] In some embodiments, the method of preparing a compound of formula V comprises reacting a compound of formula VI with [ka] contacting with a compound of formula VII [ka] to obtain a compound of formula V.

[0239] In some embodiments, the method of preparing a compound of formula VI comprises reacting a compound of formula VIII with [ka] contacting with a compound of formula IX [ka] to obtain a compound of formula VI, wherein LG is a suitable leaving group. In some embodiments, PG 1 and P.G. 2 are each independently selected from Boc (tert-butoxycarbonyl), Fmoc (fluorenylmethyloxycarbonyl), Cbz (benzylchloroformate), Troc (2,2,2-trichloroethoxycarbonyl), trityl (triphenylmethyl), phthalimide, tetrachlorophthalimide, and trifluoroacemide.

[0240] In some embodiments, LG is selected from iodo, bromo, chloro, methylsulfonate, trichloromethylsulfonate, and p-toluenesulfonate.

[0241] Illustrative Embodiments The following numbered embodiments are non-limiting examples of certain aspects of the present disclosure. Embodiment 1. A compound of Formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein: A is A 1 , A 2 , or A 3 and [ka] R 1 and R 2 each independently, in each instance, H, R a , and -C(O)-R a Selected from R 1 or R 2 At least one instance of is not H, Each R a But independently, C1-C 20 Aliphatic, C3-C 20 cycloaliphatic, C5-C6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But there is one or more R b optionally replaced by Each R b are independently halogen, -N3, -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c , and -NHC(O)NHR c is selected from Each Rc are independently optionally substituted C-C 20 Aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S- and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently replaced with -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, -C(O)NHSO2-, -SONHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO2-; each Cy independently represents an optionally substituted C3-C 14 cycloaliphatic, a 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S, and an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; Z 1 and Z 2 each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z, or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5; However, A is A 1 If (i) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (ii) Each R 1 and R 2 is -(CH2)5-CH3, or -(CH2) 13 -CH3, not X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both cannot be -(CH2)2-, and Z 1 and Z 2 Both are -N +(H) It will never become 3, (iii) Each R 1 and R 2 But instead of -CO-(CH2)4-CH3, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both of them cannot be -(CH2)2-NH-C(S)-NH-(CH2)2-, and Z 1 and Z 2 Both are -N + (H) It will never become 3, (iv) The compound or a pharmaceutically acceptable salt thereof, wherein Cy is not triazolyl. Embodiment 2. The compound is a compound of formula Ia: [ka] or a pharmaceutically acceptable salt thereof. Embodiment 3. The compound is a compound of formula Ib: [ka] or a pharmaceutically acceptable salt thereof. Embodiment 4. The compound is a compound of formula Ic: [ka] or a pharmaceutically acceptable salt thereof. Embodiment 5.R 1 and R 2 are each independently R a , and -C(O)-R a Selected from R a But C1-C 20 The compound of any one of embodiments 1-4, which is aliphatic. Embodiment 6.R 1 and R 2 are -C(O)-R, respectively. a and R a But C1-C 14The compound of any one of embodiments 1-5, which is aliphatic. Embodiment 7. Each R a But C5-C 10 The compound of any one of embodiments 1-6, which is a straight chain alkyl. Embodiment 8.R 1 and R 2 are -C(O)-R, respectively. a and each R a But independently, [ka] 2. The compound of embodiment 1, selected from: Embodiment 9.X 1 and X 2 The compound of any one of embodiments 1-8, wherein each is —S—. Embodiment 10.Y 1 and Y 2 However, C1-C 10 Aliphatic, C0-C4-aliphatic-NHC(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-NHC(S)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(O)NH-C0-C4 aliphatic, C0-C4-aliphatic-C(S)NH-C0-C4 aliphatic A compound according to any one of embodiments 1 to 9, selected from aliphatic, C0-C4-aliphatic-NHC(O)-C0-C4 aliphatic, C0-C4-aliphatic-NHSO2-C0-C4 aliphatic, and C0-C4-aliphatic-C(O)-C0-C4 aliphatic. Embodiment 11.Y 1 and Y 2 and R are each C1-C4 aliphatic -NHC(S)NH-C1-C4 aliphatic. Embodiment 12.Y 1 and Y 2 and n is each —CH 2 —CH 2 —NHC(S)NH—CH 2 —CH 2 —. Embodiment 13. Part X 1 -Y 1 -Z 1 but, [ka] 13. The compound of any one of embodiments 1-12, wherein Embodiment 14. Part X 2 -Y 2 -Z 2 but, [ka] 14. The compound of any one of embodiments 1-13, wherein Embodiment 15.Z 1 and Z 2 are each independently N + (M)3, [ka] 15. The compound of any one of embodiments 1-14, selected from: Embodiment 16.Z 1 and Z 2 However, each independently, [ka] [ka] 15. The compound of any one of embodiments 1-14, selected from: Embodiment 17. The oligosaccharide is a compound of formula Id: [ka] or a pharmaceutically acceptable salt thereof, wherein n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6. Embodiment 18. The oligosaccharide is a compound of formula Id-i: [ka] or a pharmaceutically acceptable salt thereof. Embodiment 19. The compound of any one of embodiments 1-18, further comprising one or more suitable counterions. Embodiment 20. The compound of embodiment 1, wherein the compound is selected from Table 1. Embodiment 21. A complex comprising the compound according to any one of embodiments 1 to 20 and a nucleic acid. Embodiment 22. The complex of embodiment 21, wherein the nucleic acid is RNA. Embodiment 23. The complex of embodiment 22, wherein the RNA is modRNA, saRNA, taRNA, or uRNA. Embodiment 24. A conjugate according to embodiment 22 or 23, wherein the N / P ratio is less than 20:1. Embodiment 25. The conjugate of embodiment 24, wherein the N / P ratio is 12:1 or less. Embodiment 26. The complex of any one of embodiments 21 to 25, wherein the complex has a diameter of about 30 nm to about 300 nm. Embodiment 27. The complex of any one of embodiments 21 to 26, wherein the complex has a diameter of about 50 nm to 200 nm. Embodiment 28. The complex of any one of embodiments 21 to 27, further comprising a pharmaceutically acceptable surfactant. Embodiment 29. The complex of embodiment 28, wherein the pharmaceutically acceptable surfactant is a polysorbate. Embodiment 30. The conjugate of embodiment 28 or 29, wherein the molar ratio of the compound to the pharmaceutically acceptable surfactant is from about 1:0.0075 to about 1:3. Embodiment 31. A method of increasing or causing an increase in expression of RNA in a target in a subject, the method comprising administering to the subject a complex of any one of embodiments 21 to 30. Embodiment 32. The method of embodiment 31, wherein the target is selected from lung, liver, spleen, heart, brain, lymph nodes, bladder, kidney, and pancreas. Embodiment 33. A method of treating a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate of any one of embodiments 21 to 30. Embodiment 34. The method of embodiment 33, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease. Embodiment 35. The method of any one of embodiments 31 to 34, wherein the conjugate is administered intramuscularly. Embodiment 36. The method of embodiment 35, wherein the complex is 50 nm to 100 nm in diameter. Embodiment 37. The method of any one of embodiments 31 to 34, wherein the conjugate is administered subcutaneously. Embodiment 38. Use of a compound according to any one of embodiments 1 to 20 in medicine. Embodiment 39. Use of the conjugate according to embodiment 21 in medicine. Embodiment 40. Use of a complex according to embodiment 21 for increasing or causing an increase in the expression of RNA in a target. Embodiment 41. Use of the conjugate of embodiment 21 for the treatment of a disease, disorder, or condition. Embodiment 42. The use of embodiment 41, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease. Embodiment 43. A method for preparing an oligosaccharide of formula II, comprising: [ka] In the presence of an acid, a compound of formula III [ka] with a compound of formula IV, [ka] During the ceremony, Each R a is optionally substituted -C1-C 20 is aliphatic, Z 1 and Z 2each independently represents an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; -N + (M)3, [ka] is a cationic or ionizable group selected from Each M is independently -C0-C6 aliphatic -R z , or -C0-C6 aliphatic -N + (R z )3, Each R z are independently H, optionally substituted C1-C6 aliphatic, optionally substituted C3-C 20 selected from cycloaliphatic, optionally substituted C5-C6 aryl, optionally substituted 3-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4-12 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Z a -PG 1 But Z 1 and one R z But, PG 1 is substituted with a group, PG 1 is a suitable nitrogen protecting group; However, Z 1 and Z 2 Both are -N + (H) The method as described above, wherein the result is not 3. Embodiment 44. First contacting a compound of formula V with an acid, [ka] and then contacting the resulting product with CSC1 to obtain a compound of formula III; In the ceremony, P.G. 2 44. The method of embodiment 43, wherein: is a suitable acid-sensitive nitrogen protecting group. Embodiment 45. A compound of Formula VI is [ka] contacting with a compound of formula VII [ka] 45. The method of embodiment 44, comprising obtaining a compound of formula V: Embodiment 46. A compound of Formula VIII is [ka] contacting with a compound of formula IX [ka] obtaining a compound of formula VI, 46. ​​The method of embodiment 45, wherein LG is a suitable leaving group.

[0242] The foregoing is a description of certain non-limiting embodiments of the subject matter described herein. Accordingly, it should be understood that the embodiments described herein are merely exemplary of the subject matter reported herein. Reference to details of the illustrated embodiments is not intended to limit the scope of the claims, which themselves recite those features deemed essential.

[0243] The systems and methods of the claimed subject matter are intended to encompass variations and adaptations developed using information from the embodiments described herein. Adaptations, modifications, or both of the systems and methods described herein may be performed by those skilled in the relevant art.

[0244] Throughout the description, when a system is described as having, including, or comprising particular components, or a method is described as having, including, or comprising particular steps, it is further contemplated that there are systems within the inventive subject matter that consist essentially of or consist of the recited components, and that there are methods within the inventive subject matter that consist essentially of or consist of the recited processing steps.

[0245] It should be understood that the order of steps or order for performing certain actions is immaterial so long as any embodiment of the subject matter described herein remains operable. Moreover, two or more steps or actions may be conducted simultaneously.

[0246] Acknowledgments The applicants would like to thank the Consejo Superior de Investigaciones Cientificas and FIUS / UNIVERSITY OF SEVILLE / for their support and contribution to the development of this study. [Example]

[0247] The examples provided herein document and support certain aspects of the present disclosure, but are not intended to limit the scope of any claims. The following non-limiting examples are provided to further illustrate certain teachings provided by the present disclosure. In light of this application, those skilled in the art will understand that various modifications can be made to the specific embodiments shown in these examples without departing from the spirit and scope of the teachings of the present invention.

[0248] In the examples below, the following abbreviations may be used: aq. (aqueous); ACN (acetonitrile); CSA (camphorsulfonic acid); d (days or number of days); Da / kDa (daltons / kilodaltons); DCM (dichloromethane); d# (number of days, e.g., d0 = day 0, d20 = day 20); ddH2O (double-distilled H2O); DEA (diethylamine); DHP (dihydropyran); DMF (N,N-dimethylformamide); DIPEA (N,N-diisopropylethylamine) );DMAP (4-dimethylaminopyridine);DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane);DODMA (1,2-dioleyloxy-3-dimethylaminopropane), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine);DMSO (dimethyl sulfoxide);EA (ethyl acetate);ee (enantiomeric excess);equiv. (equivalents);ethanol (EtOH);h or hr (hours or hours) time; Hex (hexane); HPLC (high-performance liquid chromatography); IPA (isopropyl alcohol); im (intramuscular); iv (intravenous); KHMDS (potassium bis(trimethylsilyl)amide); LAH (lithium aluminum hydride); LCMS (liquid chromatography-mass spectrometry); LDA (lithium diisopropylamide); LiHMDS (lithium bis(trimethylsilyl)amide); MeOH (methanol); min (minutes or minutes); NMR (nuclear magnetic resonance); Pd / C (palladium on carbon); PEI (polyethyleneimine); PPhO (triphenylphosphine oxide); Pt / C (platinum on carbon); rb (round-bottom); Rf (retention); rt or RT (room temperature); sc (subcutaneous); SM (starting material); TEA (triethylamine); THF (tetrahydrofuran); THP (tetrahydropyran); TLC (thin-layer chromatography); TsOH (p-toluenesulfonic acid or tosylate); and UV (ultraviolet).

[0249] Example 1 - Conjugates and methods for preparing the conjugates The following conjugates were prepared using various embodiments described herein: [Table 3]

[0250] This example describes certain complexes comprising oligosaccharides and nucleic acids (e.g., RNA). In the examples provided, paO refers to "polycationic amphiphilic oligosaccharides."

[0251] As described herein, the N / P ratio was determined by calculating the molar ratio of positive charges (e.g., protonation or protonatable or permanent charges on the nitrogen atom of amines / guanidines (N)) to cationic charges (phosphates) on RNA (P). Therefore, the amount of RNA and oligosaccharides in a particular complex is determined by the N / P ratio calculation and the desired final RNA concentration of the formulation. The complexation itself is generated by asymmetric volumetric mixing of an RNA-containing solution and an oligosaccharide-containing solution. For the RNA solution, the required concentration of RNA was prepared by diluting appropriate volumes of ddHO, RNA stock, and buffer (6x). The oligosaccharide-containing solution was prepared in a separate tube by diluting the oligosaccharides in DMSO to the required concentration. RNA complexation was performed by mixing the RNA-oligosaccharide phase at a 9:1 volume ratio (RNA:oligosaccharide). The formulated complex was incubated at room temperature for 5-10 minutes for stabilization. The buffer used for formulation in all experiments was MGB (MES buffered glucose (10 mM MES, pH 6.1, 5% D-glucose)).

[0252] The size of the complexes described in this example was analyzed by a DynaPro PlateReader II using dynamic light scattering (DLS) to calculate the hydrodynamic diameter of the complexes. Formulations were measured by diluting samples to 0.0125 mg / mL RNA in 120 μl of 5% MGB (10 mM MES, pH 6.1, 5% D-glucose) in wells of a 96-well plate. Ten acquisitions were recorded per well, each lasting 5 seconds.

[0253] Example 2 - Intravenous Example Example 2a - Targeting Lung Expression Nine female BALB / c mice were divided into three study groups. All groups received the same amount of formulated luciferase-encoding modRNA (5 μg) intravenously (tail vein). Six hours later, ex vivo luciferase expression was quantified from each isolated organ. All groups received modRNA formulated in JRL13. The modRNA was formulated with N / P1, N / P3, N / P6, or N / P12. All N / P ratios were calculated based on the oligosaccharide-to-RNA charge ratio. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide-containing solution was 9:1 (v:v) in all cases. The formulations were characterized prior to injection to confirm their hydrodynamic diameter and zeta potential. Figure 1A is a plot showing the hydrodynamic diameter of an exemplary composition comprising a particular oligosaccharide and modRNA formulated at different N / P ratios. Figure 1B is a plot showing the zeta potential of an exemplary oligosaccharide at different N / P ratios. Figure 1C is a bar graph showing the quantified ex vivo luminescence 6 hours after injection of an exemplary composition comprising modRNA in different organs and at different N / P ratios.

[0254] Organ-selective expression of modRNA was found to be strongly dependent on the N / P ratio of the JRL13 formulation. At N / P 1, signal was observed in the spleen, but as N / P increased, the biodistribution ratio shifted completely to the lung. At N / P 3, there was mixed expression in the lung and spleen, and at N / P 6, >90% of the signal was from the lung. No differences in surface charge or hydrodynamic diameter were observed in Figures 1A and 1B. Furthermore, increasing N / P above 6 did not alter biodistribution.

[0255] The effects of altering the aliphatic chain in JRL13 were also investigated to elucidate the correlation between these factors in the targeting profile of JRL13. Six female BALB / c mice were divided into two study groups. All groups received the same amount of formulated luciferase-encoding modRNA (5 μg) intravenously (tail vein). Six hours later, ex vivo luciferase expression was quantified from each isolated organ. One group received RNA formulated with JRL13, while the other group received RNA formulated with an additional JRL13 derivative in which the aliphatic chain was replaced with a longer chain, e.g., C10, as observed with JLJB617. All groups received compositions containing modRNA formulated with N / P6. The N / P ratio was calculated based on the oligosaccharide-to-RNA charge ratio. Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide-containing solution in all cases. Figure ID is a bar graph showing the hydrodynamic diameter of exemplary compositions containing modRNA. Figure IE is a bar graph showing the zeta potential of exemplary compositions. Figure IF is a bar graph showing the quantified ex vivo luminescence 6 hours after injection of exemplary compositions containing modRNA in different organs.

[0256] The introduction of longer aliphatic chains (e.g., C10, as observed with JLJB617) did not affect the overall surface charge or hydrodynamic diameter of the complexes formed by JLJB617 compared with JRL13. However, biodistribution was affected by the introduction of longer aliphatic chains (see Figure 1F). JLR13 showed >90% lung-derived modRNA expression, whereas this was reduced to only 21% with JLJB617. In parallel, spleen expression increased from 5% with JRL13 to 70% with JLJB617.

[0257] The influence of the disaccharide scaffold on the targeting profile of JRL13 was investigated. Six female BALB / c mice were divided into two study groups. All groups received the same amount of formulated luciferase-encoding modRNA (5 μg) intravenously (tail vein). Six hours later, ex vivo luciferase expression was quantified from each isolated organ. One group received RNA formulated with JRL13, and the other group received RNA formulated with a JRL13 analog, in which trehalose was replaced by sucrose—JLJB6 26—. All groups received modRNA formulated with N / P3. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide-containing solution was 9:1 (v:v) in all cases. Figure 1G is a bar graph showing the hydrodynamic diameter of exemplary compositions comprising modRNA. Figure 1H is a bar graph showing the zeta potential of exemplary oligosaccharide compositions. Figure 1I is a bar graph showing quantified ex vivo luminescence in the spleen 6 hours after injection of compositions comprising modRNA.

[0258] Example 2b - Targeting to the body or spleen In this example, JLJB604 was formulated with modRNA at two different N / P ratios: 3 and 6. Biodistribution of luciferase-encoding modRNA was analyzed based on organ expression. Six female BALB / c mice were divided into two study groups. All groups received the same amount of formulated luciferase-encoding modRNA (5 μg) intravenously (tail vein). Six hours later, ex vivo luciferase expression was quantified from each isolated organ. All groups received JLJB604-formulated modRNA, which was formulated at N / P3 or N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide-containing solution was 9:1 (v:v) in all cases. The formulations were characterized prior to injection to confirm their hydrodynamic diameter and zeta potential. Figure 2A is a bar graph showing the hydrodynamic diameter of exemplary compositions containing modRNA formulated at different N / P ratios. Figure 2B is a bar graph showing the zeta potential of exemplary compositions at different N / P ratios. Figure 2C is a bar graph showing the quantified ex vivo luminescence 6 hours after injection of exemplary compositions containing modRNA in different organs and at different N / P ratios.

[0259] Example 2c - Targeting spleen expression In this example, modRNA was directly formulated using a combination of JLJB619 and JLJB604 at an N / P ratio of 6, compared to a formulation currently in clinical development and widely published for mRNA expression in the spleen (a formulation containing F12, a 3:1 molar ratio of DOTMA:DOPE, and an N / P ratio of 0.65). Biodistribution of luciferase-encoding modRNA was analyzed based on organ expression. Six female BALB / c mice were divided into two study groups. All groups received the same amount of formulated luciferase-encoding modRNA (5 μg) intravenously (i.v.) via the tail vein. Six hours later, ex vivo luciferase expression from each isolated organ was quantified. The first group received modRNA formulated with an equimolar mixture of JLJB619 and JLJB604, but the modRNA was ultimately formulated at an N / P ratio of 6. The formulations were prepared in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide solution. The second group received modRNA formulated in F12, with the N / P ratio calculated based on the cation:anion charge between DOTMA and RNA. F12 was prepared in ddH2O with a final NaCl concentration of 0.112 mM and a final RNA concentration of 0.05 mg / ml. All formulations were characterized prior to injection to confirm hydrodynamic diameter and zeta potential. Figure 2D is a bar graph showing the hydrodynamic diameter of exemplary compositions containing modRNA. Figure 2E is a bar graph showing the zeta potential of exemplary compositions. Figure 2F is a bar graph showing quantified ex vivo luminescence in the spleen 6 hours after injection of a composition containing modRNA. FIG. 2G is a bar graph showing the quantified ex vivo luminescence in different organs 6 hours after injection of a composition containing modRNA.

[0260] Example 2d-mod RNA Delivery vs. DNA Delivery Six female BALB / c mice were divided into two study groups. All groups received the same amount of formulated luciferase-encoding modRNA (10 μg) intravenously (i.v., tail vein). Six hours later, ex vivo luciferase expression from each isolated organ was quantified. All groups received modRNA formulated with either JRL13 or JRL45 at N / P3. Furthermore, to more broadly investigate the binding properties of modRNA and the zeta potential of different formulations containing modRNA, modRNA was formulated with either JRL13 or JRL45 at different N / P ratios. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide-containing solution was 9:1 (v:v) in all cases. The formulations were characterized prior to injection to confirm their hydrodynamic diameter and zeta potential. Figure 3A is a bar graph showing the percentage of free RNA quantified by gel electrophoresis of exemplary compositions containing modRNA at different N / P ratios ranging from 0 to 3 for either JRL13 or JRL45. Figure 3B is a plot showing the zeta potential after formulating exemplary compositions containing modRNA at different N / P ratios with either JRL13 or JRL45. Figure 3C is a plot showing the hydrodynamic diameter of exemplary compositions containing modRNA at different N / P ratios with either JRL13 or JRL45. Figure 3D is a bar graph showing the expression of luciferase-encoding modRNA after transfection of C2C12 cells. The exemplary compositions were prepared at N / P 6 and contained 25 ng of RNA / well of modRNA with either JRL13 or JRL45. Data here represent three independent experiments (n=3) that were technically repeated three times. Figure 3E is a bar graph showing the quantified ex vivo luminescence in different organs 6 hours after injection of 10 μg of an exemplary composition containing modRNA formulated in N / P3 with either JRL13 or JRL45. Figure 3F is a bar graph showing the quantified ex vivo luminescence in different organs 6 hours after injection, assessing the ratio of total flux [p / s] from the JRL13 group to the JRL45 group.

[0261] The JRL45 and JRL13 oligosaccharides are two molecules from a library described in the literature (Garcia Fernandez et al. 2019, DOI 10.1039 / c9cc04489b) for delivery of pDNA after intravenous injection. In the publication by Garcia Fernandez, JRL45 is referred to as compound 10, and JRL13 is referred to as compound 8. The complex reported by Garcia Fernandez contained oligosaccharides at a pDNA N / P ratio of 20. For example, Figure 3G is a bar graph showing quantified ex vivo luminescence in different organs after injection of a composition containing pDNA complexed with either JRL13 (compound 8) or JRL45 (compound 10).

[0262] Garcia Fernandez's formulations were prepared in Hepes buffer (20 mM) at pH 7.4, diluting the pDNA to the desired concentration in the buffer and diluting the oligosaccharides by simple dispersion and mixing. Expression of pDNA was primarily in the liver for JRL13 (compound 8) and in the lung for JRL45 (compound 10). See Figure 3G. When the complexes of the present invention contained RNA, JRL13 was primarily expressed in the spleen and lung, as seen in Figure 3E, whereas JRL45 expression was significantly reduced (Figure 3F) and observed only in the spleen. The results obtained in this example not only contradict published results but also highlight the impact that appropriate formulation parameters play in providing a desirable vehicle for RNA compared to DNA.

[0263] Example 3 - Intramuscular Delivery Example 3a - modRNA and saRNA delivery and N / P ratio Eighteen female BALB / c mice were divided into 11 study groups. All groups received the same amount of formulated luciferase-encoding modRNA or saRNA (1 μg) administered intravenously into each leg. In vivo luciferase expression was measured in the administered tissues at seven time points (6 h, 24 h, 72 h, 6 days, 8 days, and 20 days). Three modRNA groups were formulated with JRL13 at three different N / P ratios (1, 6, or 12), and three saRNA groups were formulated with JRL13 at three different N / P ratios (1, 6, or 12). N / P ratios were calculated based on the JRL13-RNA charge ratio, as described herein. Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide-containing solution in all cases. Formulations were characterized prior to injection to confirm hydrodynamic diameter and zeta potential. Figure 4A is a plot showing the hydrodynamic diameter of exemplary complexes containing RNA formulated at different N / P ratios. Figure 4B is a bar graph showing the zeta potential of exemplary compositions containing RNA at different N / P ratios. Figure 4C is a bar graph showing the quantified bioluminescence over the experimental period of exemplary compositions containing modRNA and JRL13 with the indicated N / P ratios. Figure 4D is a bar graph showing the quantified bioluminescence over the experimental period of exemplary compositions containing saRNA and JRL13 with the indicated N / P ratios.

[0264] After im administration of modRNA, expression could be observed for negatively charged N / P ratios (N / P1), but increasing the overall N / P ratio of the formulation resulted in a complete loss of modRNA expression. JRL13 formulations containing modRNA exhibited a shift in surface charge from negative to positive (Figure 4B), but appeared to show little difference in complex size with increasing N / P (Figure 4A). In contrast, saRNA formulations showed that size was affected by the N / P ratio. For example, at lower N / P ratios (e.g., N / P1), complexes were approximately 170 nm, and at higher N / Ps (e.g., N / Ps of 6–12), size decreased to nanometers (90 nm). At a given dose, saRNA formulations showed highest expression at N / P12, in contrast to modRNA, where highest modRNA expression was achieved at N / P1 (Figure 4C–Figure 4D).

[0265] Example 3b - Cationic Oligosaccharide Screening This example investigates the effect of different cationic groups on intramuscular delivery of saRNA. Forty-eight female BALB / c mice were divided into 16 study groups. All groups received the same amount of formulated luciferase-encoding saRNA (2 μg) administered intramuscularly into each leg. In vivo luciferase expression was measured in the administered tissues at six time points (6 hours, 24 hours, 72 hours, 6 days, 9 days, and 20 days). All groups received saRNA formulated with N / P 6. Each group received saRNA formulated with one of the following oligosaccharides: JRL13, JLJB619, JLF58, JLF41, JLF42, JLF102, JLF120, JLF94, JLF96, JLF97, JLF135, JLF90, JLF130, JLF82, JLF93, and JLF99. Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide-containing solution in all cases. Formulations were characterized prior to injection to confirm their hydrodynamic diameter. Figure 5A is a bar graph showing the hydrodynamic diameter of complexes containing saRNA and different oligosaccharides formulated with N / P6. Figure 5B is a bar graph showing the quantified bioluminescence over the experimental period, normalized to the JRL13-saRNA group. Figure 5C is a plot showing the quantified bioluminescence at each measurement time point for exemplary compositions.

[0266] Most of the tested formulations containing saRNA at N / P6 had hydrodynamic diameters in the 50-100 nm range (Figure 5A), while the formulation containing JLF99 had a diameter of approximately 150 nm. Of the different oligosaccharides tested, at least four were confirmed to be comparable to JRL13: JLF102, JLF94, JLF97, and JLF93 (Figure 5B). Furthermore, certain combinations of primary and secondary amines (e.g., JLF102) exhibit a positive effect, resulting in a two-fold signal increase compared to JRL13.

[0267] Example 3c - Screening of N / P ratios of selected oligosaccharides Based on previous observations (e.g., as seen in Figure 4C), additional cationic derivatives were tested at different N / P ratios to identify the types of amines suitable for modRNA delivery. Oligosaccharides with different types of amines were tested, including primary amines (JRL13), secondary amines (JLJB619 and JLF58), tertiary amines (JLF41), and quaternary ammonium (JLF42).

[0268] Thirty female BALB / c mice were divided into 10 study groups. All groups received the same amount of formulated luciferase-encoding modRNA (2 μg) administered im into each leg. In vivo luciferase expression was measured in the administered tissues at five time points (6 hours, days 1, 2, 3, and 6). Half of the groups received modRNA formulated with N / P1, and the other half received modRNA formulated with N / P6. Two groups received modRNA formulated with JRL13, two with JLJB619, two with JLF58, two with JLF41, and two with JLF42. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide-containing solution was 9:1 (v:v) in all cases. Formulations were characterized prior to injection to confirm hydrodynamic diameter. Figure 6A is a bar graph showing the hydrodynamic diameter of exemplary complexes formulated with modRNA and different oligosaccharides at different N / P ratios. Figure 6B is a bar graph showing quantified bioluminescence over the duration of the experiment.

[0269] In all tested formulations, the lowest N / P ratio (N / P1) resulted in the formation of significantly larger nanoparticles (Figure 6A). For JLJB619, JLF58, and JLF41, the difference in particle size between N / P1 and N / P6 was large, whereas for JRL13 and JLF42 formulations, the difference between N / P1 and N / P6 was small. Without being bound by theory, this is thought to be because JRL13 has a primary amine that is substantially charged at any physiological pH, while JLF42 has a quaternary ammonium that is a permanent cation. Both groups interact with RNA and have favorable condensation capabilities. JLJB619, JLF58, and JLF41 have amines with pKas within the physiological range. JLF58 and JLF41 contain spatially hindered amines. Bioluminescence was highest with JLF141 for both tested N / Ps (Figure 6B). The N / P6 group was 1.5-fold higher than the N / P1 group. JRL13 and JLF58 showed no significant difference in modRNA expression between both tested N / Ps.

[0270] Example 3 Screening of Additional Oligosaccharides for d-mod RNA Delivery Forty-eight female BALB / c mice were divided into 16 study groups. All groups received the same amount of formulated luciferase-encoding saRNA (2 μg) administered intramuscularly into each leg. In vivo luciferase expression was measured in the administered tissues at six time points (6 hours, days 1, 2, 3, and 6). All groups received modRNA formulated with N / P6. Each group received modRNA formulated with one of the following oligosaccharides: JRL13, JLJB619, JLF58, JLF42, JLF41, JLF128, JLF142, JLF131, JLF96, JLF97, JLF135, JLF94, JLF90, JLF99, JLF82, and JLF138. Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide-containing solution in all cases. Formulations were characterized prior to injection to confirm their hydrodynamic diameter. Figure 7A is a bar graph showing the hydrodynamic diameter of complexes formulated with modRNA and different oligosaccharides at N / P6. Figure 7B is a bar graph showing the bioluminescence quantified over the experimental period, normalized to the JLF41-modRNA group.

[0271] JLF99 shows promising modRNA expression (Figure 7B). Certain oligosaccharides (JLF142, JLF131, JLF99) formed complexes with modRNAs exceeding 100 nm.

[0272] Example 3 Screening of cationic head groups at different N / P ratios for e-mod RNA delivery Twenty-four female BALB / c mice were divided into eight study groups. All groups received the same amount of formulated luciferase-encoding modRNA (5 μg) sc in their right flank. In vivo luciferase expression was measured in the administered tissues at five time points (6 h, 24 h, 48 h, 72 h, and 6 days). Two groups received modRNA formulated with JRL13 (one N / P1 and one N / P6). Two groups received modRNA formulated with JLJB619 (one N / P1 and one N / P6). Two groups received modRNA formulated with JLJB604 (one N / P1 and one N / P6). The final two groups received modRNA formulated with JLJB605 (one N / P1 and one N / P6). Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide-containing solution in all cases. Formulations were characterized prior to injection to confirm hydrodynamic diameter and zeta potential. Figure 8A is a bar graph showing the hydrodynamic diameter of complexes formulated at different N / P ratios. Figure 8B is a bar graph showing the zeta potential of compositions containing modRNA at different N / P ratios. Figure 8C is a bar graph showing quantified bioluminescence over the experimental period for various exemplary compositions.

[0273] Example 3 Screening of Aliphatic Chain Length for f-mod RNA Delivery Thirty-six female BALB / c mice were divided into 12 study groups. All groups received the same amount of formulated luciferase-encoding modRNA (5 μg) sc in their right flank. In vivo luciferase expression was measured in the administered tissues at seven time points (6 h, 24 h, 72 h, 6 days, 9 days, and 20 days). Three groups were composed of luciferases with different aliphatic chain lengths: C6 (JRL13), C 10 (JLJB617), C 14 The three groups received oligosaccharides with different aliphatic chain lengths, e.g., C6 (JLJB619), C7 (JLJB618), and C8 (JLJB619).10 (JLF43), C 14 The three groups received oligosaccharides with different aliphatic chain lengths, e.g., C6 (JLJB604), C7 (JLF31), C8 (JLF31), C9 (JLF31), C10 (JLF31), C11 (JLF31), C12 (JLF31), C13 (JLF31), C14 (JLF31), C15 (JLF31), C16 (JLF31), C17 (JLF31), 10 (JLF41), C 14 The three groups received oligosaccharides with different aliphatic chain lengths, e.g., C6 (JLJB605), C7 (JFL25), and C8 (JFL25). 10 (JLF42), C 14 All formulations were tested at an N / P ratio of 6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide-containing solution in all cases. The formulations were characterized prior to injection to confirm hydrodynamic diameter and zeta potential. Figure 9A is a bar graph showing the hydrodynamic diameter of exemplary compositions. Figure 9B is a bar graph showing the quantified bioluminescence over the experimental period for exemplary oligosaccharide formulations.

[0274] Example 3 Screening of aliphatic chain length for g-saRNA delivery Thirty-six female BALB / c mice were divided into 12 study groups. All groups received the same amount of formulated luciferase-encoding saRNA (5 μg) sc in their right flank. In vivo luciferase expression was measured in the administered tissues at seven time points (6 h, 24 h, 72 h, 6 days, 8 days, and 20 days). Three groups contained luciferases with different aliphatic chain lengths, e.g., C6 (JRL13), C7 (JRL14), C8 (JRL15), C9 (JRL16), C10 (JRL17), C11 (JRL18), C12 (JRL19), C13 (JRL19), C14 (JRL19), C15 (JRL19), C16 (JRL19), C17 (JRL19), C18 (JRL19), C19 (JRL19), C20 (JRL19), C21 (JRL19), C22 (JRL19), C30 (JRL19), C40 (JRL19), C50 (JRL19), C60 (JRL19), C18 (JRL19), C21 (JRL19), C22 (JRL19), C30 (JRL19), C40 (JRL19), C50 (JRL19), C60 (JRL19), C19 (JRL19), C21 (JRL19), C22 (JRL19), C30 (JRL19), C40 (JRL19), C50 (JRL19), C60 (JRL19), C15 (JRL19), C21 (JRL19), C22 (JRL19), C30 (JRL19), C40 (JRL19), C50 (JRL19), C60 (JRL19), C60 (JRL19), C70 (JRL 10 (JLJB617), C 14 The three groups received oligosaccharides with different aliphatic chain lengths, e.g., C6 (JLJB619), C7 (JLJB618), and C8 (JLJB619). 10 (JLF43), C 14 The three groups received oligosaccharides with different aliphatic chain lengths, e.g., C6 (JLJB604), C7 (JLF31), C8 (JLF31), C9 (JLF31), C10 (JLF31), C11 (JLF31), C12 (JLF31), C13 (JLF31), C14 (JLF31), C15 (JLF31), C16 (JLF31), C17 (JLF31), C18 (JLF31), C19 (JLF31), C20 (JLF31), C21 (JLF31), C22 (JLF31), C23 (JLF31), C24 (JLF31), C25 (JLF31), C30 (JLF31), C40 (JLF31), C50 (JLF31), C60 (JLF31), C19 (JLF31), C25 (JLF31), C2 10 (JLF41), C 14The three groups received oligosaccharides with different aliphatic chain lengths, e.g., C6 (JLJB605), C7 (JFL25), and C8 (JFL25). 10 (JLF42), C 14 All formulations were tested at an N / P ratio of 6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing and oligosaccharide-containing solutions in all cases. The formulations were characterized prior to injection to confirm their hydrodynamic diameter and zeta potential. Figure 10A is a bar graph showing the hydrodynamic diameter of a particular complex. Figure 10B is a bar graph showing the quantified bioluminescence of exemplary oligosaccharide formulations over the experimental period. Figure 10C is a bar graph showing the quantified response of CD8+ T cells from spleen samples of treated mice 20 days after sc administration. CD8 responses to luciferase peptides presented by mouse MHC were quantified via IFN release in an ELISPOT assay. An irrelevant peptide served as a control to demonstrate that the CD8 response to the luciferase peptide was specific.

[0275] Example 3: Effect of N / P ratio on delivery of h-modRNA and saRNA Eighteen female BALB / c mice were divided into six study groups. All groups received the same amount of formulated luciferase-encoding saRNA (5 μg) or modRNA (5 μg) sc in their right flank. In vivo luciferase expression in the administered tissues was measured at seven time points (6 h, 24 h, 72 h, 6 days, 8 days, and 20 days). Three groups received modRNA formulated with JLJB619 at three different N / P ratios (3, 6, and 12). Three additional groups received saRNA formulated with JLJB619 at three different N / P ratios (3, 6, and 12). Three groups received oligosaccharides with secondary amines containing different aliphatic chain lengths, e.g., C6 (JLJB619), C10 (JLF43), and C14 (JLF31). Three groups received oligosaccharides with tertiary amines containing different aliphatic chain lengths, e.g., C6 (JLJB604), C10 (JLF41), and C14 (JFL25). All N / P ratios were calculated based on the oligosaccharide-to-RNA charge ratio. Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the JLJB619-containing solution was 9:1 (v:v) in all cases. Formulations were characterized prior to injection to confirm their hydrodynamic diameter and zeta potential. Figure 11A is a bar graph showing the hydrodynamic diameter of complexes containing RNA formulated at different N / P ratios. Figure 11B is a bar graph showing the zeta potential of RNA at different N / P ratios. Figure 11C is a bar graph showing quantified bioluminescence over the experimental period for the modRNA group. Figure 11D is a bar graph showing quantified bioluminescence over the experimental period for the saRNA groups.

[0276] Example 3 Immunization against H1N1 / Cal07 / HA after i-saRNA delivery Fifteen female BALB / c mice were divided into three groups. One group received buffer only as a negative control, and the other group received 2 μg of formulated saRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009 complexed with JLJB619. The third group received 2 μg of formulated saRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009 complexed with LNP (DODMA, cholesterol, DOPE, and PEG2000-ceramide C16, molar ratio 40:48:10:2). All saRNA formulations were applied subcutaneously. saRNA complexed with JLJB619 was formulated with N / P6. saRNA formulated with LNP was prepared with N / P4. The N / P ratio of LNP was determined by the DODMA / RNA ratio.

[0277] The JLJB619 formulation was complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the paO-containing solution was 9:1 (v:v) in all cases. LNP formulations were produced in PBS according to standard LNP production methods widely described in the literature. See Nogueira, et al., ACS Appl. Nano. Mater., 3(11):10634-10645 (2020). LNPs were produced using a mixture of saRNA in citrate buffer (pH 4.5) and a lipid mixture in ethanol at a 3:1 ratio, with a mixing rate of 12 mL / min. The LNPs were then dialyzed in PBS for 3 hours. Animals underwent noninvasive serological monitoring at different time points (days 0, 14, 21, 28, and 49) over 49 days, and spleens were harvested at the end of the experiment to quantify CD4 / CD8 T cell responses to influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme-linked immunosorbent assay (ELISA). CD4 / CD8 T cell responses were quantified via IFN-ELISPOT of splenocytes. Figure 12A is a bar graph showing the hydrodynamic diameter of complexes formulated at different N / P ratios and containing RNA. Figure 12B is a plot showing the serological levels of specific IgG against HA over the course of the experiment at a serum dilution of 1:300. Figure 12C is a plot showing the endpoint titration of serological levels of specific IgG against HA. Figure 12D is a bar graph showing CD8 / CD4 responses to HA peptide pools.

[0278] Example 3j - Cationic Oligosaccharide Combination Conjugates This example considers complexes containing JLF99 and modRNA in N / P6 in combination with polysorbates (e.g., Tween 20 and Tween 40). Nine female BALB / c mice were divided into three study groups. All groups received the same amount of formulated luciferase-encoding modRNA (2 μg) administered im into each leg. In vivo luciferase expression was measured in the administered tissues at five time points (6 hours, days 1, 2, 3, and 6). The first group received modRNA formulated exclusively in JLF99, the second group received modRNA formulated in a mixture of JLF99 and Tween 20 (1:0.5 molar ratio), and the third group received modRNA formulated in a mixture of JLF99 and Tween 20 (1:1 molar ratio). All groups received modRNA formulated in N / P6. Formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of RNA-containing solution to oligosaccharide / Tween 20-containing solution was 9:1 (v:v) in all cases. Formulations were characterized prior to injection to confirm their hydrodynamic diameter. Figure 13A shows the hydrodynamic diameter of N / P6-formulated complexes in combination with different surfactants, with surfactant to JLF99 ratios ranging from 0:1 to 0.5:1 (C14-pMeOx45). 14 Alkyl-poly(2-methyl-2-oxazoline) 45 and C14pSar23 is C14 alkyl-poly(sarcosine) 23(where Tween 20 is polysorbate 20). Figure 13B shows the hydrodynamic diameter of complexes formulated with either Tween 20 or Tween 40 at N / P6 and surfactant to JLF99 ratios between 0 and 1.5. Figure 13C is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of C2C12 cells. Exemplary compositions have N / P6, modRNA, and either Tween 20 or Tween 40 at different surfactant to JLF99 ratios formulated at 100 ng of RNA / well. This example represents three independent experiments (n=3) that were technically repeated three times. Figure 13D is a plot showing the expression of luciferase-encoding modRNA 24 hours after transfection of HepG2 cells. The exemplary composition has N / P6, where modRNA and either Tween 20 or Tween 40 at different detergent to JLF99 ratios were formulated at 100 ng of RNA / well. This example represents three independent experiments (n=3) that were technically repeated three times. Figure 13E is a bar graph showing the hydrodynamic diameter of complexes formulated with N / P6 using different oligosaccharide to detergent ratios (T20 refers to Tween 20). Figure 13F shows the quantified bioluminescence over the entire duration of the experiment, expressed as the area under the curve (T20 refers to Tween 20). Figure 13G shows the quantified bioluminescence over the entire duration of the experiment (T20 refers to Tween 20). FIG. 13H is an image showing bioluminescence in the ventral axis 6 hours after injection of each group with a composition containing modRNA (T20 refers to Tween 20).

[0279] Example 3 Intramuscular vaccination with k-cationic oligosaccharides and saRNA Forty female BALB / c mice were divided into six groups. One group received buffer only as a negative control, and the other five groups received 1 μg of formulated saRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009. All saRNA formulations were administered i.m. into one of the legs. All saRNA groups were formulated with N / P12 but with different oligosaccharides (JRL13, JLF102, JLF97, JLF94) or with linear polyethyleneimine 22.5 kDa (AVROXA, Ghent, Belgium), PEI500, as a benchmark. The N / P ratio of PEI500-formulated saRNA was determined by the secondary amine:RNA charge ratio. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the cationic oligosaccharide-containing solution was 9:1 (v:v) in all cases. Animals were subjected to noninvasive serological monitoring at different time points (days 0, 14, 21, 28, and 49) over 49 days and harvested to quantify CD4 / CD8 T cell responses to influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme-linked immunosorbent assay. Virus neutralization titers were quantified by VNT assay. CD4 / CD8 T cell responses were quantified via IFN-ELISPOT of splenocytes.

[0280] Example 4 - Synthesis Example Unless otherwise specified, all reagents and solvents used in the preparations disclosed in the following examples were purchased from commercial sources and used without further purification. Thin layer chromatography (TLC) was performed on silica gel 60F. 254 Analysis was performed on Merck-coated aluminum sheets by visualization with UV light (λ 254 nm) and charring with 10% ethanolic H2SO4, 0.1% ethanolic ninhydrin, and heating at 100 °C. Column chromatography was performed on Silice 60 ACC Chromagel (SDS 70-200 and 35-70 μm). The structures of all compounds described herein, including synthetic intermediates and precursors, are1 H and 13 The results were confirmed by C nuclear magnetic resonance (NMR) and mass spectrometry (MS). NMR experiments were performed at 300 (75.5) and 500 (125.7, 202) MHz using a Bruker 300 ADVANCE and 500 DRX. 1D TOCSY, 2D COSY, HMQC, and HSQC experiments were used to assist in NMR assignments. Mass spectra (high-resolution mass spectra) were performed on a Bruker Daltonics Esquire 6000™ (LTQ-Orbitrap XL ETD). Samples were introduced via a solid probe heated to 30-280°C. ESI was used as the ionization source (electrospray ionization) with methanol as the solvent. Samples were introduced by direct infusion using a Cole-Parmer syringe at a flow rate of 2 μl / min. Ions were scanned between 300 and 3000 Da at a scan rate of 13000 Da / s with unit resolution using resonant ejection at multipole resonance at one-third of the radio frequency (Ω = 781.25 kHz).

[0281] method Scheme 1 illustrates the synthesis of compounds of formula I, where A is A 1 and R 1 and R 2 are both -C(O)-R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + (Compound 4T in Scheme 1). Scheme 1 also shows general routes (Routes A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of Formula I, where A is A 1 and R 1 and R 2 are both -C(O)-R a and X 1 and X 2 are both -S- and Y 1 and Y2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 are identical (compound 6T in Scheme 1). [ka]

[0282] Scheme 2 illustrates the synthesis of compounds of formula I, where A is A 2 and R 1 and R 2 are both -C(O)--R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + (Compound 4S in Scheme 2). Scheme 2 also shows general routes (Routes A1 and A2) that can be implemented for the synthesis of compounds of formula I, where A is A 2 and R 1 and R 2 are both -(C=O)R a and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 are identical. [ka]

[0283] Scheme 3 illustrates the synthesis of compounds of formula I, where A is A 1 and R 1 and R 2 are both -C(O)R a and X 1 and X 2are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is -N(CH3)H2 + (Compound 8T in Scheme 3) or -N(CH3)2H + (Compound 9T in Scheme 3). [ka]

[0284] Scheme 4 illustrates the synthesis of compounds of formula I, where A is A 3 and R 1 is -C(O)-R a and R 2 is -C(O)-R a or methyl, and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2- and Z 1 and Z 2 is NH3 + and p is 1 (compound 4M in Scheme 4). Scheme 4 also shows general routes (route A1, A2, B1, and B2) that can be implemented for the synthesis of compounds of formula I, where A is A 3 and R 1 is -C(O)-R a and R 2 is -(C=O)R a or methyl, and X 1 and X 2 are both -S- and Y 1 and Y 2 are both -(CH2)2-NHC(S)NH-(CH2)2-, and Z 1 and Z 2 are identical. [ka]

[0285] In some embodiments, R 1 and R 2 are both -C(O)-R a The synthesis of compounds of formula I, wherein: [ka]

[0286] In an exemplary embodiment, the synthesis of a compound of Formula I according to Scheme 1 or 2 involves the addition of a cationic head group Z 1 and Z 2 In the reaction step leading to the installation of the following isothiocyanate or amine reagent: [ka] [ka] [ka]

[0287] material In some exemplary embodiments, the following precursors used in the synthesis of certain compounds described herein were prepared according to known methods. 6,6'-Diiodo-6,6'-dideoxy-α,α'-trehalose (1T) was prepared from commercially available reagents according to the procedure described in JM Garcia Fernandez, C. Ortiz Mellet, JL Jimenez Blanco, J. Fuentes Mota, A. Gadelle, A. Coste-Sarguet, J. Defaye, Carbohydr. Res. 1995, 268, 57-71.

[0288] 6,6'-Diiodo-6,6'-dideoxy-sucrose (1S) was prepared from commercially available reagents according to literature procedures. See J.M. Garcia Fernandez, A. Gadelle, J. Defaye, Carbohydr. Res. 1994, 265, 249-269.

[0289] Methyl 6,6'-diiodo-6,6'-dideoxy-2,3,2',3',4'-penta-O-acetyl-β-maltoside (1M) was prepared from commercially available reagents according to the procedure described in the literature. G.O. Aspinall, R.C. Carpenter, L. Khondo, Carbohydr. Res. 1987, 165, 281-298.

[0290] As used herein, an arrow followed by a code in parentheses, e.g., "(→ code)" indicates the lipophilic tail (R in compounds of Formula I) provided by the aforementioned reagent during synthesis. 1 and R 2 substituent) or cationic head group (Z in compounds of formula I) 1 and Z 2 For example, "hexanoic anhydride (→L1)" is intended to refer to the moiety L1 attached to the compound via the use of hexanoic anhydride, as set forth in the table above.

[0291] Hexanoic anhydride (CAS#2051-49-2, →L1) and octanoyl (CAS#111-64-8, →L2), decanoyl (CAS#112-13-0, →L3), 2-ethylhexanoyl (CAS#39053-77-5, →L3.1), 4-ethyloctanoyl (CAS#16493-81-5, →L3.2), lauroyl (CAS#112-16-3, →L4), myristoyl (CAS#112-64-1, →L5), stearoyl (CAS#112-76-5, →L7), and oleoyl (CAS#112-77-6, →L7.1) chlorides were purchased from commercial sources.

[0292] 2-(N-tert-butoxycarbonylamino)ethanethiol (CAS#67385-09-5, C1SH), 2-(N,N-dimethylamino)ethyl isothiocyanate (CAS#7097-89-4, →C3), 2-(4-methylpiperazin-1-yl)ethanamine (CAS#934-98-5, →C7), 2-(4-isopropylpiperazin-1-yl)ethanamine (CAS#132740-59-1, →C7.1), tert-butyl 4 -(2-Aminoethyl)piperazine-1-carboxylate (CAS#192130-34-0, →C8), 2-morpholinoethanamine (CAS#2038-03-1, →C9), 2-morpholinoethyl isothiocyanate (CAS#2038-03-1, →C9), 1-(2-aminoethyl)piperidine (CAS#63224-35-1, →C9.1), 2-(1H-imidazol-1-yl)ethanamine (CAS#5739-10-6, →C10) ), 2-(1H-imidazol-2-yl)ethanamine (CAS#19225-96-8, →C10.1), 2-(1H-imidazol-4-yl)ethan-1-amine (CAS#51-45-6, →C10.2), 2,2'-(piperazine-1,4-diyl)diethanamine (CAS#6531-38-0, →C14), tert-butyl(2-aminoethyl)(ethyl)carbamate (CAS#105628-63-5, →C15), N,N-diethanamine Ethylethylenediamine (CAS#100-36-7, →C16), 1,4-bis-Boc-1,4,7-triazaheptane (CAS#120131-72-8, →C18), 1-(2-aminoethyl)pyrrolidine (CAS#7154-73-6, →C47.1), N-(2-aminoethyl)-1,4-oxazepane (CAS#878155-50-1, →C48), 1-(2-aminoethyl)homopiperidine (CAS#51388-00-2, →C48).1), tert-butyl N-(2-aminoethyl)-N-(2-hydroxyethyl)carbamate (CAS#364056-56-4, →OH1), N,N-bis(2-hydroxyethyl)ethylenediamine (CAS#3197-06-6, →OH5), 3,3'-((2-aminoethyl)azanediyl)bis(propan-1-ol) (CAS#50331-68-5, →OH6), 4,4'-((2-aminoethyl)azanediyl)bis(butan-1-ol) (CAS#197966-97-5, →OH7), 2-((2-aminoethyl)amino)-2-(hydroxymethyl)propane-1,3-diol ( CAS#1211477-35-8, → OH10), 2-(4-(2-aminoethyl)piperazin-1-yl)ethanol (CAS#20542-08-9, → OH12), 1-(2-aminoethyl)piperidin-4-one (CAS#1196887-97-4, → C54), N-(2-aminoethyl)-4-piperidinol (CAS#129999-60-6, → C59), [1-(2-amino-ethyl)-piperidin-3-yl]-methanol (CAS#857637-03-7, → C59.1), 2-(4-methoxy-piperidin-1-yl)-ethylamine (CAS#911300-69-1, → C59.2), 2-(4,4-difluoropiperidin-1-yl)ethanamine (CAS#605659-03-8, →C60), 4-(2-aminoethyl)-thiomorpholine (CAS#53515-36-9, →C61), 4-(2-aminoethyl)thiomorpholine-1,1-dioxide (CAS#89937-52-0, →C63), 1-[4-(2-aminoethyl)piperazin-1-yl]ethenone (CAS#148716-35-2, →C66), 4-(2-aminoethyl)piperazin-2-one (CAS#145625-71-4 , → C68), 1-(2-aminoethyl)piperidine-4-carboxamide (CAS#443897-95-8, → C69), [1-(2-aminoethyl)piperidin-4-yl]methanol dihydrochloride (CAS#1311315-83-9, → C70), 2-[N-methyl-N-(tert-butoxycarbonyl)amino]ethanethiol (CAS#134464-53-2, C2SH), and 2-(N,N-dimethylamino)ethanethiol (CAS#108-02-1, C3SH) were purchased from commercial sources.

[0293] 2-(N-tert-butoxycarbonylamino)ethyl isothiocyanate (→C1), D. M. Kneeland, K. Ariga, V. M. Lynch, C.Y. Huang, E. V. Anslyn, J. Am. Chem. Soc. 1993, 115, 10042-10055. 2-(N-methyl-N-tert-butoxycarbonylamino)ethyl isothiocyanate (→C2), T. Kim, Y.-J. Kim, I.-H. Ha n, D. Lee, J. Ham, K.S. Kan, J.W. Lee, Bioorg.Med.Chem.Lett. 2015, 25, 62-66. 2-(N,N,N-trimethylamino)ethyl isothiocyanate (→C4), Y.-J. Ghang, J.J. Lloyd, M.P. Moehlig, J.K. Arguelles, M. Mettry, X. Zhang, R.R. Julian, Q. Cheng, R.J. Hooley, Langmuir 2014,30,10160-10166. 2-(2-Aminoethyl)-1,3-di-(tert-butoxycarbonyl)guanidine (→C11), S.M. Hickey, T.D. Ashton, J.M. White, J. Li, R.L. Nation, H.Y. Yu, A.G. Elliott, M.S. Butler, J.X. Huang, M.A. Crooper, F.M. Pfeffer, RSC Adv. 2015,5,28582-28596. N,N-Bis[2-(tert-butoxycarbonylamino)ethyl]ethylenediamine (→ C43) was prepared according to the procedure described in Y. Wu, A. Kaur, E. Fowler, M. M. Wiedmann, R. Young, W. R. J. D. Galloway, L. Olsen, H. F. Score, A. Chattopadhyay, T. T.-L. Kwan, W. Xu, S. J. Walsh, P. de Andrade, M. Janecek, S. Arumugam, L. S. Itzhaki, Y. Heng Lau, D. R. Spring, ACS Chem. Biol. 2019, 14, 526-533. N,N-Bis(2-acetamidoethyl)ethylenediamine (→ C45) was prepared according to the procedure described in L. Liu, M. Rozenman, R. Breslow, J. Am. Chem. Soc. 2002, 124, 12660-12661.

[0294] N I ,N I -Dimethyl-N II N-tert-butoxycarbonyl-diethylenetriamine (→C12), N-(3-hydroxypropyl)-N-(tert-butoxycarbonyl)ethylenediamine (→OH2), and N-(4-hydroxybutyl)-N-(tert-butoxycarbonyl)ethylenediamine (→OH3) were obtained from commercially available N I ,N I They were synthesized from -dimethyl-diethylenetriamine, N-(3-hydroxypropyl)ethylenediamine, and N-(4-hydroxybutyl)ethylenediamine, respectively, by sequential primary amine trifluoroacetylation with ethyl trifluoroacetate, carbamoylation of the remaining amino group with BocO, and base-promoted trifluoroacetide hydrolysis.

[0295] N-(2-aminoethyl)-1,3-oxazolidine (CAS#67626-78-2, →C47) was synthesized from commercially available N-(2-hydroxyethyl)-1,3-oxazolidine (CAS#20073-50-1) by sequential hydroxylmesylation using mesyl chloride, displacement with sodium azide, and final catalytic hydrogenation using H-Pd / C.

[0296] 4-(2-Aminoethyl)-thiomorpholine-1-oxide (→C62) was synthesized by sequential primary amine carbamoylation with BocO, thioether oxidation with m-chloroperbenzoic acid, and final acid-promoted carbamate cleavage.

[0297] N I -(tert-butoxycarbonylmethyl)-N II -(2-Isothiocyanatoethyl)-ethylenediamine (→C5) was synthesized from commercially available diethylenetriamine according to the following scheme (Scheme 5). [ka]

[0298] Synthetic intermediates 2T, 2S, 2M, 3T, 3S, and 3M in the reaction sequences shown in Schemes 1, 2, and 4 were prepared as described below.

[0299] 6,6'-Bis[2-(tert-butoxycarbonylamino)ethylthio]-α,α'-trehalose (2T). To a mixture of diiodo-trehalose 1T (14.3 g, 25.44 mmol) and CsCO (23.45 g, 71.23 mmol) in anhydrous DMF (150 mL) under N was added a solution of 2-(N-tert-butoxycarbonylamino)ethanethiol (CSH, 13.6 mL, 76.32 mmol) in anhydrous DMF (100 mL) under N. The reaction mixture was stirred overnight at room temperature, and the solid remaining in suspension was decanted and filtered. The solvent was then removed under reduced pressure, and the resulting residue was triturated with EtO (500 mL) to generate a sticky solid. The residue was filtered, triturated with EtOH (250 mL), and the remaining solid was filtered again. The solvent was finally evaporated to dryness to give analytically pure compound 2T in essentially quantitative yield (16.8 g). 26 H 48 N2O 13 S2. Molecular weight: 660.26. ESI-MS(m / z)705.51([M+HCO2] - ).

[0300] 6,6'-Bis[2-(tert-butoxycarbonylamino)ethylthio]sucrose (2S). To a mixture of diiodo-sucrose 1S (1.07 g, 1.9 mmol) and CsCO (1.75 g, 5.33 mmol) in anhydrous DMF (30 mL) under a N atmosphere, 2-(tert-butoxycarbonylamino)ethyl mercaptan (1.0 mL, 5.7 mmol) was added. The reaction mixture was stirred overnight at room temperature. The solvent was then removed under reduced pressure, and the resulting residue was triturated with EtO (100 mL) to generate a sticky solid. The residue was filtered, triturated with EtOH (50 mL), and the remaining solid was filtered again. The solvent was finally evaporated to dryness to give analytically pure compound 2S in essentially quantitative yield (1.25 g). Chemical formula: C26H48N2O13S2. Molecular weight: 660.26. ESI-MS(m / z)705.56([M+HCO2]-).

[0301] Methyl 6,6'-bis[2-(tert-butoxycarbonylamino)ethylthio]-β-maltoside (2M). To a mixture of 1M methyl 6,6'-dideoxy-6,6'-diiodo-β-maltoside (1.20 g, 1.5 mmol) and CsCO (1.38 g, 4.20 mmol) in anhydrous DMF (40 mL) under a N atmosphere, 2-(tert-butoxycarbonylamino)ethyl mercaptan (CSH, 0.80 mL, 4.50 mmol) was added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with a 1:1 EtO-toluene mixture (200 mL) and extracted with water (2 × 100 mL). The organic phase was dried over NaSO, filtered, and concentrated to dryness. The resulting residue was chromatographed using a 1:1 EtOAc-petroleum ether mixture as eluent to give the per-O-acetylated intermediate in 90% yield (1.20 g). Acetate removal was achieved by treatment with NaOMe (0.67 mmol, 36 mg) in MeOH (25 mL) for 1 h, followed by Amberlite IR120 (H + ) Quantitative purification was achieved by neutralizing with ion exchange resin, filtering, and evaporating to dryness. Chemical formula: C 27 H 20 N2O 13S2. Molecular weight: 674.82. ESI-MS(m / z)719.50([M+HCO2] - ).

[0302] General procedure for the complete hydroxyl acylation of 2T, 2S, and 2M to give intermediates 3T, 3S, and 3M. To a solution of the corresponding acylating agent (listed in the lipid reagent list above → L1–L7.1, 2T and 2S are 46 mmol, 2M is 38 mmol) in anhydrous DMF (20 mL) at 0 °C under an inert N atmosphere, a solution of 2T, 2S, or 2M (5.1 mmol) and DMAP (2T and 2S are 92 mmol, 2M is 76 mmol) in anhydrous DMF (100 mL) was added dropwise over 10 min. The reaction mixture was allowed to warm to room temperature over 2 h and further stirred overnight. The reaction was then diluted with a 1:1 water-DCM mixture (400 mL). The organic layer was decanted and further washed with water (100 mL), 2N H2SO4 (2 x 100 mL), saturated NaHCO3 (100 mL), and water (100 mL), dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure. The resulting syrupy residue was purified by column chromatography using the eluent indicated in each case to give the R 1000 (R 1000) as defined by codes L1 to L7.1 in the lipid reagent list above. a The corresponding 3T, 3S, or 3M reaction intermediates bearing the substituents were obtained. [Table 1]

[0303] General procedure for the hydrolysis of the tert-butoxycarbonyl group in reaction intermediates 3T (→ 4T), 3S (→ 4S), and 3M (→ 4M). To a solution of 3T, 3S, or 3M (1 mmol) in DCM (10 mL) was added trifluoroacetic acid (TFA, 10 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 hour, and then the solvent was evaporated under reduced pressure. Traces of acid were removed by repeated coevaporation with water. The resulting residue was lyophilized from 10 mM HCl to give the corresponding diamines 4T, 4S, and 4M as hydrochloride salts in quantitative yield. In some preferred embodiments, the following compounds of Formula I, characterized by the structure 4T, were synthesized according to Scheme 2 using the procedure described above: JLF19, JLF150, JLF20, JLF155, JLF23, and JLF46.

[0304] In some preferred embodiments, the following compounds of formula I characterized by structure 4S were synthesized according to Scheme 1 following the procedures described above: JLF50, JLF62.

[0305] General Procedure for the Synthesis of Diisothiocyanate Reaction Intermediates 5T, 5S, and 5M in Schemes 1, 2, and 4: To a solution of 4T, 4S, or 4M (1 mmol) in a heterogeneous mixture of water and DCM (1:1 mL), CaCO3 (0.48 g, 4.8 mmol), and Cl2CS (0.22 mL, 2.4 mmol) was added sequentially. The mixture was vigorously stirred at room temperature for 1 hour, then transferred to a decantation funnel and diluted with water and DCM (1:1, 100 mL). The organic layer was decanted, washed with water (50 mL) and saturated aqueous NaHCO3 (50 mL), dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure to give the R2000 series, as defined by the codes in the Lipid Reagents List. a The target diisothiocyanate reaction intermediates 5T, 5S, or 5M bearing substituents were obtained.

[0306] Compound 5T-L1: Yield 99%. Chemical formula: C 54 H 88 N2O 15 S4. MW:1133.54. ESI-MS(m / z)1155.58([M+Na] +). Compound 5T-L3): Yield 90%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS(m / z)1514.87([M+HCO2] - ). Compound 5T-L3.1: Yield 78%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS(m / z)1513.88([M+HCO2] - ). Compound 5T-L3.2: Yield 94%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS(m / z)1487.22([M+NH4] + ) Compound 5S-L1: Yield 99%. Chemical formula:C 54 H 88 N2O 15 S4. MW:1133.54. ESI-MS(m / z)1155.58([M+Na] + ). Compound 5S-L3: Yield 90%. Chemical formula:C 78 H 136 N2O 15 S4. MW:1470.19. ESI-MS(m / z)1514.87([M+HCO2] - ). Compound 5M-L3: Yield 93%. Chemical formula:C 69 H 120 N2O 15 S4. MW:1329.96. ESI-MS(m / z)1375.09([M+HCO2] - ).

[0307] A general synthetic procedure for the compounds of formula I for スキーム1, 2, and び4, A1, A2, B1, and びB2. Route A1 (Scheme 1, 2, or 4): To a solution of the corresponding diamine dihydrochloride (4T, 4S, or 4M, 0.1 mmol) in DCM (10 mL) and triethylamine (EtN, 0.3 mmol, 41 μL) was added the corresponding isothiocyanate reagent SCN-(CH)-Z in DCM (5 mL). a -PG 1 A solution of 4T, 4S, or 4M was added over time. The reaction mixture was stirred at room temperature for 16 hours, monitoring the pH to ensure it remained basic (if the pH was found to be below neutral, it should be readjusted to slightly basic (approximately pH 8) by adding aliquots of EtN). Once the reaction was complete (TLC showed the complete disappearance of the starting material 4T, 4S, or 4M, and a higher R f After 2 min, the reaction mixture was concentrated to dryness, and the crude material was purified by column chromatography using the indicated eluent. The resulting intermediate with a Boc-protected amino group was then treated with a 1:1 DCM-TFA mixture (10 mL) at room temperature for 1 h, followed by evaporation of the solvent under reduced pressure. Traces of TFA were removed by coevaporation with toluene (3 × 10 mL). Lyophilization from 10 mM HCl afforded the target product 6T, 6S, or 6M in the indicated yield in each case.

[0308] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, Route A1: JLF31, JLF32, JLF33, JLF35, JLF43, JLF58, JLF78, JLJB617, JLJB618, JLJB619.

[0309] In some embodiments, the following compounds of formula I, characterized by structure 6S, were synthesized according to Scheme 2, Route A1: JLF59, JLF60, JLF68, JLF69, JLF76, JLF77

[0310] Route A2 (Scheme 1, 2, or 4): Similarly to Route A1, Route A2 involves the reaction of compounds of structure 4T, 4S, or 4M with the isothiocyanate reagent SCN-(CH)-Z using a similar protocol. 1 This refers to a coupling reaction with 6T. Upon completion of the reaction, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO or NaSO, filtered, and evaporated under reduced pressure. In these cases, column chromatography purification was performed. The resulting products were lyophilized from 10 mM HCl to give the target products 6T, 6S, or 6M in the yields indicated in each case.

[0311] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, route A2: JLF25, JLF26, JLF29, JLF30, JLF41, JLF42, JLF154, JLF158, JLF170, JLJB604, JLJB605.

[0312] In some embodiments, the following compounds of formula I, characterized by structure 6S, were synthesized according to Scheme 2, route A2: JLF54, JLF55, JLF66, JLF67.

[0313] Route B1 (Scheme 1, 2, or 4): To a solution of the corresponding diisothiocyanate reaction intermediate 5T, 5S, or 5M (1 mmol) in DCM (10 mL) is added the corresponding amine reagent HN-(CH)-Z in DCM (5 mL). a -PG 1 (0.3 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours while monitoring the pH to ensure it remained basic. Once the reaction was complete (TLC showed complete disappearance of the starting material 5T, 5S, or 5M, and a lower R fAfter 2 min, the reaction mixture was concentrated to dryness, and the crude material was purified by column chromatography using the indicated eluent. The resulting intermediate was further treated with a 1:1 DCM-TFA mixture (10 mL) at room temperature for 1 h, followed by evaporation of the solvent under reduced pressure, coevaporation of traces of acidic material with toluene (3 × 10 mL), and lyophilization from 10 mM HCl to give the target products 6T, 6S, or 6M in the indicated yields in each case.

[0314] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, Route B1: JLF93, JLF94, JLF96, JLF97, JLF98, JLF102, JLF103, JLF111, JLF115, JLF120, JLF121, JLF139, JLF141, JLF200, JLF201, JLF220, PER20.

[0315] Route B2: Similarly to Route B1, Route B2 involves the reaction of compounds of structure 5T, 5S, or 5M with the amine reagent H2N-(CH2)2-Z using a similar protocol. 1 This refers to a coupling reaction with 6T. Upon reaction completion, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO or NaSO, filtered, and evaporated under reduced pressure. In these cases, column chromatography purification was not necessary. The resulting products were lyophilized from 10 mM HCl to give the target products 6T, 6S, or 6M in the indicated yields.

[0316] In some embodiments, the following compounds of formula I characterized by structure 6T were synthesized according to Scheme 1, Route B2: JLF81, JLF82, JLF87, JLF90, JLF95, JLF99, JLF106, JLF108, JLF110, JLF111, JLF125, JLF128, JLF130, JLF131, JLF134, JLF135, JLF138, JLF142, JLF163, JLF164, JLF165, JLF190, JLF197, JLF223, JLF234, JLF237, JLF238, JLF244, JLF245 , JLF248, JLF301, JLF601, JLF602, JLF604, JLF605, JLF606, JLF607, JLF608, PRX051, NC117, NC118.

[0317] In some embodiments, the following compounds of formula I characterized by structure 6S were synthesized according to Scheme 2, route B2: JLF218, PRX052, PRX093, PRX094, PRX096.

[0318] In some embodiments, the following compounds of formula I characterized by structure 6M were synthesized according to Scheme 4, route B2: JMB500, JMB501, JMB503.

[0319] General procedure for the synthesis of compounds of formula I according to Scheme 3, Routes C1 and C2.

[0320] The diiodotrehalose derivative 1T was per-O-acylated according to a procedure similar to the general procedure for the complete hydroxyl acylation of 2T and 2S to give the above-mentioned intermediates 3T and 3S. The resulting crude product was subjected to column chromatography purification (1:10 EtOAc-petroleum ether) to give intermediate 7T in 67% yield.

[0321] In a preferred embodiment, R a The diiodo reactive intermediate 7T, whose substituents are defined by the code L1 (7T-L1), was prepared according to this procedure.

[0322] Route C1: To a mixture of 7T (0.1 mmol) and CsCO (91 mg, 0.28 mmol) in anhydrous DMF (3 mL) under a N atmosphere, 2-[N-methyl-N-(tert-butoxycarbonyl)amino]ethathiol (CSH, 52 μL, 0.3 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The solvent was then removed under reduced pressure, and the resulting residue was purified by column chromatography (1:6 EtOAc-petroleum ether). The resulting intermediate was treated with a 1:1 DCM-TFA mixture (4 mL) at room temperature for 1 h. The solvent was evaporated under reduced pressure, and traces of acid were repeatedly coevaporated with water. The residue was lyophilized from 10 mM HCl to give 8T in 60% yield.

[0323] In a preferred embodiment, the following compound of formula I, characterized by structure 8T, was synthesized according to Scheme 3, route C1: JLF40.

[0324] Route C2: Similar to Route C1, Route C2 represents the coupling reaction between 7T and 2-(N,N-dimethylamino)ethanethiol (C3SH) following a similar protocol. Upon completion of the reaction, the reaction mixture was transferred to a decantation funnel and partitioned between DCM and 0.1 N aqueous HCl (1:1, 20 mL). The organic layer was decanted, dried over MgSO4 or Na2SO4, filtered, and evaporated under reduced pressure. In this case, column chromatography purification was not necessary. The resulting product was lyophilized from 10 mM HCl to give compound 8T in 82% yield.

[0325] In a preferred embodiment, the following compound of formula I, characterized by structure 8T, was synthesized according to Scheme 3, route C2: JLF48.

[0326] Example 4a - Compound JLF19 It was synthesized from compound 3T-L7 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 124 H 238 Cl2N2O 15 S2. Molecular weight: 2132.29 ESI-MS (m / z) 1031.08 ([M-2Cl] 2+).

[0327] Example 4b - Compound JLF20 It was synthesized from compound 3T-L5 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 100 H 190 Cl2N2O 15 S2. Molecular weight: 1795.64 ESI-MS (m / z) 1723.23 ([M-2HCl+H] + ), 862.20([M-2Cl] 2+ ).

[0328] Example 4c - Compound JLF23 It was synthesized from compound 3T-L3 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 76 H 142 Cl2N2O 15 S2. Molecular weight: 1458.99 ESI-MS (m / z) 1385.93 ([M-2HCl+H] + ), 693.98([M-2Cl] 2+ ).

[0329] Example 4d - Compound JLF25 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 72%. Chemical formula: C 110 H 210 Cl2N6O 15 S4. Molecular weight: 2056.06 ESI-MS (m / z) 992.56 ([M-2Cl] 2+ ).

[0330] Example 4e - Compound JLF26 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 76%. Chemical formula: C 112 H 214 I2N6O 15 S4. Molecular weight: 2267.02 ESI-MS (m / z) 1006.49 ([M-2I] 2+ ).

[0331] Example 4f - Compound JLF29 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 77%. Chemical formula: C 132 H 254 Cl2N6O 15 S4. Molecular weight: 2264.65 ESI-MS (m / z) 1160.74 ([M-2Cl] 2+ ).

[0332] Example 4g ​​- Compound JLF30 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 87%. Chemical formula: C 134 H 258 I2N6O 15 S4. Molecular weight: 2575.61 ESI-MS (m / z) 1174.68 ([M-2I] 2+ ).

[0333] Example 4h - Compound JLF31 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 91%. Chemical formula: C 108 H 206 Cl2N6O 15 S4. Molecular weight: 2028.00 ESI-MS (m / z) 978.06 ([M-2Cl] 2+ .

[0334] Example 4i - Compound JLF32 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 66%. Chemical formula: C 128 H 246 Cl2N6O 15 S4. Molecular weight: 2308.54 ESI-MS (m / z) 1132.20 ([M-2Cl] 2+ ).

[0335] Example 4j - Compound JLF33 Compound 4T-L7 was synthesized from the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 86%. Chemical formula: C 130 H 250 Cl2N6O 15 S4. Molecular weight: 2336.60 ESI-MS (m / z) 1146.25 ([M-2Cl] 2+ ).

[0336] Example 4k - Compound JLF35 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C5) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 89%. Chemical formula: C 66 H 122 Cl4N8O 19 S4. Molecular weight: 1601.78 ESI-MS (m / z) 728.30 ([M-2HCl-2Cl] 2+ ).

[0337] Example 4l - Compound JLF40 Synthesized from precursor 7T-L1 and HS-(CH)NMe(CSH) according to Scheme 3, Route C2 (steps 7T-8T). Yield: 82%. Chemical formula: C 56 H 102 Cl2N2O 15 S2. Molecular weight: 1178.45 ESI-MS (m / z) 1105.68 ([M-HCl-Cl] + ), 553.47([M-2Cl] 2+ ).

[0338] Example 4m - Compound JLF41 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 55%. Chemical formula: C 86 H 162 Cl2N6O 15 S4. Molecular weight: 1719.41 ESI-MS (m / z) 1645.95 ([M-HCl-Cl] + ), 824.06([M-2Cl]2+ ).

[0339] Example 4n - Compound JLF42 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 57%. Chemical formula: C 88 H 166 I2N6O 15 S4. Molecular weight: 1930.37 ESI-MS (m / z) 838.06 ([M-2I] 2+ ).

[0340] Example 4o - Compound JLF43 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 52%. Chemical formula: C 84 H 158 Cl2N6O 15 S4. Molecular weight: 1691.36 ESI-MS (m / z) 810.09 ([M-2Cl] 2+ ).

[0341] Example 4p - Compound JLF46 It was synthesized from compound 3T-L7.1 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 124 H 226 Cl2N2O 15 S2. Molecular weight:2021.19 ESI-MS(m / z)1024.38([M-2Cl] 2+ ).

[0342] Example 4q - Compound JLF48 Synthesized from precursor 7T-L1 and HS-(CH2)2N(Boc)Me(C2SH) according to Scheme 3, Route C1 (steps 7T-8T). Yield: 60%. Chemical formula: C 54 H 98 Cl2N2O 15 S2. Molecular weight: 1150.40 ESI-MS (m / z) 1077.63 ([M-HCl-Cl] + ), 536.44([M-2Cl] 2+ ).

[0343] Example 4r - Compound JLF50 It was synthesized from compound 3S-L1 according to Scheme 2 (steps 3S-4S) in quantitative yield. Chemical formula: C 52 H 94 Cl2N2O 15 S2. Molecular weight: 1122.34 ESI-MS (m / z) 1049.63 ([M-HCl-Cl] + ), 525.44([M-2Cl] 2+ ).

[0344] Example 4s - Compound JLF54 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C3) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 59%. Chemical formula: C 62 H 114 Cl2N6O 15 S4. Molecular weight: 1382.76 ESI-MS (m / z) 1309.71 ([M-HCl-Cl] + ), 655.57([M-2Cl] 2+ ).

[0345] Example 4t-Compound JLF55 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C4) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 59%. Chemical formula: C 64 H 118 I2N6O 15 S4. Molecular weight: 1593.72 ESI-MS (m / z) 1338.63 ([M-HI-I] + ),1338.63([M-HI-Me3NI] + ),669.80([M-2I] 2+ ),639.99([MI-Me3NI] 2+ ).

[0346] Example 4u - Compound JLF58 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code OH1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 69%. Chemical formula: C 62 H 114 Cl2N6O 17 S4. Molecular weight: 1414.76 ESI-MS (m / z) 1341.70 ([M-HCl-Cl] + ), 671.61([M-2Cl] 2+ ).

[0347] Example 4v - Compound JLF59 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C1) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 62%. Chemical formula: C 58 H 106 Cl2N6O 15 S4. Molecular weight: 1326.65 ESI-MS (m / z) 1253.69 ([M-HCl-Cl] + ), 627.59([M-2Cl] 2+ ).

[0348] Example 4w - Compound JLF60 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C2) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 49%. Chemical formula: C 60 H 110 Cl2N6O 15 S4. Molecular weight: 1354.71 ESI-MS (m / z) 1284.69 ([M-HCl-Cl] + ), 641.59([M-2Cl] 2+ ).

[0349] Example 4x - Compound JLF62 It was synthesized from compound 3S-L3 according to Scheme 2 (steps 3S-4S) in quantitative yield. Chemical formula: C 76 H 142 Cl2N2O 15 S2. Molecular weight: 1458.99 ESI-MS (m / z) 1385.98 ([M-2HCl+H] + ), 693.95([M-2Cl]2+ ).

[0350] Example 4y - Compound JLF66 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C3) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 81%. Chemical formula: C 86 H 162 Cl2N6O 15 S4. Molecular weight: 1719.41 ESI-MS (m / z) 1646.99 ([M-HCl-Cl] + ), 824.14([M-2Cl] 2+ ).

[0351] Example 4z - Compound JLF67 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C4) according to Scheme 2, Route A2 (steps 4S-6S). Yield: 85%. Chemical formula: C 88 H 166 I2N6O 15 S4. Molecular weight: 1930.37 ESI-MS (m / z) 1615.91 ([M-HI-I] + ),838.21([M-2I] 2+ ).

[0352] Example 4aa - Compound JLF68 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C1) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 57%. Chemical formula: C 82 H 154 Cl2N6O 15 S4. Molecular weight: 1663.30 ESI-MS (m / z) 1590.90 ([M-HCl-Cl] + ), 796.06([M-2Cl] 2+ ).

[0353] Example 4ab - Compound JLF69 According to Scheme 2, Route A1 (steps 4S-6S), compound 4S-L3 was synthesized from the corresponding isothiocyanate reagent (code C2). Yield: 73%. It was synthesized according to Route A1 by coupling compounds 4S-L3 and C2. Overall yield (2 steps) from 4S-L3 was 73%. Chemical formula: C 84 H 158 Cl2N6O 15 S4. Molecular weight: 1691.36 ESI-MS (m / z) 1618.92 ([M-HCl-Cl] + ), 810.09([M-2Cl] 2+ ).

[0354] Example 4ac - Compound JLF76 This compound was synthesized from compound 4S-L1 and the corresponding isothiocyanate reagent (code C5) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 66%. Chemical formula: C 66 H 122 Cl4N8O 19 S4. Molecular weight: 1601.78 ESI-MS (m / z) 1454.66 ([M-4HCl-H] - ).

[0355] Example 4ad - Compound JLF77 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C5) according to Scheme 2, Route A1 (steps 4S-6S). Yield: 62%. Chemical formula: C 90 H 170 Cl4N8O 19 S4. Molecular weight: 1938.43 ESI-MS (m / z) 897.20 ([M-2HCl-2Cl] 2+ ).

[0356] Example 4ae - Compound JLF78 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C5) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 68%. Chemical formula: C 90 H 170 Cl4N8O 19S4. Molecular weight: 1938.43 ESI-MS (m / z) 897.20 ([M-2HCl-2Cl] 2+ ).

[0357] Example 4af - Compound JLF81 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 86%. Chemical formula: C 66 H 118 Cl2N6O 17 S4. Molecular weight: 1466.84 ESI-MS (m / z) 1393.77 ([M-HCl-Cl] + ), 697.87([M-2Cl] 2+ ).

[0358] Example 4ag - Compound JLF82 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C7) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 66%. Chemical formula: C 68 H 126 Cl4N8O 15 S4. Molecular weight: 1565.84 ESI-MS (m / z) 1419.81 ([M-3HCl-Cl] + ), 710.90([M-2HCl-2Cl] 2+ ), 1418.96([M-4HCl-H] - ).

[0359] Example 4ah - Compound JLF87 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C10) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 89%. Chemical formula: C 64 H 108 Cl2N8O 15 S4. Molecular weight: 1428.75 ESI-MS (m / z) 1355.67 ([M-HCl-Cl] + ), 678.77([M-2Cl] 2+ ).

[0360] Example 4ai - Compound JLF90 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C10.2) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 73%. Chemical formula: C 64 H 108 Cl2N8O 15 S4. Molecular weight: 1428.75 ESI-MS (m / z) 1355.68 ([M-HCl-Cl] + ), 678.77([M-2Cl] 2+ ), 1354.61([M-2HCl-H] - ).

[0361] Example 4aj - Compound JLF93 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C8) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 81%. Chemical formula: C 66 H 122 Cl4N8O 15 S4. Molecular weight: 1537.78 ESI-MS (m / z) 1391.74 ([M-3HCl-Cl] + ), 696.90([M-2Cl] 2+ ), 647.65([M-Hexanoyl-2Cl] 2+ ), 1390.84([M-4HCl-H] - ).

[0362] Example 4ak - Compound JLF94 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C11) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 95%. Chemical formula: C 60 H 110 Cl2N 10 O 15 S4. Molecular weight: 1410.74 ESI-MS (m / z) 1337.68 ([M-HCl-Cl] + ), 669.73([M-2Cl] 2+ ), 1336.62([M-2HCl-H] - ).

[0363] Example 4a1 - Compound JLF95 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C10.1) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 42%. Chemical formula: C 64 H 108 Cl2N8O 15 S4. Molecular weight: 1428.75 ESI-MS (m / z) 1355.65 ([M-HCl-Cl] + ), 678.79([M-2Cl] 2+ ), 1354.62([M-2HCl-H] - ).

[0364] Example 4am - Compound JLF96 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH2) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 97%. Chemical formula: C 64 H 118 Cl2N6O 17 S4. Molecular weight: 1442.81 ESI-MS (m / z) 1369.76 ([M-HCl-Cl] + ), 685.79([M-2Cl] 2+ ).

[0365] Example 4an - Compound JLF97 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH3) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 34%. Chemical formula: C 66 H 122 Cl2N6O 17 S4. Molecular weight: 1470.87 ESI-MS (m / z) 1397.78 ([M-HCl-Cl] + ), 699.81([M-2Cl] 2+ ).

[0366] Example 4ao - Compound JLF98 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C11) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 99%. Chemical formula: C 84 H158 Cl2N 10 O 15 S4. Molecular weight: 1747.38 ESI-MS (m / z) 838.07 ([M-2Cl] 2+ ).

[0367] Example 4ap - Compound JLF99 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 45%. Chemical formula: C 90 H 166 Cl2N6O 17 S4. Molecular weight: 1803.48 ESI-MS (m / z) 1731.03 ([M-HCl-Cl] + ), 866.19([M-2Cl] 2+ ).

[0368] Example 4aq - Compound JLF102 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C18) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 94%. Chemical formula: C 62 H 118 Cl4N8O 15 S4. Molecular weight: 1485.71 ESI-MS (m / z) 1339.69 ([M-HCl-Cl] + ), 670.54([M-2Cl] 2+ ), 1338.93([M-2HCl-H] - ).

[0369] Example 4ar-Compound JLF103 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C18) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 62%. Chemical formula: C 86 H 166 Cl4N8O 15 S4. Molecular weight: 1822.36 ESI-MS (m / z) 1677.15 ([M-3HCl-Cl] + ), 839.10([M-2HCl-2Cl] 2+ ).

[0370] Example 4a - Compound JLF106 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C14) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 94%. Chemical formula: C 62 H 110 Cl2N6O 15 S4. Molecular weight: 1378.73 ESI-MS (m / z) 1305.94 ([M-HCl-Cl] + ), 653.86([M-2Cl] 2+ ), 1350.66([M-2HCl+HCO2] - ).

[0371] Example 4 at-Compound JLF108 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C7) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 78%. Chemical formula: C 92 H 174 Cl4N8O 15 S4. Molecular weight: 1902.49 ESI-MS (m / z) 1757.06 ([M-3HCl-Cl] + ), 879.22([M-2HCl-2Cl] 2+ ), 1755.25([M-4HCl-H] - ).

[0372] Example 4au-Compound JLF110 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C10) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 72%. Chemical formula: C 88 H 156 Cl2N8O 15 S4. Molecular weight: 1765.40 ESI-MS (m / z) 1691.98 ([M-HCl-Cl] + ), 847.16([M-2Cl] 2+ ).

[0373] Example 4av - Compound JLF111 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C10.2) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 49%. This compound was synthesized via Route B1 by coupling compounds 5T-L3 and C10.2. Overall yield (2 steps) from 5T-L3 was 49%. Chemical formula: C 88 H 156 Cl2N8O 15 S4. Molecular weight: 1765.70 ESI-MS (m / z) 1692.93 ([M-HCl-Cl] + ), 847.13([M-2Cl] 2+ ), 1691.14([M-2HCl-H] - ).

[0374] Example 4aw - Compound JLF115 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C8) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 68%. Chemical formula: C 90 H 170 Cl4N8O 15 S4. Molecular weight: 1874.43 ESI-MS (m / z) 1571.05 ([M-3HCl-Cl] + ), 865.23([M-2HCl-2Cl] 2+ ).

[0375] Example 4ax - Compound JLF120 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C43) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 88%. Chemical formula: C 66 H 130 Cl6N 10 O 15 S 10 . Molecular weight: 1644.76 ESI-MS (m / z) 1426.74 ([M-5HCl-Cl] + ), 713.56([M-4HCl-2Cl] 2+ ), 1424.65([M-6HCl-H] - ).

[0376] Example 4ay - Compound JLF121 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C43) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 55%. This compound was synthesized via Route B1 by coupling compounds 5T-L3 and C43. Overall yield (2 steps) from 5T-L3 was 55%. Chemical formula: C 90 H 178 Cl6N 10 O 15 S 10 . Molecular weight: 1981.41 ESI-MS (m / z) 1763.11 ([M-5HCl-Cl] + ), 882.20([M-4HCl-2Cl] 2+ ), 1761.32 ([M-6HCl-H] - ).

[0377] Example 4az - Compound JLF125 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C16) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 60%. Chemical formula: C 66 H 122 Cl2N6O 15 S4. Molecular weight: 1438.87 ESI-MS (m / z) 1365.77 ([M-HCl-Cl] + ), 683.99([M-2Cl] 2+ ), 1364.81([M-2HCl-H] - ).

[0378] Example 4ba - Compound JLF128 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C18) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 76%. This compound was synthesized via Route B2 by coupling compounds 5T-L3 and C18. Yield: 76% from 5T-L3. Chemical formula: C 90 H 170 Cl2N6O 15 S4. Molecular weight: 1775.52 ESI-MS (m / z) 1703.07 ([M-HCl-Cl] +), 852.21([M-2Cl] 2+ ), 1701.28([M-2HCl-H] - ).

[0379] Example 4bb - Compound JLF130 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH12) according to Scheme 1, Route B2 (steps 5T-6T) in 71% yield. Chemical formula:C 70 H 130 Cl4N8O 17 S4. Molecular weight: 1625.89 ESI-MS(m / z)1479.81([M-3HCl-Cl] + ), 740.95([M-2HCl-2Cl] 2+ ), 1478.81([M-4HCl-H] - ).

[0380] Example 4bc - Compound JLF131 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C46) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 40%. Chemical formula: C 98 H 182 Cl2N 10 O 19 S4. Molecular weight: 2003.73 ESI-MS (m / z) 1931.17 ([M-HCl-Cl] + ), 966.35([M-2Cl] 2+ ), 1929.40([M-2HCl-H] - ), 1965.40([M-HCl-H] - ).

[0381] Example 4bd - Compound JLF134 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH5) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 74%. Chemical formula: C 66 H 122 Cl2N6O 19S4. Molecular weight: 1502.87 ESI-MS (m / z) 1429.97 ([M-HCl-Cl] + ), 715.89([M-2Cl] 2+ ), 1428.72([M-2HCl-H] - ).

[0382] Example 4be - Compound JLF135 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH10) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 61%. Chemical formula: C 66 H 122 Cl2N6O 21 S4. Molecular weight: 1534.86 ESI-MS (m / z) 1461.79 ([M-HCl-Cl] + ), 731.90([M-2Cl] 2+ ), 1460.71([M-2HCl-H] - ).

[0383] Example 4bf - Compound JLF138 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C7.1) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 90%. Chemical formula: C 72 H 134 Cl4N6O 15 S4. Molecular weight: 1621.95 ESI-MS (m / z) 1475.94 ([M-3HCl-Cl] + ), 739.04([M-2HCl-2Cl] 2+ ), 1475.01([M-4HCl-H] - ).

[0384] Example 4bg - Compound JLF139 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C15) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 99%. Chemical formula: C 62 H 114 Cl2N6O 15S4. Molecular weight: 1382.76 ESI-MS (m / z) 1309.84 ([M-HCl-Cl] + ), 655.88([M-2Cl] 2+ ), 1308.96([M-2HCl-H] - ).

[0385] Example 4bh - Compound JLF141 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C12) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 78%. Chemical formula: C 66 H 126 Cl4N8O 15 S4. Molecular weight: 1541.82 ESI-MS (m / z) 1395.90 ([M-3HCl-Cl] + ), 698.68([M-2HCl-2Cl] 2+ ), 1394.92([M-4HCl-H] - ).

[0386] Example 4 bi-compound JLF142 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code OH5) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 39%. Chemical formula: C 66 H 126 Cl4N8O 15 S4. Molecular weight: 1541.82 ESI-MS (m / z) 1767.15 ([M-3HCl-Cl] + ), 884.24([M-2HCl-2Cl] 2+ ), 1765.37([M-4HCl-H] - ).

[0387] Example 4bj - Compound JLF150 It was synthesized from precursor 3T-L2 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 64 H 118 Cl2N2O 15 S4. Molecular weight: 1290.67. ESI-MS(m / z)1217.91([M-HCl-Cl] +), 609.45([M-2Cl] 2+ ).

[0388] Example 4bk - Compound JLF154 Compound 4T-L2 was synthesized from the corresponding isothiocyanate reagent (code C9) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 72%. Chemical formula: C 78 H 142 Cl2N6O 17 S4. Molecular weight: 1635.16. ESI-MS(m / z)1561.98([M-HCl-Cl] + ), 781.99([M-2Cl] 2+ ).

[0389] Example 4bl - Compound JLF155 It was synthesized from the diamine precursor 3T-L4 according to Scheme 1 (steps 3T-4T) in quantitative yield. Chemical formula: C 88 H 166 Cl2N2O 15 S4. Molecular weight: 1627.32. ESI-MS(m / z)1555.21([M-HCl-Cl] + ), 778.15([M-2Cl] 2+ ).

[0390] Example 4bm - Compound JLF158 Compound 4T-L4 was synthesized from the corresponding isothiocyanate reagent (code C9) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 61%. Chemical formula: C 102 H 190 Cl2N6O 17 S4. Molecular weight: 1971.81. ESI-MS(m / z)950.19([M-2Cl] 2+ ).

[0391] Example 4bn - Compound JLF163 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C30) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 87%. Chemical formula: C 68 H 110 Cl2N6O15 S4. Molecular weight: 1450.80. ESI-MS(m / z)1377.69([M-HCl-Cl] + ), 689.41([M-2Cl] 2+ ).

[0392] Example 4 bo-Compound JLF164 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C9.1) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 99%. Chemical formula: C 68 H 122 Cl2N6O 15 S4. Molecular weight: 1462.89. ESI-MS(m / z)1389.81([M-HCl-Cl] + ), 695.45([M-2Cl] 2+ ).

[0393] Example 4bp-Compound JLF165 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH6) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 72%. Chemical formula: C 70 H 132 Cl2N6O 17 S4. Molecular weight: 1558.79. ESI-MS(m / z)1485.80([M-HCl-Cl] + ), 743.90([M-2Cl] 2+ ).

[0394] Example 4bq - Compound JLF170 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 4T-6T). Yield: 86%. Chemical formula: C 114 H 214 Cl2N6O 17 S4. Molecular weight: 2140.13. ESI-MS(m / z)2106.80([M-HCl-Cl] + ), 1034.29([M-2Cl] 2+ ).

[0395] Example 4br-Compound JLF200 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C52) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 68%. Chemical formula: C 62 H 114 Cl2N6O 15 S4. Molecular weight: 1382.76. ESI-MS(m / z)1309.80([M-HCl-Cl] + ), 655.44([M-2Cl] 2+ ).

[0396] Example 4bs - Compound JLF201 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C53) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 70%. Chemical formula: C 60 H 110 Cl2N6O 15 S4. Molecular weight: 1354.71. ESI-MS(m / z)1281.7([M-HCl-Cl] + ), 641.42([M-2Cl] 2+ ).

[0397] Example 4bt-Compound JLF218 This compound was synthesized from compound 4S-L3 and the corresponding isothiocyanate reagent (code C9) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 56%. Chemical formula: C 90 H 166 Cl2N6O 17 S4. Molecular weight: 1803.48. ESI-MS(m / z)1731.08([M-HCl-Cl] + ), 866.11([M-2Cl] 2+ ).

[0398] Example 4bu-Compound JLF220 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code C65) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 79%. Chemical formula: C 62 H 114 Cl2N 10O 15 S4. Molecular weight: 1438.79. ESI-MS(m / z)1365.77([M-HCl-Cl] + ), 683.45([M-2Cl] 2+ ).

[0399] Example 4bv - Compound JLF223 This compound was synthesized from the diisothiocyanate precursor 5T-L1 and the corresponding amine reagent (code OH7) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 75%. Chemical formula: C 74 H 138 Cl2N6O 19 S4. Molecular weight: 1615.08. ESI-MS(m / z)1541.90([M-HCl-Cl] + ), 771.97([M-2Cl] 2+ ).

[0400] Example 4bw - Compound JLF234 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C70) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 51%. Chemical formula: C 94 H 174 Cl2N6O 17 S4. Molecular weight: 1859.59. ESI-MS(m / z)1787.35([M-HCl-Cl] + ), 894.28([M-2Cl] 2+ ).

[0401] Example 4bx - Compound JLF237 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C26) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 23%. Chemical formula: C 88 H 160 Cl2N 16 O 15 S4. Molecular weight: 1881.49. ESI-MS(m / z)905.17([M-2Cl] 2+ ).

[0402] Example 4bx - Compound JLF238 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C59.2) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 66%. Chemical formula: C 94 H 174 Cl2N6O 17 S4. Molecular weight: 1859.59. ESI-MS(m / z)894.19([M-2Cl] 2+ ).

[0403] Example 4 by-compound JLF244 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C63) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 66%. Chemical formula: C 94 H 172 Cl2N8O 17 S4. Molecular weight: 1885.59. ESI-MS(m / z)1813.12([M-HCl-Cl] + ), 907.18([M-2Cl] 2+ ).

[0404] Example 4bz - Compound JLF245 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C68) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 60%. Chemical formula: C 90 H 164 Cl2N8O 17 S4. Molecular weight: 1829.48. ESI-MS(m / z)1757.08([M-HCl-Cl] + ), 879.15([M-2Cl] 2+ ).

[0405] Example 4ca - Compound JLF248 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C59.1) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 58%. Chemical formula: C 94 H 174 Cl2N6O 17 S4. Molecular weight: 1859.59. ESI-MS(m / z)1786.13([M-HCl-Cl]+ ), 894.17([M-2Cl] 2+ ).

[0406] Example 4cb - Compound JLF301 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C66) according to Scheme 1, Route B1 (steps 4T-6T). Yield: 77%. Chemical formula: C 94 H 172 Cl2N8O 17 S4. Molecular weight: 1885.59. ESI-MS(m / z)1812.25([M-HCl-Cl] + ), 907.19([M-2Cl] 2+ ).

[0407] Example 4 cc - Compound JLJB604 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C3) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 69%. Chemical formula: C 62 H 114 Cl2N6O 15 S4. Molecular weight: 1382.76 ESI-MS (m / z) 1309.62 ([M-HCl-Cl] + ), 655.53([M-2Cl] 2+ ).

[0408] Example 4cd - Compound JLJB605 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C4) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 94%. Chemical formula: C 64 H 118 I2N6O 15 S4. Molecular weight: 1593.72 ESI-MS (m / z) 1278.58 ([MI-Me3NI] + ),669.80([M-2I] 2+ ), 1382.20([M-2HI+Cl] - ), 1323.49([M-HI-Me3NI+HCO2] + ).

[0409] Example 4ce - Compound JLJB617 This compound was synthesized from compound 4T-L3 and the corresponding isothiocyanate reagent (code C1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 21%. Chemical formula: C 82 H 154 Cl2N6O 15 S4. Molecular weight: 1663.30 ESI-MS (m / z) 795.97 ([M-2Cl] 2+ ).

[0410] Example 4cf - Compound JLJB618 Compound 4T-L5 was synthesized from the corresponding isothiocyanate reagent (code C1) according to Scheme 1, Route A1 (steps 4T-6T). Yield: 50%. Chemical formula: C 106 H 202 Cl2N6O 15 S4. Molecular weight: 1999.95 ESI-MS (m / z) 1927.39 ([M-HCl-Cl] + ), 964.29([M-2Cl] 2+ ).

[0411] Example 4cg - Compound JLJB619 Compound 4T-L1 was synthesized from the corresponding isothiocyanate reagent (code C2) according to Scheme 1, Route A2 (steps 4T-6T). Yield: 52%. Chemical formula: C 60 H 110 Cl2N6O 15 S4. Molecular weight: 1354.71 ESI-MS (m / z) 1281.40 ([M-HCl-Cl] + ), 641.22([M-2Cl] 2+ ).

[0412] Example 4ch - Compound PER20 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code OH1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 59%. Chemical formula: C 86 H 162 Cl2N6O 17S4. Molecular weight: 1751.41 ESI-MS (m / z) 840.14 ([M-2Cl] 2+ ).

[0413] Example 4ci - Compound JLF190 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C9.1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 87%. Chemical formula: C 92 H 170 Cl2N6O 15 S4. Molecular weight: 1799.54. ESI-MS(m / z)1727.11([M-HCl-Cl] + ), 864.11([M-2Cl] 2+ ).

[0414] Example 4cj - Compound JLF601 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C47) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 10%. Chemical formula: C 88 H 160 NO 17 S4. Molecular weight: 1702.51. ESI-MS(m / z)1701.11([MH] - ).

[0415] Example 4ck-Compound JLF602 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C48) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 84%. Chemical formula: C 92 H 170 Cl2N6O 17 S4. Molecular weight: 1831.54. ESI-MS(m / z)880.17([M-2Cl] 2+ ).

[0416] Example 4 cl-Compound JLF604 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C54) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 24%. Chemical formula: C 92H 166 Cl2N6O 17 S4. Molecular weight: 1827.51. ESI-MS(m / z)1773.11([M-HCl-Cl+H2O] + ), 896.21([M-2Cl+2H2O] 2+ ).

[0417] Example 4 cm - Compound JLF605 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C59) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 58%. Chemical formula: C 92 H 166 Cl2N6O 17 S4. Molecular weight: 1831.54. ESI-MS(m / z)1759.10([M-HCl-Cl] + ), 880.15([M-2Cl] 2+ ).

[0418] Example 4cn - Compound JLF606 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C60) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 90%. Chemical formula: C 92 H 166 Cl2F4N6O 15 S4. Molecular weight: 1871.50. ESI-MS(m / z)1799.06([M-HCl-Cl] + ), 900.11([M-2Cl] 2+ ).

[0419] Example 4 co-compound JLF607 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C61) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 85%. Chemical formula: C 90 H 166 Cl2N6O 15 S6. Molecular weight: 1835.51. ESI-MS(m / z)1762.30([M-HCl-Cl] + ), 881.65([M-2Cl] 2+ ).

[0420] Example 4 cp-compound JLF608 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C62) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 51%. Chemical formula: C 90 H 166 Cl2N6O 15 S6. Molecular weight: 1867.60. ESI-MS(m / z)1795.05([M-HCl-Cl] + ), 898.12([M-2Cl] 2+ ).

[0421] Example 4cq - Compound JLF197 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C63) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 95%. Chemical formula: C 90 H 166 Cl2N6O 19 S6. Molecular weight: 1899.60. ESI-MS(m / z)1827.02([M-2Cl] 2+ ).

[0422] Example 4cr-Compound PRX051 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C48.1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 86%. Chemical formula: C 92 H 170 Cl2N6O 17 S4. Molecular weight: 1827.59. ESI-MS(m / z)1755.18([M-HCl-Cl] + ), 878.18([M-2Cl] 2+ ).

[0423] Example 4cs - Compound PRX052 This compound was synthesized from the diisothiocyanate precursor 5T-L3 and the corresponding amine reagent (code C47.1) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 90%. Chemical formula: C 90 H 166 Cl2N6O15 S4. Molecular weight: 1771.49. ESI-MS(m / z)1699.11([M-HCl-Cl] + ), 850.12([M-2Cl] 2+ ).

[0424] Example 4ct - Compound PRX093 This compound was synthesized from the diisothiocyanate precursor 5S-L3 and the corresponding amine reagent (code C10) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 88%. Chemical formula: C 90 H 166 Cl2N6O 15 S4. Molecular weight: 1765.40. ESI-MS(m / z)1692.15([M-HCl-Cl] + ), 847.10([M-2Cl] 2+ ).

[0425] Example 4cu-Compound PRX094 This compound was synthesized from the diisothiocyanate precursor 5S-L3 and the corresponding amine reagent (code C59) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 76%. Chemical formula: C 90 H 166 Cl2N6O 15 S4. Molecular weight: 1831.54. ESI-MS(m / z)1759.23([M-HCl-Cl] + ), 880.18([M-2Cl] 2+ ).

[0426] Example 4cv - Compound PRX096 This compound was synthesized from the diisothiocyanate precursor 5S-L3 and the corresponding amine reagent (code C66) according to Scheme 1, Route B1 (steps 5T-6T). Yield: 63%. Chemical formula: C 90 H 166 Cl2N6O 15 S4. Molecular weight: 1885.59. ESI-MS(m / z)1812.23([M-HCl-Cl] + ), 907.22([M-2Cl] 2+ ).

[0427] Example 4cw - Compound NC117 This compound was synthesized from the diisothiocyanate precursor 5S-L3.1 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 76%. Chemical formula: C 90 H 166 Cl2N6O 17 S4. Molecular weight: 1803.48. ESI-MS(m / z)1731.20([M-HCl-Cl] + ), 866.17([M-2Cl] 2+ ).

[0428] Example 4cx - Compound NC118 This compound was synthesized from the diisothiocyanate precursor 5S-L3.2 and the corresponding amine reagent (code C9) according to Scheme 1, Route B2 (steps 5T-6T). Yield: 65%. Chemical formula: C 90 H 166 Cl2N6O 17 S4. Molecular weight: 1803.48. ESI-MS(m / z)1731.21([M-HCl-Cl] + ), 866.18([M-2Cl] 2+ ).

[0429] Example 4 cy-Compound JMB500 This compound was synthesized from the diisothiocyanate precursor 5M-L3 and the corresponding amine reagent (code C9) according to Scheme 4, Route B2 (steps 5M-6M). Yield: 91%. Chemical formula: C 81 H 150 Cl2N6O 16 S4. Molecular weight: 1663.26. ESI-MS(m / z)1591.13([M-HCl-Cl] + ), 796.10([M-2Cl] 2+ ).

[0430] Example 4cz-Compound JMB501 This compound was synthesized from the diisothiocyanate precursor 5M-L3 and the corresponding amine reagent (code C10.1) according to Scheme 4, Route B2 (steps 5M-6M). Yield: 89%. Chemical formula: C 79 H 140 Cl2N6O16 S4. Molecular weight: 1625.17. ESI-MS(m / z)1552.16([M-HCl-Cl] + ), 777.06([M-2Cl] 2+ ).

[0431] Example 4da - Compound JMB503 This compound was synthesized from the diisothiocyanate precursor 5M-L3 and the corresponding amine reagent (code C59) according to Scheme 4, Route B2 (steps 5M-6M). Yield: 95%. Chemical formula: C 83 H 154 Cl2N6O 16 S4. Molecular weight: 1691.31. ESI-MS(m / z)1619.17([M-HCl-Cl] + ), 810.13([M-2Cl] 2+ ).

[0432] Example 5 - Intramuscular vaccination Forty female BALB / c mice were divided into six groups. One group received buffer only as a negative control, and the other five groups received 1 μg of saRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009 formulated with different oligosaccharides (JRL13, JLF102, JLF97, and JLF94). All saRNA formulations were administered i.m. into one leg. All saRNA groups were formulated at N / P6 for the different oligosaccharides or at N / P6 for linear polyethyleneimine 22.5 kDa (AVROXA, Ghent, Belgium), PEI500, as a benchmark. N / P ratios were calculated based on the oligosaccharide-RNA or secondary amine-RNA charge ratio for PEI-formulated saRNA. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide-containing solution was 9:1 (v:v) in all cases. Polyethylenimine was formulated by mixing the RNA-containing solution and the polymer solution in an equal volume ratio. Animals underwent noninvasive serological monitoring at different time points (days 0, 14, 21, 28, and 49) over 49 days, and spleens were removed at the end of the experiment. Anti-influenza HA antibodies in the serum were quantified by enzyme-linked immunosorbent assay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 14A is a graph showing the hydrodynamic diameter of compositions containing saRNA complexed with different oligosaccharides. Figure 14B shows the serological levels of specific IgG against HA over the course of the experiment. Figure 14C shows the endpoint titration of serological levels of specific IgG to HA. Figure 14D shows the CD8 / CD4 response to the HA peptide pool.

[0433] From all tested groups, JLF94, which contains a guanidine group, performed best overall at both the humoral and cellular levels (Figures 14B-D). JLF97 induced a strong humoral response, but the overall T cell response was lower compared to JLF94 (Figure 14D).

[0434] Example 6 - Effect of surfactants Fifteen female BALB / c mice were divided into three study groups. All groups received the same amount of formulated luciferase-encoding modRNA (2 μg) administered im into each leg. Each group received a combination of JLF99 and either Tween 20, Tween 40, or Tween 60 at a 1:0.5 molar ratio (oligosaccharide:Tween (20 / 40 / 60)). All groups received modRNA formulated with an N / P of 6. The N / P was calculated based on the oligosaccharide-to-RNA charge ratio. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.1 mg / ml. The mixing ratio of the RNA-containing solution and the JLF99 + Tween (20 / 40 / 60)-containing solution was 9:1 (v:v) in all cases. Formulations were characterized prior to injection to confirm hydrodynamic diameter. In vivo luciferase expression in administered tissues was measured at five time points (6 hours, 1 day, 2 days, 3 days, and 6 days). Figure 15A is a bar graph showing the hydrodynamic diameter of compositions containing JLF99 and modRNA formulated with different polysorbates in N / P6. Figure 15B shows quantified bioluminescence at the injection site at different time points over the course of the experiment. Figure 15C shows quantitative bioluminescence in the liver 6 hours and 24 hours after injection of modRNA.

[0435] Example 7 - Intramuscular vaccination with JLF99 and modRNA Fifteen female BALB / c mice were divided into three study groups. All groups received the same amount (1 μg) of formulated modRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009. All formulations were administered im into one leg in a prime / boost schedule (d0 / d28). All modRNA groups were formulated with N / P 6. The N / P ratio was calculated based on the ratio of amine to phosphate charge. One group received modRNA formulated with a combination of JLF99 and Tween 20 at a 1:0.5 molar ratio (oligosaccharide:Tween 20). One group received modRNA formulated in benchmark LNPs containing ionizable lipids, cholesterol, DSPC, and C14-pSar23 at a molar ratio of 47.5:38.5:10:4. One group received buffer alone as a negative control. The JLF99 composition was complexed with RNA in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, and the mixing ratio of the RNA-containing solution and the JLF99 + Tween 20-containing solution was 9:1 (v:v) in all cases.

[0436] LNP formulations were produced in HEPES-buffered sucrose (HBS, HEPES 10 mM, 10% w / v sucrose) according to standard LNP production methods widely described in the literature. See Nogueira, et al., ACS Appl. Nano. Mater., 3(11):10634-10645 (2020). Briefly, LNPs were produced at a molar ratio of lipid mixture in ethanol mixed with modRNA in citrate buffer (pH 4.5) at a 3:1 ratio and a mixing rate of 12 mL / min. The LNPs were then dialyzed for 3 hours with a final exchange into HBS. Animals were subjected to noninvasive serological monitoring at different time points (days 0, 14, 21, 28, and 49) over 49 days, and spleens were removed at the end of the experiment to quantify CD4 / CD8 T cell responses to influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme-linked immunosorbent assay. Virus neutralization titers were quantified by VNT assay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 16A shows the serological levels of specific IgG to HA over the course of the experiment. Figure 16B shows influenza-specific neutralization titers over the course of the experiment. Figure 16C shows the endpoint titration of serological levels of specific IgG to HA. Figure 16D shows the CD8 / CD4 responses to HA peptide pools. The presented results (Figures 16A-D) demonstrate that the provided compositions provide robust immunological results that are at least comparable to current LNP standards in the field. Following the evolution of IgG against the HA antigen over the course of the experiment in Figure 16A, no clear differences were detected between the JLF99 formulation and the LNP benchmark. The same findings were achieved with virus neutralization titers, shown in Figure 16B. Finally, antibody concentrations at the end of the experiment (day 49), shown in Figure 16C, also demonstrated that serological concentrations of IgG were comparable to the LNP group. The CD4-CD8 responses of the LNP benchmark and JLF99 did not show significant differences (Figure 16D).

[0437] Example 8 - Intramuscular vaccination with JLF99 and different RNA platforms Twenty female BALB / c mice were divided into four study groups. All groups received the same amount (1 μg) of a different RNA platform, all encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009 formulated in JLF99 and Tween 20 (1:0.5 molar ratio). In the first group, mice received an RNA platform consisting of a trans-amplifying RNA (taRNA) consisting of two RNAs: one encoding the viral replicase and the second RNA encoding the HA antigen. In the second group, mice received RNA containing a self-amplifying RNA (saRNA). In the third group, the RNA consisted of m1Y-modified mRNA (modRNA). In the third group, mice received buffer only as a negative control. All formulations were administered im in one leg in a prime / boost schedule (i.e., doses administered on days 0 and 28). All formulations were prepared in N / P6. The JLF99-containing composition was complexed with RNA in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, and the mixing ratio of the RNA-containing solution to the JLF99+Tween20-containing solution was 9:1 (v:v) in all cases.

[0438] Animals were subjected to noninvasive serological monitoring at different time points (days 0, 14, 21, 28, and 49) for 49 days. At the end of the experiment, spleens were harvested and CD4 / CD8 T cell responses to influenza HA peptides were quantified. Anti-influenza HA antibodies in serum were quantified by enzyme-linked immunosorbent assay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 17A is a plot showing the serological levels of specific IgG against HA using different RNA complexes formulated with JLF99 at different time points over the course of the experiment. Figure 17B shows the endpoint titration of serological levels of specific IgG against HA using different RNA platforms formulated with JLF99. Figure 17C shows the CD8 / CD4 responses to HA peptide pools from different RNA platforms formulated with JLF99.

[0439] This example demonstrates that the oligosaccharides described herein provide for delivery of a wide variety of different mRNAs. In this experiment, the length of the RNA varied dramatically: saRNA was approximately 9200 nucleotides in length, taRNA was approximately 7200 nucleotides in length (replicase RNA) and approximately 2100 nucleotides in length (HA mRNA), and modRNA was 2100 nucleotides in length. Regardless of the length of the RNA and whether the RNA was replicating or non-replicating, JLF99 functionally delivered all RNAs upon im injection and elicited a strong immune response.

[0440] Example 9 - Effects of intravenous delivery of heterocyclic amines on the liver This example compares two modRNA (encoding luciferase) formulations complexed with either JLF99 or JLF218.

[0441] Six female BALB / c mice were divided into two groups. One group received modRNA formulated with JLF218 and Tween 40. The other group received modRNA formulated with JLF99 and Tween 40. A total of 2 μg of formulated modRNA was injected retro-orbitally. Six hours later, in vivo biodistribution was quantified by measuring luciferase expression in different organs. All RNA groups were formulated with N / P 6. The N / P ratio was calculated based on the ratio of amine to phosphate charge ratio. Oligosaccharide formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.02 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharide + Tween 40-containing solution. Figure 18A is a plot showing the average liver radiance of exemplary compositions containing JLF99 or JLF218. FIG. 18B is an image showing bioluminescence in the ventral axis 6 hours after injection of each group with an exemplary formulation.

[0442] Example 10 - Vaccine adjuvant activity This example reports the adjuvant activity of six different formulations of the present disclosure. [Table 4]

[0443] All groups received modRNA formulated in N / P6. The formulation was complexed with RNA in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.15 mg / ml, with a mixing ratio of 9:1 (v:v) between the RNA-containing solution and the oligosaccharides + Tween 40-containing solution in all cases. 6 IL-6, TNF-α, IL-1β, and IFN-γ secretion 24 hours after transfection of hPMBCs was assessed in the supernatant using the MSD kit standard protocol.

[0444] Figure 19A is a plot showing IL-6 secretion by hPBMCs upon exposure to different doses of the test formulation. Figure 19B is a plot showing TNF-α secretion by hPBMCs upon exposure to different doses of the test formulation. Figure 19C is a plot showing IL-1β secretion by hPBMCs upon exposure to different doses of the test formulation. Figure 19D is a plot showing IFN-γ secretion by hPBMCs upon exposure to different doses of the test formulation. In the second part of the experiment, the same test formulations were used in vaccination studies.

[0445] Thirty-five female BALB / c mice were divided into seven groups. Each group received 0.5 μg of modRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009 im in one leg in a prime / boost schedule (day 0 / day 28). In total, six different formulations containing modRNA encoding HA were tested. [Table 5]

[0446] One group received buffer as a negative control.

[0447] All groups received modRNA formulated with N / P 6. N / P was calculated based on the oligosaccharide-to-RNA charge ratio. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.025 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide + Tween 40-containing solution was 9:1 (v:v) in all cases. Animals underwent noninvasive serological monitoring at different time points throughout the course of the experiment (days 0, 14, 21, 28, and 49), and their spleens were removed at the end of the experiment to quantify CD4 / CD8 T cell responses to influenza HA peptides. Anti-influenza HA antibodies in the serum were quantified by enzyme-linked immunosorbent assay. CD4 / CD8 T cell responses were quantified via IFN-ELISPOT of splenocytes. Figure 19E is a plot showing the serological levels of specific IgG against HA formulated with different oligosaccharides. Figure 19F is a plot showing the endpoint titration of serological levels of specific IgG to HA. Figure 19G is a bar graph showing the CD8 / CD4 response to HA peptide pools. Figure 19H is a bar graph showing the hydrodynamic diameter of different test formulations.

[0448] The results presented here demonstrate that JLF99 and the other tested oligosaccharides exhibit strong adjuvant activity. As shown in Figures 19A-D, the highest levels of secretion of proinflammatory cytokines, IL-6, TNF-α, IL-1β, and IFN-γ, were induced by JLF244, whereas JLF110 produced moderate levels, followed by JLF99 and JLF218. The secretion levels of proinflammatory cytokines correlated with the induced immune response to the HA antigen. As shown in Figure 19E, the highest IgG concentration was detected with JLF244, followed by JLF110, then JLF99 and JLF218.

[0449] Example 11 - Mycobacterium tuberculosis-Ag85a antigen This example illustrates the use of an antigen associated with tuberculosis. Here, the Mycobacterium tuberculosis Ag85a antigen was used. A total of 15 female BALB / c mice were divided into three groups. Each group received 1 μg of modRNA encoding the secreted Ag85a protein of Mycobacterium tuberculosis im in one leg in a prime / boost schedule (d0 / d21). In total, two different formulations containing modRNA encoding AG85a were tested: one formulation containing JLF99 and Tween 40 (1:0.5 molar ratio), and LNP benchmark. One final group received buffer as a negative control. All groups received modRNA formulated with N / P6. The JLF99 formulation was complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.05 mg / ml, with a 9:1 (v:v) ratio of RNA-containing solution to oligosaccharide + Tween 40-containing solution. Benchmark LNPs contained ionizable lipids, cholesterol, DSPC, and C14-pSar23 in a molar ratio of 47.5:38.5:10:4. LNP formulations were produced in Hepes-buffered sucrose (HBS, 10 mM Hepes, 10% w / v sucrose) according to standard LNP production methods widely described in the literature. Briefly, LNPs were produced in a 3:1 ratio of lipid mixture in ethanol mixed with modRNA in citrate buffer (pH 4.5) at a flow rate of 12 mL / min. The LNPs were then dialyzed for 3 hours with a final exchange into HBS.

[0450] Animals were subjected to noninvasive serological monitoring at different time points (d0, d14, d21, d49) over 49 days, and spleens were removed at the end of the experiment to quantify CD4 / CD8 T cell responses to the AG85a peptide. Anti-AG85a antibodies in serum were quantified by enzyme-linked immunosorbent assay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 20A shows the serological levels of specific IgG against HA over the course of this example. Figure 20B shows the endpoint titration of serological levels of specific IgG against HA. Figure 20C shows the CD8 / CD4 responses to the HA peptide pool.

[0451] Example 12 - Structural Variations of Oligosaccharides for Vaccination This example examines the impact of the structural variations of the oligosaccharides described herein when incorporated into a vaccine. Thirty female BALB / c were divided into six groups. Each group received 0.5 μg of modRNA encoding the hemagglutinin (HA) protein of the influenza strain California / 7 / 2009 i.m. in one leg according to a prime / boost schedule (d0 / d28). In total, five different formulations containing modRNA encoding HA were tested. [Table 6]

[0452] One final group received buffer as a negative control.

[0453] All groups received modRNA formulated with N / P6. The formulation was complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.025 mg / ml, and the mixing ratio of the RNA-containing solution and the paO+Tween40-containing solution was 9:1 (v:v) in all cases. The animals were subjected to non-invasive serological monitoring over 49 days at different time points (d0, d14, d21, d28, d49), and the spleen was removed at the end of the experiment to quantify the CD4 / CD8 T cell response against the influenza HA peptide. Anti-influenza HA antibodies in the serum were quantified by enzyme immunoassay. The CD4 / CD8 T cell response was quantified by IFN-ELISPOT of splenocytes. Figure 21A shows the serological levels of specific IgG against HA over the course of the example. Figure 21B shows the endpoint titration of the serological levels of specific IgG against HA. Figure 21C shows the CD8 / CD4 response against the HA peptide pool.

[0454] In the dataset, the calculated theoretical pKa was lowest for JLF197, followed by JLF608 < JLF301 < JLF110 < JLF110.

[0455] Example 13 - Further investigation of structural variations in oligosaccharides This example examines the impact of structural variations in the oligosaccharides described herein when incorporated into taRNA-containing vaccines. Twenty female BALB / c mice were divided into five groups. Each group received 0.5 μg of taRNA encoding the hemagglutinin (HA) protein of influenza strain California / 7 / 2009 im in one leg in a prime / boost schedule (d0 / d28). In total, five different formulations containing HA-encoding taRNA were tested. [Table 7]

[0456] One final group was formulated with a replication-deficient taRNA, JLF99, and Tween 40, which is unable to express HA protein, as a negative control.

[0457] All groups received taRNA formulated with N / P6. The formulations were complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.025 mg / ml. The mixing ratio of the RNA-containing solution to the oligosaccharide + Tween 40-containing solution was 9:1 (v:v) for all formulations. Animals underwent noninvasive serological monitoring at different time points (d0, d14, d21, d28, and d49) over 49 days, and spleens were harvested at the end of the experiment to quantify CD4 / CD8 T cell responses to influenza HA peptides. Anti-influenza HA antibodies in serum were quantified by enzyme-linked immunosorbent assay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 22A shows the serological levels of specific IgG against HA over the course of the experiment. Figure 22B shows the endpoint titration of specific IgG against HA. FIG. 22C shows the CD8 / CD4 response to the HA peptide pool.

[0458] Example 14 - Antigen Variation JLF99 was further tested with a different viral antigen, which is significantly less immunogenic than influenza HA. ​​In this example, 12 female C57BL / 6IFNAR- / - mice were divided into two study groups. All groups received the same amount (1.3 μg) of formulated saRNA encoding the glycoprotein (Gc) of Crimean-Congo hemorrhagic fever virus (CCHFV). All formulations were administered im in one leg in a prime / boost schedule (d0 / d28). All saRNA groups were formulated with N / P6.

[0459] The first group received saRNA formulated with a combination of JLF99 and Tween 40 (1:0.5 molar ratio), and the second group received saRNA formulated with benchmark LNP. The JLF99 formulation was complexed in MBG buffer (final concentration 5% w / v glucose, 10 mM MES, pH 6.1) at a final RNA concentration of 0.065 mg / ml, with a 9:1 (v:v) mixing ratio between the RNA-containing solution and the JLF99 + Tween 40-containing solution. Benchmark LNP contains ionizable lipids, cholesterol, DSPC, and C14pSar23 in a molar ratio of 47.5:38.5:10:4. LNP formulations were produced in Hepes-buffered sucrose (HBS, 10 mM Hepes, 10% w / v sucrose) according to standard LNP production methods widely described in the literature. Briefly, LNPs were produced using a mixture of lipids in ethanol at a 3:1 ratio with modRNA in citrate buffer (pH 4.5) at a flow rate of 12 mL / min. The LNPs were then dialyzed for 3 hours with a final exchange into HBS.

[0460] Animals were subjected to noninvasive serological monitoring at different time points (d0, d14, d21, d28, d49) for 49 days, and spleens were removed at the end of the experiment to quantify CD4 / CD8 T cell responses to CCHFV-Gc peptide. Anti-CCHFV Gc antibodies in serum were quantified by enzyme immunoassay. CD4 / CD8 T cell responses were quantified by IFN-ELISPOT of splenocytes. Figure 23A shows the serological levels of specific IgG to Gc over the course of the experiment. Figure 23B shows the endpoint titration of serological levels of specific IgG to Gc. Figure 23C shows the T cell response to Gc peptide.

[0461] JLF99 was able to induce a strong immunological response even with a poorly immunogenic antigen such as CCHFV-Gc. Although the antibody titers at time point (d14) were lower than those achieved by LNP, after d28 (before the boost), the antibody levels were identical to those achieved by the LNP benchmark. T cell responses were equally strong for both test conditions.

Claims

1. A compound of formula I, 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, A is A 1 , A 2 , or A 3 and 【Chemistry 2】 R 1 and R 2 each independently at each instance is H, R a and -C(O)-R a is selected from R 1 Or R 2 At least one instance of is not H, Each R a But independently, C 1 -C 20 aliphatic, C 3 -C 20 cycloaliphatic, C 5 -C 6 aryl, 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S; a But one or more R b optionally replaced by Each R b are independently halogen, -N 3 , -R c , -OR c , -SR c , -NHR c , -C(O)-R c , -OC(O)R c , -NHC(O)R c , -C(O)NHR c and -NHC(O)NHR c is selected from Each R c is independently an optionally substituted C 1 -C 20 Aliphatic, optionally substituted C 3 -C 20 Cycloaliphatic, optionally substituted C 5 -C 6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S; X 1 and X 2 are each independently selected from -S-, and -NH-; Y 1 and Y 2 each independently represents an optionally substituted C 1-30 an aliphatic group in which one or more carbons are optionally and independently selected from -Cy-, -NH-, -NHC(O)-, -C(O)NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -NHC(S)NH-, -C(S)NH-, and -C(O)NHSO 2 -, -SO 2 NHC(O)-, -OC(O)O-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO 2 - is replaced by Each Cy is independently an optionally substituted C 3 -C 14 cycloaliphatic, 5-14 membered heterocyclyl rings having 1-3 heteroatoms selected from N, O, and S, and optionally substituted 5-14 membered heteroaryl rings having 1-3 heteroatoms selected from N, O, and S; Z 1 and Z 2 are each independently an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; + (M) 3 , 【Chemistry 3】 is a cationic or ionizable group selected from Each M is independently -C 0 -C 6 Aliphatic-R z , or -C 0 -C 6 Aliphatic-N + (R z ) 3 and Each R z are independently H, optionally substituted C 1 -C 6 Aliphatic, optionally substituted C 3 -C 20 Cycloaliphatic, optionally substituted C 5 -C 6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; p is an integer selected from 1, 2, 3, 4, or 5; However, A is A 1 If (i) Each R 1 and R 2 is -CO-(CH 2 ) 4 -CH 3 Instead, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both are -(CH 2 ) 2 It never becomes -, Z 1 and Z 2 Both are -N + (H) 3 It will not be, (ii) Each R 1 and R 2 But -(CH 2 ) 5 -CH 3 , or -(CH 2 ) 13 -CH 3 Instead, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both are -(CH 2 ) 2 It never becomes -, Z 1 and Z 2 Both are -N + (H) 3 It will not be, (iii) Each R 1 and R 2 is -CO-(CH 2 ) 4 -CH 3 Instead, X 1 and X 2 Both cannot be -S-, and Y 1 and Y 2 Both are -(CH 2 ) 2 -NH-C(S)-NH-(CH 2 ) 2 It never becomes -, Z 1 and Z 2 Both are -N + (H) 3 It will not be, (iv) The compound, or a pharma- ceutically acceptable salt thereof, wherein Cy is not triazolyl.

2. The compound is of formula Ia, 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof.

3. The compound is of formula Ib, 【Chemistry 5】 or a pharma- ceutically acceptable salt thereof.

4. The compound is of formula Ic, 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof.

5. R 1 and R 2 Each independently represents R a and -C(O)-R a is selected from R a But, C 1 -C 20 The compound according to any one of claims 1 to 4, which is aliphatic.

6. R 1 and R 2 are each -C(O)-R a and R a But, C 1 -C 14 The compound according to any one of claims 1 to 5, which is aliphatic.

7. Each R a But, C 5 -C 10 The compound according to any one of claims 1 to 6, which is a straight chain alkyl.

8. R 1 and R 2 are each -C(O)-R a and each R a But independently, 【Chemistry 7】 2. The compound of claim 1 , selected from:

9. X 1 and X 2 The compound according to any one of claims 1 to 8, wherein each is -S-.

10. Y 1 and y 2 が、each々、C 1 -C 10 Aliphatic, C 0 -C 4 -Aliphatic-NHC(O)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-NHC(S)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-C(O)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-C(S)NH-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-NHC(O)-C 0 -C 4 Aliphatic, C 0 -C 4 -Aliphatic-NHSO 2 -C 0 -C 4 Aliphatics, and C 0 -C 4 -Aliphatic -C(O)-C 0 -C 4 Compounds described in claims 1 to 9 of claims 1 to 9.

11. Y 1 and Y 2 However, each 1 -C 4 Aliphatic-NHC(S)NH-C 1 -C 4 The compound according to any one of claims 1 to 10, which is aliphatic.

12. Y 1 and Y 2 are each -CH 2 -CH 2 -NHC(S)NH-CH 2 -CH 2 The compound according to any one of claims 1 to 11, wherein

13. Part X 1 -Y 1 -Z 1 but, 【Chemistry 8】 The compound according to any one of claims 1 to 12,

14. Part X 2 -Y 2 -Z 2 but, 【Chemistry 9】 The compound according to any one of claims 1 to 13,

15. Z 1 and Z 2 Each independently represents N + (M) 3 , 【Chemistry 10】 The compound according to any one of claims 1 to 14, selected from:

16. Z 1 and Z 2 However, each independently, 【Chemistry 11】 【Chemistry 12】 The compound according to any one of claims 1 to 14, selected from:

17. The oligosaccharide is a compound of formula Id, 【Chemistry 13】 or a pharma- ceutically acceptable salt thereof, wherein n and m are each independently selected from 0, 1, 2, 3, 4, 5, or 6.

18. The oligosaccharide is a compound of formula Id-i, 【Chemistry 14】 or a pharma- ceutically acceptable salt thereof.

19. The compound of any one of claims 1 to 18, further comprising one or more suitable counter ions.

20. The compound of claim 1 , wherein the compound is selected from Table 1.

21. A complex comprising the compound according to any one of claims 1 to 20 and a nucleic acid.

22. The complex of claim 21 , wherein the nucleic acid is RNA.

23. 23. The complex of claim 22, wherein the RNA is modRNA, saRNA, taRNA, or uRNA.

24. 24. The complex of claim 22 or 23, wherein the N / P ratio is less than 20:

1.

25. 25. The complex of claim 24, wherein the N / P ratio is 12:1 or less.

26. The complex of any one of claims 21 to 25, wherein the complex has a diameter of about 30 nm to about 300 nm.

27. The complex of any one of claims 21 to 26, wherein the complex has a diameter of about 50 nm to 200 nm.

28. The complex of any one of claims 21 to 27, further comprising a pharma- ceutically acceptable surfactant.

29. 29. The complex of claim 28, wherein the pharma- ceutically acceptable surfactant is a polysorbate.

30. 30. The complex of claim 28 or 29, wherein the molar ratio of the compound to the pharma- ceutically acceptable surfactant is from about 1:0.0075 to about 1:

3.

31. A method for increasing or causing an increase in expression of RNA in a target in a subject, the method comprising administering to the subject a complex according to any one of claims 21 to 30.

32. 32. The method of claim 31 , wherein the target is selected from the lung, liver, spleen, heart, brain, lymph nodes, bladder, kidney, and pancreas.

33. 31. A method of treating a disease, disorder, or condition in a subject, comprising administering to the subject a conjugate according to any one of claims 21 to 30.

34. 34. The method of claim 33, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.

35. The method of any one of claims 31 to 34, wherein the complex is administered intramuscularly.

36. The method of claim 35, wherein the complex is between 50 nm and 100 nm in diameter.

37. The method of any one of claims 31 to 34, wherein the complex is administered subcutaneously.

38. Use of a compound according to any one of claims 1 to 20 in medicine.

39. 22. Use of the conjugate of claim 21 in medicine.

40. 22. Use of the complex of claim 21 to increase or cause an increase in expression of RNA in a target.

41. 22. Use of the conjugate of claim 21 for the treatment of a disease, disorder, or condition.

42. 42. The use of claim 41, wherein the disease, disorder, or condition is an infectious disease, cancer, a genetic disorder, an autoimmune disease, or a rare disease.

43. A method for preparing an oligosaccharide of formula II, comprising the steps of: 【Chemistry 15】 In the presence of an acid, a compound of formula III is reacted with 【Chemistry 16】 with a compound of formula IV 【Chemistry 17】 During the ceremony, Each R a is optionally substituted -C 1 -C 20 It is aliphatic, Z 1 and Z 2 are each independently an optionally substituted 5- to 14-membered heterocyclyl ring having 1 to 3 heteroatoms selected from N, O, and S; an optionally substituted 5- to 14-membered heteroaryl ring having 1 to 3 heteroatoms selected from N, O, and S; + (M) 3 , 【Chemistry 18】 is a cationic or ionizable group selected from Each M is independently -C 0 -C 6 Aliphatic-R z , or -C 0 -C 6 Aliphatic-N + (R z ) 3 and Each R z are independently H, optionally substituted C 1 -C 6 Aliphatic, optionally substituted C 3 -C 20 Cycloaliphatic, optionally substituted C 5 -C 6 aryl, optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, and optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; or Two or more R's z can be taken together with the atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclyl containing 1-3 heteroatoms selected from N, O, and S, or an optionally substituted 4- to 12-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; Z a -PG 1 But, Z 1 and one R z But, P.G. 1 is substituted with a group, P.G. 1 is a suitable nitrogen protecting group; However, Z 1 and Z 2 Both are -N + (H) 3 The above-mentioned method does not result in

44. First, a compound of formula V is contacted with an acid; 【Chemistry 19】 The resulting product was then dissolved in CSCl 2 to obtain a compound of formula III, In the formula, P.G. 2 is a suitable acid sensitive nitrogen protecting group.

45. The compound of formula VI is 【Chemistry 20】 Contacting with a compound of formula VII 【Chemistry 21】 45. The method of claim 44, comprising obtaining a compound of formula V.

46. The compound of formula VIII is 【Chemical 22】 Contacting with a compound of formula IX 【Chemistry 23】 obtaining a compound of formula VI 46. ​​The method of claim 45, wherein LG is a suitable leaving group.

Citation Information

Patent Citations

  • Oligosaccharide complexes and uses

    JP2024540979A

  • Oligosaccharide complexes and uses

    JP2024543721A